Note: Descriptions are shown in the official language in which they were submitted.
CA 02328062 2000-11-08
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTS PARTIE DE CETTE DEMANDS OU CE BREVET
COMPREND PLUS D'UN TOME.
CECI EST LE TOME - I DE
NOTE: ~ Pour les tomes additionels, veuillez contacter le Bureau canadien des
brevets
JUMBO APPLlCATlONSIPATENTS
THIS SECTION OF THE APPLICAT10N/PATENT CONTAINS MORE
THAN ONE VOLUME
THIS IS VOLUME - ' ~= OF ~
NOTE: For additional volumes please contact the Canadian Patent Office
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM
This application is a continuation-in-part of the following applications:
(1) provisional application Ser. No. 60/075,118, filed February 11,1998, now
abandoned;
(2) application Ser. No. 09/248,059, filed February 10, 1999; which is a
continuation in-part of provisional application Ser. No. 60/075,118, filed
February 11,
1998, now abandoned;
(3) provisional application Ser. No. 60/080,969, filed April 7, 1998, now
2 0 abandoned;
(4) application Ser. No. 09/287,150, filed April 6,1999; which is a
continuation
in-part of provisional application Ser. No.60/080,969, filed April 7,1998, now
abandoned;
(5) provisional application Ser. No. 60/085,472, filed May 14,1998;
(6} provisional application Ser. No. 60/096,824, filed August 17,1998;
2 5 (7) provisional application Ser. No. 60/099,950, filed September 11,1998;
(8) provisional application Ser. No. 60/099,843, filed September 11,1998;
(9) provisional application Ser. No. 60/100,424, filed September 15,1998;
(10) provisional application Ser. No. 60/102,329, filed September 29,1998;
(11) provisional application Ser. No. 60/103,615, filed October 9,1998;
30 (12) provisional application Ser. No. 60/111,799, filed December 11,1998;
(13) provisional application Ser. No. 60/112,159, filed December 14,1998;
(14) provisional application Ser. No. 60/114,415, filed December 31,1998;
all of which are incorporated by reference herein.
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99/10843
FOLD OF THE INVENTION
The present invention provides novel polynucleotides and proteins encoded by
such polynucleotides, along with therapeutic, diagnostic and research
utilities for these
polynucleotides and proteins.
BACKGROUND OF THE INVENTION
Technology aimed at the discovery of protein factors (including e.g.,
cytokines,
such as lymphokines, interferons, CSFs and interleukins) has matured rapidly
over the
past decade. The now routine hybridization cloning and expression cloning
techniques
clone novel polynucleotides "directly" in the sense that they rely on
information directly
2 0 related to the discovered protein (i.e., partial DNA/amino acid sequence
of the protein
in the case of hybridization cloning; activity of the protein in the case of
expression
cloning). More recent "indirect" cloning techniques such as signal sequence
cloning, which
isolates DNA sequences based on the presence of a now well-recognized
secretory leader
sequence motif, as well as various PCR-based or low stringency hybridization
cloning
2 5 techniques, have advanced the state of the art by making available large
numbers of
DNA/amino acid sequences for proteins that are known to have biological
activity by
virtue of their secreted nature in the case of leader sequence cloning, or by
virtue of the
cell or tissue source in the case of PCR-based techniques. It is to these
proteins and the
polynucleotides encoding them that the present invention is directed.
2
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99/10843
SU1~IARY OF THE INVENTION
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:1;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:1 from nucleotide 29 to nucleotide 253;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yal5_1 deposited under accession
number
ATCC 98650;
(d} a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yal5_1 deposited under accession number ATCC 98650;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yal5_1 deposited under accession number ATCC
98650;
(f) a polynudeotide encoding a mature protein encoded by the cDNA
insert of clone yal5_1 deposited under accession number ATCC 98650;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:2;
2 0 (h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:2 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:2;
{i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
2 5 (j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h} above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
3 0 one of the polynucleotides specified in (ar(h) and that has a length that
is at least
25% of the length of SEQ ID NO:1.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:1 from nucleotide 29 to nucleotide 253; the nucleotide sequence of the full-
length
protein coding sequence of clone yal5_1 deposited under accession number ATCC
98650;
3
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
or the nucleotide sequence of a mature protein coding sequence of clone yal5_1
deposited
under accession number ATCC 98650. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yal5_1 deposited under accession number ATCC 98650. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID NO:2 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:2, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:2
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 32
to amino acid 41 of SEQ ID N0:2.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID NO:1.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
{a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
2 0 (aa) SEQ ID N0:1, but excluding the poly(A) tail at the
3' end of SEQ ID NO:l; and
(ab} the nucleotide sequence of the cDNA insert of clone
yal5_1 deposited under accession number ATCC 98650;
(ii) hybridizing said probes) to human genomic DNA in
2 5 conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
3 0 (i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID NO:1, but excluding the poly(A) tail at the
3' end of SEQ ID NO:1; and
4
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
(bb) the nucleotide sequence of the cDNA insert of clone
yal5_1 deposited under accession number ATCC 98650;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:1, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
NO:1 to
a nucleotide sequence corresponding. to the 3' end of SEQ ID N0:1 , but
excluding the
poly(A) tail at the 3' end of SEQ ID NO:1. Also preferably the polynucleotide
isolated
according to the above process comprises a nucleotide sequence corresponding
to the
cDNA sequence of SEQ ID N0:1 from nucleotide 29 to nucleotide 253, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of said
sequence of
SEQ ID NO:1 from nucleotide 29 to nucleotide 253, to a nucleotide sequence
corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 29
to
nucleotide 253.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:2;
(b) a fragment of the amino acid sequence of SEQ ID N0:2, the
fragment comprising eight contiguous amino acids of SEQ ID N0:2; and
(c) the amino acid sequence encoded by the cDNA insert of clone
2 5 yal5_1 deposited under accession number ATCC 98650;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:2. In further preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:2 having biological activity, the fragment
preferably
3 0 comprising eight (more preferably twenty, most preferably thirty)
contiguous amino acids
of SEQ ID N0:2, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:2 having biological activity, the fragment comprising the amino acid
sequence from
amino acid 32 to amino acid 41 of SEQ ID N0:2.
5
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:3;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:3 from nucleotide 151 to nucleotide 288;
(c) a polynucleatide comprising the nucleotide sequence of SEQ ID
N0:3 from nucleotide 196 to nucleotide 288;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ya24_1 deposited under accession
number
ATCC 98650;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ya24_1 deposited under accession number ATCC 98b50;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ya24_1 deposited under accession number ATCC
98650;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ya24_1 deposited under accession number ATCC 98650;
(h) a polynucleotide encoding a protein comprising the amino acid
2 0 sequence of SEQ ID N0:4;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:4 having biological activity, the fragment
comprisingeight contiguous amino acids of SEQ ID N0:4;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
2 5 (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
3 0 (m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:3.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:3 from nucleotide 151 to nucleotide 288; the nucleotide sequence of SEQ ID
N0:3 from
6
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
nucleotide 196 to nucleotide 288; the nucleotide sequence of the full-length
protein coding
sequence of clone ya24_1 deposited under accession number ATCC 98450; or the
nucleotide sequence of a mature protein coding sequence of clone ya24_1
deposited under
accession number ATCC 98650. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone ya24_1
deposited under accession number ATCC 98650. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:4 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:4, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:4 having biological activity,
the
fragment comprising the amino acid sequence from amino acid 18 to amino acid
27 of SEQ
ID N0:4.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:3.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
2 0 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID NO:3, but excluding the poly(A) tail at the
3' end of SEQ ID N0:3; and
(ab) the nucleotide sequence of the cDNA insert of clone
2 5 ya24_1 deposited under accession number ATCC 98650;
(ii) hybridizing said probe{s) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
piobe(s);
3 0 and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
7
CA 02328062 2000-11-08
WO 99158642 PCTNS99/10843
(ba) SEQ ID N0:3, but excluding the poly(A) tail at the
3' end of SEQ ID N0:3; and
(bb) the nucleotide sequence of the cDNA insert of clone
ya24_1 deposited under accession number ATCC 98650;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii}.
Preferably the polynucleotide isolated according to the above process
comprises a
2 0 nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:3, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:3 to
a nucleotide sequence corresponding to the 3' end of SEQ ID N0:3 , but
excluding the
poly(A) tail at the 3' end of SEQ ID N0:3. Also preferably the polynucleotide
isolated
according to the above process comprises a nucleotide sequence corresponding
to the
cDNA sequence of SEQ ID N0:3 from nucleotide 151 to nucleotide 288, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of said
sequence of
SEQ ID N0:3 from nucleotide 152 to nucleotide 288, to a nucleotide sequence
corresponding to the 3' end of said sequence of SEQ ID N0:3 from nucleotide
151 to
nucleotide 288. Also preferably the polynucleotide isolated according to the
above
2 0 process comprises a nucleotide sequence corresponding to the cDNA sequence
of SEQ ID
N0:3 from nucleotide 196 to nucleotide 288, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:3 from
nucleotide 196 to nucleotide 288, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:3 from nucleotide 196 to nucleotide 288.
2 5 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:4;
(b) a fragment of the amino acid sequence of SEQ ID N0:4, the
3 0 fragment comprising eight contiguous amino atids of SEQ ID N0:4; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ya24_1 deposited under accession number ATCC 98650;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:4. In further preferred
8
CA 02328062 2000-11-08
WO 99158642 PCT/US99/10843
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:4 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:4, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:4 having biological activity, the fragment comprising the amino acid
sequence from
amino acid 18 to amino acid 27 of SEQ ID N0:4.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:5;
(b} a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:5 from nucleotide 615 to nucleotide 908;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:5 from nucleotide 774 to nucleotide 908;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yb42_1 deposited under accession
number
ATCC 98650;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yb42_1 deposited under accession number ATCC 98650;
2 0 (f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yb42_1 deposited under accession number ATCC
98650;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yb42_1 deposited under accession number ATCC 98650;
2 5 (h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:6;
{i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:6 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:6;
3 0 (j} a polynucleotide which is an allelic variant of a polynucleotide of
(a)-{g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
9
CA 02328062 2000-11-08
WO 99158642 PCT/US99/10843
(1) a polynucleotide that hybridizes under stringent rnnditions to any
one of the polynucleotides specified in (a}-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:5.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:5 from nucleotide 615 to nucleotide 908; the nucleotide sequence of SEQ ID
N0:5 from
nucleotide 774 to nucleotide 908; the nucleotide sequence of the full-length
protein coding
sequence of clone yb42_1 deposited under accession number ATCC 98650; or the
nucleotide sequence of a mature protein coding sequence of clone yb42_1
deposited under
accession number ATCC 98650. In other preferred embodiments, the
polynucleotide
encodes the full length or a mature protein encoded by the cDNA insert of
clone yb42_1
deposited under accession number ATCC 98650. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:6 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:6, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:6 having biological activity,
the
fragment comprising the amino acid sequence from amino acid 44 to amino acid
53 of SEQ
2 0 ID N0:6.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:5.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
2 5 (a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:5, but excluding the poly(A) tail at the
3 0 3' end of SEQ ID N0:5; and
(ab) the nucleotide sequence of the cDNA insert of clone
yb42_1 deposited under accession number ATCC 98650;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
CA 02328062 2000-11-08
WO 99158642 PCT/US99/10843
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:5, but excluding the poly(A) tail at the
3' end of SEQ ID N0:5; and
(bb) the nucleotide sequence of the cDNA insert of clone
yb42_1 deposited under accession number ATCC 98650;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:5, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:5 to
a nucleotide sequence corresponding to the 3' end of SEQ ID N0:5 , but
excluding the
2 0 poly(A) tail at the 3' end of SEQ ID N0:5. Also preferably the
polynucleotide isolated
according to the above process comprises a nucleotide sequence corresponding
to the
cDNA sequence of SEQ ID N0:5 from nucleotide 615 to nucleotide 908, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of said
sequence of
SEQ ID N0:5 from nucleotide 615 to nucleotide 908, to a nucleotide sequence
2 5 corresponding to the 3' end of said sequence of SEQ ID N0:5 from
nucleotide 615 to
nucleotide 908. Also preferably the polynucleotide isolated according to the
above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:5 from nucleotide 774 to nucleotide 908, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:5 from
3 0 nucleotide 774 to nucleotide 908, to a nucleotide sequence corresponding
to the 3' end of
said sequence of SEQ ID N0:5 from nucleotide 774 to nucleotide 908.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
11
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(a) the amino acid sequence of SEQ ID N0:6;
(b) a fragment of the amino acid sequence of SEQ ID N0:6, the
fragment comprising eight contiguous amino acids of SEQ ID N0:6; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yb42_1 deposited under accession number ATCC 98650;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:6. In further preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:6 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:6, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:6 having biological activity, the fragment comprising the amino acid
sequence from
amino acid 44 to amino acid 53 of SEQ ID N0:6.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:7;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:7 from nucleotide 1203 to nucleotide 2327;
2 0 (c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yc9_1 deposited under accession number
ATCC 98650;
{d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yc9_1 deposited under accession number ATCC 98650;
2 5 (e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone y~ 1 deposited under accession number ATCC
98650;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone y~ 1 deposited under accession number ATCC 98650;
3 0 (g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:8;
{h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:8 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:8;
12
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:7.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:7 from nucleotide 1203 to nucleotide 2327; the nucleotide sequence of the
full-length
protein coding sequence of clone y~ 1 deposited under accession number ATCC
98650;
or the nucleotide sequence of a mature protein coding sequence of clone y~ 1
deposited
under accession number ATCC 98650. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone y~ 1 deposited under accession number ATCC 98650. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:8 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
2 0 preferably thirty) contiguous amino acids of SEQ ID N0:8, or a
polynucleotide encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:8
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 182
to amino acid 191 of SEQ ID N0:8.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 5 ID N0:7.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
3 0 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:7, but excluding the poly(A} tail at the
3' end of SEQ ID N0:7; and
13
CA 02328062 2000-11-08
WO 99/58642 PC'fNS99/10843
(ab) the nucleotide sequence of the cDNA insert of clone
y~ 1 deposited under accession number ATCC 98650;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:7, but excluding the poly(A) tail at the
3' end of SEQ ID N0:7; and
{bb} the nucleotide sequence of the cDNA insert of clone
yc9_1 deposited under accession number ATCC 98650;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:7, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:7 to
a nucleotide sequence corresponding to the 3' end of SEQ ID N0:7 , but
excluding the
poly(A) tail at the 3' end of SEQ ID N0:7. Also preferably the polynucleotide
isolated
2 5 according to the above process comprises a nucleotide sequence
corresponding to the
cDNA sequence of SEQ ID N0:7 from nucleotide 1203 to nucleotide 2327, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of said
sequence of
SEQ ID N0:7 from nucleotide 1203 to nucleotide 2327, to a nucleotide sequence
corresponding to the 3' end of said sequence of SEQ ID N0:7 from nucleotide
1203 to
3 0 nucleotide 2327.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:8;
14
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(b) a fragment of the amino acid sequence of SEQ ID N0:8, the
fragment comprising eight contiguous amino acids of SEQ ID N0:8; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yc9_1 deposited under accession number ATCC 98650;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:8. In further preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:8 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
~ of SEQ ID N0:8, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:8 having biological activity, the fragment comprising the amino acid
sequence from
amino acid 182 to amino acid 191 of SEQ ID N0:8.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:9;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:9 from nucleotide 230 to nucleotide 823;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:9 from nucleotide 584 to nucleotide 823;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ycl9_1 deposited under accession
number
ATCC 98650;
(e) a polynucleotide encoding the full-length protein encoded by the
2 5 cDNA insert of clone ycl9_1 deposited under accession number ATCC 98650;
{f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ycl9_1 deposited under accession number ATCC
98650;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
3 0 insert of clone ycl9_1 deposited under accession number ATCC 98650;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID NO:10;
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:10 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID NO:10;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(ar(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:9.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:9 from nucleotide 230 to nucleotide 823; the nucleotide sequence of SEQ ID
N0:9 from
nucleotide 584 to nucleotide 823; the nucleotide sequence of the full-length
protein coding
sequence of clone ycl9_1 deposited under accession number ATCC 98650; or the
nucleotide sequence of a mature protein coding sequence of clone ycl9_1
deposited under
accession number ATCC 98650. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone ycl9_1
2 0 deposited under accession number ATCC 98650. In further preferred
embodiments, the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:10 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID NO:10, or a polynucleotide encoding a protein comprising
a
2 5 fragment of the amino acid sequence of SEQ ID N0:10 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 94 to amino acid
103 of
SEQ ID N0:10.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:9.
3 0 Further embodiments of the invention provide isolated polynucleotides
produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
16
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:9, but excluding the poly(A) tail at the
3' end of SEQ ID N0:9; and
(ab) the nucleotide sequence of the cDNA insert of clone
ycl9_1 deposited under accession number ATCC 98650;
(ii) hybridizing said probes} to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:9, but excluding the poly(A) tail at the
3' end of SEQ ID N0:9; and
(bb} the nucleotide sequence of the cDNA insert of clone
2 0 ycl9_1 deposited under accession number ATCC 98650;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:9, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:9 to
a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9 , but
excluding the
poly(A) tail at the 3' end of SEQ ID N0:9. Also preferably the polynucleotide
isolated
3 0 according to the above process comprises a nucleotide sequence
corresponding to the
cDNA sequence of SEQ ID N0:9 from nucleotide 230 to nucleotide 823, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of said
sequence of
SEQ ID N0:9 from nucleotide 230 to nucleotide 823, to a nucleotide sequence
corresponding to the 3' end of said sequence of SEQ ID N0:9 from nucleotide
230 to
17
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
nucleotide 823. Also preferably the polynucleotide isolated according to the
above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:9 from nucleotide 584 to nucleotide 823, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:9 from
nucleotide 584 to nucleotide 823, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:9 from nucleotide 584 to nucleotide 823.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID NO:10;
(b) a fragment of the amino acid sequence of SEQ ID NO:10, the
fragment comprising eight contiguous amino acids of SEQ ID NO:10; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ycl9_1 deposited under accession number ATCC 98650;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID NO:10. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID NO:10 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 0 of SEQ ID N0:10, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:10 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 94 to amino acid 103 of SEQ ID NO:10.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
2 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:11;
(h) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:11 from nucleotide 292 to nucleotide 534;
(c) a polynucleotide comprising the nucleotide sequence of the full-
3 0 length protein coding sequence of clone yc20_1 deposited under accession
number
ATCC 98650;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yc20_1 deposited under accession number ATCC 98650;
18
CA 02328062 2000-11-08
WO 99/58642 PCTNS99I10843
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yc20_1 deposited under accession number ATCC
98650;
(f) a polynudeotide encoding a mature protein encoded by the cDNA
insert of clone yc20_1 deposited under accession number ATCC 98650;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:12;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:12 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:12;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID NO:11.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:11 from nucleotide 292 to nucleotide 534; the nucleotide sequence of the
full-length
prabein coding sequence of clone yc20_l deposited under accession number ATCC
98650;
or the nucleotide sequence of a mature protein coding sequence of clone yc20_1
deposited
under accession number ATCC 98650. In other preferred embodiments, the
2 5 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone yc20_1 deposited under accession number ATCC 98650. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:12 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
3 0 preferably thirty) contiguous amino aclds of SEQ ID N0:12, or a
polynucleotide encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:12
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 35
to amino acid 44 of SEQ ID N0:12.
19
CA 02328062 2000-11-08
WO 99158642 PCTNS99110843
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:11.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:11, but excluding the poly(A) tail at the
3' end of SEQ ID NO:11; and
(ab) the nucleotide sequence of the cDNA insert of clone
yc20_1 deposited under accession number ATCC 98650;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
2 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID NO:11, but excluding the poly(A) tail at the
3' end of SEQ ID N0:11; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 5 yc20_1 deposited under accession number ATCC 98650;
(ii) hybridizing said primers} to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b}(iii).
3 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:11, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:11 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:11,
but
excluding the poly(A) tail at the 3' end of SEQ ID N0:11. Also preferably the
CA 02328062 2000-11-08
WO 99/58642 PCT/US99I10843
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:11 from nucleotide 292 to
nucleotide
534, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:11 from nucleotide 292 to nucleotide 534, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:11 from
nucleotide
292 to nucleotide 534.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:12;
{b) a fragment of the amino acid sequence of SEQ ID N0:12, the
fragment comprising eight contiguous amino acids of SEQ ID N0:12; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yc20_1 deposited under accession number ATCC 98650;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:12. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:12 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 0 of SEQ ID N0:12, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:12 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 35 to amino acid 44 of SEQ ID N0:12.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
2 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:13;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:13 from nucleotide 45 to nucleotide 590;
(c} a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:13 from nucleotide 126 to nucleotide 590;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ya9_1 deposited under accession number
ATCC 98724;
21
CA 02328062 2000-11-08
PCT/US99/10843
(e) a polynudeotide encoding the full-length protein encoded by the
cDNA insert of clone ya9_1 deposited under accession number ATCC 98724;
(f) a polynudeotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ya9_1 deposited under accession number ATCC
98724;
(g) a polynudeotide encoding a mature protein encoded by the cDNA
insert of clone ya9_1 deposited under accession number ATCC 98724;
(h) a polynudeotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:14;
(i) a polynudeotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:14 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:14;
(j) a polynudeotide which is an allelic variant of a polynudeotide of
{a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynudeotide that hybridizes under stringent conditions to any
one of the polynudeotides specified in (a)-(i); and
(m) a polynudeotide that hybridizes under stringent conditions to any
2 0 one of the polynudeotides specified in (a)-(i) and that has a length that
is at least
25% of the length of SEQ ID N0:13.
Preferably, such polynudeotide comprises the nucleotide sequence of SEQ ID
N0:13 from nucleotide 45 to nucleotide 590; the nucleotide sequence of SEQ ID
N0:13
from nucleotide 126 to nucleotide 590; the nucleotide sequence of the full-
length protein
2 5 coding sequence of clone ya9_1 deposited under accession number ATCC
98724; or the
nucleotide sequence of a mature protein coding sequence of done ya9_1
deposited under
accession number ATCC 98724. In other preferred embodiments, the polynudeotide
encodes the full-length or a mature protein encoded by the cDNA insert of done
ya9_1
deposited under accession number ATCC 98724. In further preferred embodiments,
the
3 0 present invention provides a polynudeotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:14 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:14, or a polynudeotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:14 having biological
activity, the
22
CA 02328062 2000-11-08
WO 99158642 PCTNS99/10843
fragment comprising the amino acid sequence from amino acid 86 to amino acid
95 of SEQ
ID N0:14.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:13.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:13, but excluding the poly(A) tail at the
3' end of SEQ ID N0:13; and
(ab) the nucleotide sequence of the cDNA insert of clone
ya9_1 deposited under accession number ATCC 98724;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii} isolating the DNA polynucleotides detected with the
probe(s);
and
2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:13, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:13; and
(bb) the nucleotide sequence of the cDNA insert of clone
ya9_1 deposited under accession number ATCC 98724;
(ii} hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step {b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
23
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
ID N0:13 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:23
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:13. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:13 from nucleotide 45 to
nucleotide
590, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:13 from nucleotide 45 to nucleotide 590, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:13 from
nucleotide
45 to nucleotide 590. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:13 from nucleotide 126 to nucleotide 590, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:13 from
nucleotide 126 to nucleotide 590, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:13 from nucleotide 126 to nucleotide 590.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
{a) the amino acid sequence of SEQ ID NO:I4;
(b) a fragment of the amino acid sequence of SEQ ID N0:14, the
fragment comprising eight contiguous amino acids of SEQ ID N0:14; and
2 0 (c} the amino acid sequence encoded by the cDNA insert of clone
ya9_1 deposited under accession number ATCC 98724;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:14. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
2 5 amino acid sequence of SEQ ID N0:14 having biological activity, the
fragment preferably
comprising eight {more preferably twenty, most preferably thirty) contiguous
amina acids
of SEQ ID N0:14, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:14 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 86 to amino acid 95 of SEQ ID N0:14.
3 0 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ TD
N0:15;
24
CA 02328062 2000-11-08
WO 99/58642 PCTlUS99/10843
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:15 from nucleotide 194 to nucleotide 466;
(c} a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:15 from nucleotide 338 to nucleotide 466;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yal l_1 deposited under accession
number
ATCC 98724;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yall 1 deposited under accession number ATCC 98724;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yal l_1 deposited under accession number ATCC
98724;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yall 1 deposited under accession number ATCC 98724;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:16;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:16 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:16;
2 0 (j) a polynucleotide which is an allelic variant of a polynucleotide of
(a}-{g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
2 5 one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:15.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
3 0 N0:15 from nucleotide 194 to nucleotide 466; the nucleotide sequence of
SEQ ID N0:15
from nucleotide 338 to nucleotide 466; the nucleotide sequence of the full-
length protein
coding sequence of clone yall_1 deposited under accession number ATCC 98724;
or the
nucleotide sequence of a mature protein coding sequence of clone yall 1
deposited under
accession number ATCC 98724. In other preferred embodiments, the
polynucleotide
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yall 1
deposited under accession number ATCC 98724. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:16 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:16, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:16 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 40 to amino acid
49 of SEQ
ID N0:16.
Other embodiments provide the.gene corresponding to the cDNA sequence of SEQ
ID N0:15.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:15, but excluding the poly(A) tail at the
3' end of SEQ ID N0:15; and
2 0 (ab) the nucleotide sequence of the cDNA insert of clone
yall 1 deposited under accession number ATCC 98724;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
2 5 probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
3 0 the group consisting of:
(ba) SEQ ID N0:15, but excluding the poly(A) tail at the
3' end of SEQ ID N0:15; and
(bb) the nucleotide sequence of the cDNA insert of clone
yall_1 deposited under accession number ATCC 98724;
26
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:15, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:15 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:15
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:15. Also preferably the
2 0 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:15 from nucleotide 194 to
nucleotide
466, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:15 from nucleotide 194 to nucleotide 466, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:15 from
nucleotide
194 to nucleotide 466. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
NO:I5 from nucleotide 338 to nucleotide 466, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
NO:15 from
nucleotide 338 to nucleotide 466, to a nucleotide sequence corresponding to
the 3' end of
2 0 said sequence of SEQ ID N0:15 from nucleotide 338 to nucleotide 466.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:16;
2 5 (b) a fragment of the amino acid sequence of SEQ ID N0:16, the
fragment comprising eight contiguous amino acids of SEQ ID N0:16; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yall_1 deposited under accession number ATCC 98724;
the protein being substantially free from other mammalian proteins. Preferably
such
3 0 protein comprises the amino acid sequence of SEQ ID N0:16. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:16 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:16, or a protein comprising a fragment of the amino acid sequence
of SEQ
27
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
ID N0:16 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 40 to amino and 49 of SEQ ID N0:16.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:17;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:17 from nucleotide 15 to nucleotide 233;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:17 from nucleotide 174 to nucleotide 233;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ya28_1 deposited under accession
number
ATCC 98724;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ya28_1 deposited under accession number ATCC 98724;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ya28_1 deposited under accession number ATCC
98724;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
2 0 insert of clone ya28_1 deposited under accession number ATCC 98724;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:18;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:18 having biological activity, the fragment
2 5 comprising eight contiguous amino acids of SEQ ID N0:18;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-{g) above;
{k) a polynucleotide which encodes a species homologue of the protein
of {h) or (i) above ;
3 0 (1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:17.
28
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:17 from nucleotide 15 to nucleotide 233; the nucleotide sequence of SEQ ID
N0:17
from nucleotide 174 to nucleotide 233; the nucleotide sequence of the full-
length protein
coding sequence of clone ya28_1 deposited under accession number ATCC 98724;
or the
nucleotide sequence of a mature protein coding sequence of clone ya28_1
deposited under
accession number ATCC 98724. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone ya28_1
deposited under accession number ATCC 98724. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:18 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:18, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:18 having biological
activity, the
fragment comprising~the amino acid sequence from amino acid 31 to amino acid
40 of SEQ
ID N0:18.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:17.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
2 0 (a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:17, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:17; and
(ab) the nucleotide sequence of the cDNA insert of clone
ya28_1 deposited under accession number ATCC 98724;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
3 0 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
29
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:17, but excluding the poly(A) tail at the
3' end of SEQ ID N0:17; and
(bb) the nucleotide sequence of the cDNA insert of clone
ya28_1 deposited under accession number ATCC 98724;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:17, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:17 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:17
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:17. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:17 from nucleotide 15 to
nucleotide
233, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
2 0 of said sequence of SEQ ID N0:17 from nucleotide 15 to nucleotide 233, to
a nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:17 from
nucleotide
15 to nucleotide 233. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:17 from nucleotide 174 to nucleotide 233, and extending contiguously from a
2 5 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
NO:17 from
nucleotide 174 to nucleotide 233, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:17 from nucleotide 174 to nucleotide 233.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
3 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:18;
(b) a fragment of the amino acid sequence of SEQ ID N0:18, the
fragment comprising eight contiguous amino acids of SEQ ID N0:18; and
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(c) the amino acid sequence encoded by the cDNA insert of clone
ya28_1 deposited under accession number ATCC 98724;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:18. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:18 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:18, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:18 having biological activity, the fragment comprising the amino acid
sequence
2 0 from amino acid 31 to amino acid 40 of SEQ ID N0:18.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting af:
(a} a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:19;
{b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:19 from nucleotide 102 to nucleotide 461;
{c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yb81 1 deposited under accession
number
ATCC 98724;
2 0 (d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yb81_1 deposited under accession number ATCC 98724;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yb81 1 deposited under accession number ATCC
98724;
2 5 (f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yb81_1 deposited under accession number ATCC 98724;
(g} a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:20;
(h) a polynudeotide encoding a protein comprising a fragment of the
3 0 amino acid sequence of SEQ ID N0:20 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:20;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
31
CA 02328062 2000-11-08
WO 99/58642 PCT/US99I10843
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h) and that has a length that is
at least
25% of the length of SEQ ID N0:19.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:19 from nucleotide 102 to nucleotide 461; the nucleotide sequence of the
full-length
protein coding sequence of clone yb81_1 deposited under accession number ATCC
98724;
or the nucleotide sequence of a mature protein coding sequence of clone yb81_1
deposited
under accession number ATCC 98724. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yb81 1 deposited under accession number ATCC 98724. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:20 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:20, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:20
having
2 0 biological activity., the fragment comprising the amino acid sequence from
amino acid 55
to amino acid 64 of SEQ ID N0:20.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:19.
Further embodiments of the invention provide isolated polynucleotides produced
2 5 according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
3 0 (aa) SEQ ID N0:19, but excluding the poly{A) tail at the
3' end of SEQ ID N0:19; and
(ab) the nucleotide sequence of the cDNA insert of clone
yb81 1 deposited under accession number ATCC 98724;
32
CA 02328062 2000-11-08
WO 99158642 PCT/US99/10843
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more poiynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:19, but excluding the poly(A) tail at the
3' end of SEQ ID N0:19; and
(bb) the nucleotide sequence of the cDNA insert of clone
yb81_1 deposited under accession number ATCC 98724;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:19, and
2 0 extending contiguously from a nucleotide sequence corresponding to the 5'
end of SEQ
ID N0:19 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:19
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:19. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:19 from nucleotide 102 to
nucleotide
2 5 461, and extending contiguously from a nucleotide sequence corresponding
to the 5' end
of said sequence of SEQ ID N0:19 from nucleotide 102 to nucleotide 461, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:19 from
nucleotide
102 to nucleotide 461.
In other embodiments, the present invention provides a composition comprising
3 0 a protein, wherein said protein comprises an amino acid sequence selected
from the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:20;
(b) a fragment of the amino acid sequence of SEQ ID N0:20, the
fragment comprising eight contiguous amino acids of SEQ ID N0:20; and
33
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(c) the amino acid sequence encoded by the cDNA insert of clone
yb81 1 deposited under accession number ATCC 98724;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:20. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:20 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N020, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:20 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 55 to amino acid 64 of SEQ ID N0:20.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:21;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:21 from nucleotide 170 to nucleotide 2968;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ycl4_1 deposited under accession
number
ATCC 98724;
2 0 (d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ycl4_1 deposited under accession number ATCC 98724;
(e) a polynudeotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ycl4_1 deposited under accession number ATCC
98724;
2 5 (f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ycl4_1 deposited under accession number ATCC 98724;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:22;
{h) a polynucleotide encoding a protein comprising a fragment of the
3 0 amino acid sequence of SEQ ID N0:22 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:22;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a}-(f) above;
34
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99/10843
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h) and that has a length that is
at least
25% of the length of SEQ ID N0:21.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:21 from nucleotide 170 to nucleotide 2968; the nucleotide sequence of the
full-length
protein coding sequence of clone ycl4_1 deposited under accession number ATCC
98724;
or the nucleotide sequence of a mature protein coding sequence of clone ycl4_1
deposited
under accession number ATCC 98724. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone ycl4_l deposited under accession number ATCC 98724. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:22 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:22, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:22
having
2 0 biological activity, the fragment comprising the amino acid sequence from
amino acid 461
to amino acid 470 of SEQ ID N0:22.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:21.
Further embodiments of the invention provide isolated polynucleotides produced
2 5 according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
3 0 ~ (aa} SEQ ID N0:21, but excluding the poly(A) tail at the
3' end of SEQ ID N0:21; and
(ab) the nucleotide sequence of the cDNA insert of clone
ycl4_1 deposited under accession number ATCC 98724;
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99/10843
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
{i} preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
{ba) SEQ ID N0:21, but excluding the poly(A) tail at the
3' end of SEQ ID N0:21; and
(bb) the nucleotide sequence of the cDNA insert of clone
ycl4_1 deposited under accession number ATCC 98724;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:21, and
2 0 extending contiguously from a nucleotide sequence corresponding to the 5'
end of SEQ
ID N0:21 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:21
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:21. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:21 from nucleotide 170 to
nucleotide
2 5 2968, and extending contiguously from a nucleotide sequence corresponding
to the 5' end
of said sequence of SEQ ID NO~1 from nucleotide 170 to nucleotide 2968, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:21 from
nucleotide
170 to nucleotide 2968.
In other embodiments, the present invention provides a composition comprising
3 0 a protein, wherein said protein comprises an amino acid sequence selected
from the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:22;
(b) a fragment of the amino acid sequence of SEQ ID N0:22, the
fragment comprising eight contiguous amino acids of SEQ ID N0:22; and
36
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(c) the amino acid sequence encoded by the cDNA insert of clone
ycl4_1 deposited under accession number ATCC 98724;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:22. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ 1D N0:22 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:22, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:22 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 461 to amino acid 47Q of SEQ ID N0:22.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a} a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:23;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:23 from nucleotide 82 to nucleotide 729;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yc24_1 deposited under accession
number
ATCC 98755;
2 0 (d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yc24_i deposited under accession number ATCC 98755;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yc24_1 deposited under accession number ATCC
98755;
2 5 (f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yc24_1 deposited under accession number ATCC 98755;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:24;
(h) a polynucleotide encoding a protein comprising a fragment of the
3 0 amino acid sequence of SEQ ID N0:24 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:24;
(i} a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
37
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(j) a polynucleotide which encodes a species homologue of the protein
of (g} or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:23.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:23 from nucleotide 82 to nucleotide 729; the nucleotide sequence of the
full-length
protein coding sequence of clone yc24_1 deposited under accession number ATCC
98755;
or the nucleotide sequence of a mature protein coding sequence of clone yc24_1
deposited
under accession number ATCC 98755. In other preferred embodiments, the
polynudeotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yc24_1 deposited under accession number ATCC 98755. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:24 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:24, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:24
having
2 0 biological activity, the fragment comprising the amino acid sequence from
amino acid 103
to amino acid 112 of SEQ ID N0:24.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:23.
Further embodiments of the invention provide isolated polynucleotides produced
2 5 according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
3 0 (aa) SEQ ID NO:23, but excluding the poly(A) tail at the
3' end of SEQ ID N0:23; and
(ab) the nucleotide sequence of the cDNA insert of clone
yc24_1 deposited under accession number ATCC 98755;
38
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) $EQ ID N0:23, but excluding the poly(A) tail at the
3' end of SEQ ID N0:23; and
(bb) the nucleotide sequence of the cDNA insert of clone
yc24_1 deposited under accession number ATCC 98755;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the poiynucleotide products of step (b)(iii}.
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:23, and
2 0 extending contiguously from a nucleotide sequence corresponding to the 5'
end of SEQ
ID N0:23 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:23
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:23. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:23 from nucleotide 82 to
nucleotide
2 5 729, and extending contiguously from a nucleotide sequence corresponding
to the 5' end
of said sequence of SEQ ID N0:23 from nucleotide 82 to nucleotide 729, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:23 from
nucleotide
82 to nucleotide 729.
In other embodiments, the present invention provides a composition comprising
3 0 a protein, wherein said protein comprises an amino and sequence selected
from the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:24;
(b) a fragment of the amino acid sequence of SEQ ID N0:24, the
fragment comprising eight contiguous amino acids of SEQ ID N0:24; and
39
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(c) the amino acid sequence encoded by the cDNA insert of clone
yc24_l deposited under accession number ATCC 98755;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:24. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID NO:24 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID NO:24, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:24 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 103 to amino acid 112 of SEQ ID NO:24.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:25;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:25 from nucleotide 7 to nucleotide 951;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:25 from nucleotide 61 to nucleotide 951;
(d) a polynucleotide comprising the nucleotide sequence of the full-
2 0 length protein coding sequence of clone yc25_1 deposited under accession
number
ATCC 98755;
{e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yc25_1 deposited under accession number ATCC 98755;
(f} a polynucleotide comprising the nucleotide sequence of a mature
2 5 protein coding sequence of clone y~ 1 deposited under accession number
ATCC
98755;
(g} a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yc25_1 deposited under accession number ATCC 98755;
(h) a polynucleotide encoding a protein comprising the amino acid
3 0 sequence of SEQ ID N0:26;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:26 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:26;
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:25.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:25 from nucleotide 7 to nucleotide 951; the nucleotide sequence of 5EQ ID
N0:25 from
nucleotide 61 to nucleotide 951; the nucleotide sequence of the full-length
protein coding
sequence of clone yc25_1 deposited under accession numbex ATCC 98755; or the
nucleotide sequence of a mature protein coding sequence of clone y~ 1
deposited under
accession number ATCC 98755. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yc25_1
deposited under accession number ATCC 98755. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0~6 having biological activity, the
fragment
2 0 preferably comprising eight (more preferably twenty, most preferably
thirty) contiguous
amino acids of SEQ ID N0:26, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:26 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 152 to amino acid
161 of
SEQ ID N0:26.
2 5 Other embodiments provide the gene corresponding to the cDNA sequence of
SEQ
ID N0:25.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
3 0 (i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:25, but excluding the poly(A) tail at the
3' end of SEQ ID N0:25; and
41
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
(ab) the nucleotide sequence of the cDNA insert of clone
yc25_1 deposited under accession number ATCC 98755;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probes};
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:25, but excluding the poly(A) tail at the
3' end of SEQ ID N0:25; and
(bb) the nucleotide sequence of the cDNA insert of clone
yc25_1 deposited under accession number ATCC 98755;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:25, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:25 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:25
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:25. Also preferably the
2 5 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:25 from nucleotide 7 to
nucleotide
951, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:25 from nucleotide 7 to nucleotide 951, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:25 from
nucleotide
3 0 7 to nucleotide 951. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:25 from nucleotide 61 to nucleotide 951, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:25 from
42
CA 02328062 2000-11-08
WO 99/58642 PCTNS991t0843
nucleotide 61 to nucleotide 951, to a nucleotide sequence corresponding to the
3' end of
said sequence of SEQ ID N0:25 from nucleotide 61 to nucleotide 951.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:26;
(b) a fragment of the amino acid sequence of SEQ ID N0:26, the
fragment comprising eight contiguous amino acids of SEQ.ID N0:26; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yc25_1 deposited under accession number ATCC 98755;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:26. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:26 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:26, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:26 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 152 to amino acid 161 of SEQ ID N0:26.
In ane embodiment, the present invention provides a composition comprising an
2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:27;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:27 from nucleotide 157 to nucleotide 1083;
2 5 (c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ye2_1 deposited under accession number
ATCC 98755;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ye2_1 deposited under accession number ATCC 98755;
3 0 (e) a polynucleotide comprising the nucleotide sequence of a mature
protein rnding sequence of clone ye2_1 deposited under accession number ATCC
98755;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ye2_1 deposited under accession number ATCC 98755;
43
CA 02328062 2000-11-08
WO 99158642 PCTNS99/10843
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:28;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:28 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:28;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
{a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:27.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:27 from nucleotide 157 to nucleotide 1083; the nucleotide sequence of the
full-length
protein coding sequence of clone ye2_1 deposited under accession number ATCC
98755;
or the nucleotide sequence of a mature protein coding sequence of clone ye2_1
deposited
under accession number ATCC 98755. In other preferred embodiments, the
2 0 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone ye2_1 deposited under accession number ATCC 98755. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:28 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
2 5 preferably thirty) contiguous amino acids of SEQ ID N0:28, or a
polynucleotide encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:28
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 149
to amino acid 158 of SEQ ID N0:28.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
3 0 ID N0:27.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
44
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
{i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:27, but excluding the poly(A) tail at the
3' end of SEQ ID N0:27; and
(ab) the nucleotide sequence of the cDNA insert of clone
ye2_1 deposited under accession number ATCC 98755;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:27, but excluding the poly(A) tail at the
3' end of SEQ ID N0:27; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 0 yet 1 deposited under accession number ATCC 98755;
(ii) hybridizing said primer{s) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii}.
2 5 Preferably the polynucleotide isolated according, to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:27, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:27 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:27
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:27. Also preferably the
3 0 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:27 from nucleotide 157 to
nucleotide
1083, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:27 from nucleotide 157 to nucleotide 1083, to a
nucleotide
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
sequence corresponding to the 3' end of said sequence of SEQ ID N0:27 from
nucleotide
157 to nucleotide 1083.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:28;
(b) a fragment of the amino acid sequence of SEQ ID N0:28, the
fragment comprising eight contiguous amino acids of SEQ ID N0:28; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ye2_1 deposited under accession number ATCC 98755;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:28. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:28 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:28, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:28 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 149 to amino acid 158 of SEQ ID N0:28.
In one embodiment, the present invention provides a composition comprising an
2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:29;
{b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:29 from nucleotide 39 to nucleotide 473;
2 5 (c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ya65-1 deposited under accession
number
ATCC 98834;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ya65_1 deposited under accession number ATCC 98834;
3 0 (e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ya65_1 deposited under accession number ATCC
98834;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ya65 1 deposited under accession number ATCC 98834;
46
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:30;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:30 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:30;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
{k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h) and that has a length that is
at least
25% of the length of SEQ ID N0:29.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:29 from nucleotide 39 to nucleotide 473; the nucleotide sequence of the
full-length
protein coding sequence of clone ya65_1 deposited under accession number ATCC
98834;
or the nucleotide sequence of a mature protein coding sequence of clone ya65_1
deposited
under accession number ATCC 98834. In other preferred embodiments, the
2 0 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone ya65_T deposited under accession number ATCC 98834. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:30 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
2 5 preferably thirty) contiguous amino acids of SEQ ID N0:30, or a
polynudeotide encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:30
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 67
to amino acid 76 of SEQ ID N0:30.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
3 0 ID N0:29.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a} a process comprising the steps of:
47
CA 02328062 2000-11-08
WO 99/58642 PC"TIUS99110843
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:29, but excluding the poly(A) tail at the
3' end of SEQ ID N0:29; and
(ab) the nucleotide sequence of the cDNA insert of clone
yak 1 deposited under accession number ATCC 98834;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:29, but excluding the poly(A) tail at the
3' end of SEQ ID N0:29; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 0 yak 1 deposited under accession number ATCC 98834;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:29, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:29 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:29
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:29. Also preferably the
3 0 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ TD N0:29 from nucleotide 39 to
nucleotide
473, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:29 from nucleotide 39 to nucleotide 473, to a
nucleotide
48
CA 02328062 2000-11-08
WO 99/58642 PCT/US99I10843
sequence corresponding to the 3' end of said sequence of SEQ ID N0:29 from
nucleotide
39 to nucleotide 473.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:30;
(b) a fragment of the amino acid sequence of SEQ ID N0:30, the
fragment comprising eight contiguous amino acids of SEQ ID N0:30; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ya65_1 deposited under accession number ATCC 98834;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:30. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:30 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:30, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:30 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 67 to amino acid 76 of SEQ ID N0:30.
In one embodiment, the present invention provides a composition comprising an
2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:31;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:31 from nucleotide 664 to nucleotide 903;
2 5 (c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yb60_1 deposited under accession
number
ATCC 98834;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yb60_1 deposited under accession number ATCC 98834;
3 0 (e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yb60_1 deposited under accession number ATCC
98834;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yb60_1 deposited under accession number ATCC 98834;
49
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:32;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:32 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:32;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j} a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:31.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:31 from nucleotide 664 to nucleotide 903; the nucleotide sequence of the
full-length
protein coding sequence of clone yb60_i deposited under accession number ATCC
98834;
or the nucleotide sequence of a mature protein coding sequence of clone yb60_1
deposited
under accession number ATCC 98834. In other preferred embodiments, the
2 0 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone yb60_1 deposited under accession number ATCC 98834. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:32 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
2 5 preferably thirty) contiguous amino acids of SEQ ID N0:32, or a
polynucleotide encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:32
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 35
to amino acid 44 of SEQ ID N0:32.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
3 0 ID N0:31.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99/10843
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:31, but excluding the poly(A) tail at the
3' end of SEQ ID N0:31; and
(ab} the nucleotide sequence of the cDNA insert of clone
yb60_1 deposited under accession number ATCC 98834;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
{iii) isolating. the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:31, but excluding the poly{A) tail at the
3' end of SEQ ID N0:31; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 0 yb60_1 deposited under accession number ATCC 98834;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b}(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:31, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:31 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:31
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:31. Also preferably the
3 0 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:31 from nucleotide 664 to
nucleotide
903, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:31 from nucleotide 664 to nucleotide 903, to a
nucleotide
51
CA 02328062 2000-11-08
WO 99158642 PCTIUS99/I0843
sequence corresponding to the 3' end of said sequence of SEQ ID N0:31 from
nucleotide
664 to nucleotide 903.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:32;
(b) a fragment of the amino acid sequence of SEQ ID N0:32, the
fragment comprising eight contiguous amino acids of SEQ ID N0:32; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yb60_1 deposited under accession number ATCC 98834;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:32. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:32 having biological activity, the fragment
preferably
2 5 comprising eight (more preferably twenty, most preferably thirty)
contiguous amino acids
of SEQ ID N0:32, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:32 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 35 to amino acid 44 of SEQ ID N0:32.
In one embodiment, the present invention provides a composition comprising an
2 0 isolated polynudeotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:33;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:33 from nucleotide 88 to nucleotide 447;
2 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:33 from nucleotide 427 to nucleotide 447;
(d) a polynudeotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yb139_1 deposited under accession
number ATCC 98834;
3 0 (e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yb139_1 deposited under accession number ATCC 98834;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yb139_1 deposited under accession number
ATCC 98834;
52
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yb139_1 deposited under accession number ATCC 98834;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:34;
(i} a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:34 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:34;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:33.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:33 from nucleotide 88 to nucleotide 447; the nucleotide sequence of SEQ ID
N0:33
from nucleotide 427 to nucleotide 447; the nucleotide sequence of the full-
length protein
2 0 coding sequence of clone yb139_1 deposited under accession number ATCC
98834; or the
nucleotide sequence of a mature protein coding sequence of clone ybI39_i
deposited
under accession number ATCC 98834. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yb139_1 deposited under accession number ATCC 98834. In further
preferred
2 5 embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:34 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:34, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:34
having
3 0 biological activity, the fragment comprising the amino acid sequence from
amino acid 55
to amino acid 64 of SEQ ID N0:34.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:33.
53
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
Further embodiments of the invention provide isolated polynudeotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:33, but excluding the poly(A) tail at the
3' end of SEQ ID N0:33; and
{ab) the nucleotide sequence of the cDNA insert of clone
yb139_1 deposited under accession number ATCC 98834;
{ii) hybridizing said probes) to human aPnn",;~ tn~re ;"
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
2 0 (ba) SEQ ID N0:33, but excluding the poly(A) tail at the
3' end of SEQ ID N0:33; and
(bb) the nucleotide sequence of the cDNA insert of clone
yb139_1 deposited under accession number ATCC 98834;
(ii) hybridizing said primers) to human genomic DNA in
2 5 conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:33, and
3 0 extending contiguously from a nucleotide sequence corresponding to the 5'
end of SEQ
ID N0:33 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:33
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:33. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:33 from nucleotide 88 to
nucleotide
54
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
447, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:33 from nucleotide 88 to nucleotide 447, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:33 from
nucleotide
88 to nucleotide 447. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:33 from nucleotide 427 to nucleotide 447, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:33 from
nucleotide 427 to nucleotide 447, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:33 from nucleotide 427 to nucleotide 447.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:34;
(b) a fragment of the amino acid sequence of SEQ ID N0:34, the
fragment comprising eight contiguous amino acids of SEQ ID N0:34; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yb139_1 deposited under accession number ATCC 98834;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:34. In further
preferred
2 0 embodiments, the present invention provides a protein comprising a
fragment of the
amino acid sequence of SEQ ID N0:34 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:34, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:34 having biological activity, the fragment comprising the amino acid
sequence
2 5 from amino acid 55 to amino acid 64 of SEQ ID N0:34.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:35;
3 0 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:35 from nucleotide 93 to nucleotide 1481;
(c} a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yc29_1 deposited under accession
number
ATCC 98834;
CA 02328062 2000-11-08
WO 99/58642 PCT/US99I10843
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yc29_1 deposited under accession number ATCC 98834;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yc29_1 deposited under accession number ATCC
98834;
{f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yc29_1 deposited under accession number ATCC 98834;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:36;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:36 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:36;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
2 0 one of the polynucleotides specified in (a)-(h) and that has a length that
is at least
25% of the length of SEQ ID N0:35.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:35 from nucleotide 93 to nucleotide 1481; the nucleotide sequence of the
full-length
protein coding sequence of clone yc29_1 deposited under accession number ATCC
98834;
2 5 or the nucleotide sequence of a rriature protein coding sequence of clone
yc29_1 deposited
under accession number ATCC 98834. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yc29_1 deposited under accession number ATCC 98834. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
3 0 comprising a fragment of the amino acid sequence of SEQ ID N0:36 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:36, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:36
having
56
CA 02328062 2000-11-08
PCT/US99/10843
biological activity, the fragment comprising the amino acid sequence from
amino acid 226
to amino acid 235 of SEQ ID N0:36.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:35.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa} SEQ ID N0:35, but excluding the poly(A) tail at the
3' end of SEQ ID N0:35; and
(ab) the nucleotide sequence of the cDNA insert of clone
yc29_1 deposited under accession number ATCC 98834;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 0 (b} a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:35, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:35; and
(bb) the nucleotide sequence of the cDNA insert of clone
yc29_1 deposited under accession number ATCC 98834;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:35, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
57
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
ID N0:35 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:35
, but
excluding the poly{A) tail at the 3' end of SEQ ID N0:35. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:35 from nucleotide 93 to
nucleotide
~ 1481, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:35 from nucleotide 93 to nucleotide 1481, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:35 from
nucleotide
93 to nucleotide 1481.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:36;
{b) a fragment of the amino acid sequence of SEQ ID N0:36, the
fragment comprising eight contiguous amino acids of SEQ ID N0:36; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yc29_1 deposited under accession number ATCC 98834;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:36. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
2 0 amino acid sequence of SEQ ID N0:36 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:36, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:36 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 226 to amino acid 235 of SEQ ID N0:36.
2 5 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:37;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:37 from nucleotide 482 to nucleotide 751;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:37 from nucleotide 611 to nucleotide 751;
58
CA 02328062 2000-11-08
WO 99158642 PCT/US99110843
(d) a polynucleotide.comprising the nucleotide sequence of the full-
length protein coding sequence of clone yc40_1 deposited under accession
number
ATCC 98834;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yc40_1 deposited under accession number ATCC 98834;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yc40_1 deposited under accession number ATCC
98834;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yc40_1 deposited under accession number ATCC 98834;
(h) a polynucleotide encoding a protein comprising the amino and
sequence of SEQ ID N0:38;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:38 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:38;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
2 0 (1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(i) and that has a length that is
at least
25% of the length of SEQ ID N0:37.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:37 from nucleotide 482 to nucleotide 751; the nucleotide sequence of SEQ ID
N0:37
from nucleotide 611 to nucleotide 751; the nucleotide sequence of the full-
length protein
coding sequence of clone yc40_1 deposited under accession number ATCC 98834;
or the
nucleotide sequence of a mature protein coding sequence of clone yc40_1
deposited under
3 0 accession number ATCC 98834. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yc40_1
deposited under accession number ATCC 98834. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:38 having biological activity, the
fragment
59
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:38, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:38 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 40 to amino acid
49 of SEQ
ID NO:38.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:37.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:37, but excluding the poly(A) tail at the
3' end of SEQ ID N0:37; and
(ab) the nucleotide sequ~ce of the cDNA insert of clone
yc40_1 deposited under accession number ATCC 98834;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 0 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
2 5 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:37, but excluding the poly(A) tail at the
3' end of SEQ ID N0:37; and
(bb) the nucleotide sequence of the cDNA insert of clone
3 0 yc40_1 deposited under accession number ATCC 98834;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
CA 02328062 2000-11-08
WO 99158642 PCTIUS99/10843
Preferably the polynudeotide isolated according to the above process comprises
a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:37, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:37 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:37
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:37. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:37 from nucleotide 482 to
nucleotide
751, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:37 from nucleotide 482 to nucleotide 751, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:37 from
nucleotide
482 to nucleotide 751. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:37 from nucleotide 611 to nucleotide 751, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ TD
N0:37 from
nucleotide 611 to nucleotide 751, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:37 from nucleotide 611 to nucleotide 751.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
2 0 (a) the amino acid sequence of SEQ ID N0:38;
(b) a fragment of the amino acid sequence of SEQ ID N0:38, the
fragment comprising eight contiguous amino acids of SEQ ID N0:38; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yc40_1 deposited under accession number ATCC 98834;
2 5 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:38. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:38 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino ands
3 0 of SEQ ID N0:38, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:38 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 40 to amino acid 49 of SEQ ID N0:38.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
61
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:39;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:39 from nucleotide 179 to nucleotide 601;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:39 from nucleotide 356 to nucleotide 601;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ydl0_1 deposited under accession
number ATCC 98834;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ydl0_1 deposited under accession number ATCC 98834;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ydl0_1 deposited under accession number
ATCC 98834;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ydl0_1 deposited under accession number ATCC 98834;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:40;
(i) a polynucleotide encoding a protein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:40 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:40;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
2 5 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
3 0 25% of the length of SEQ ID N0:39.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:39 from nucleotide 179 to nucleotide 601; the nucleotide sequence of SEQ ID
N0:39
from nucleotide 356 to nucleotide 601; the nucleotide sequence of the full-
length protein
coding sequence of clone ydl0_1 deposited under accession number ATCC 98834;
or the
62
CA 02328062 2000-11-08
WO 99/58642 ' PCTIUS99/10843
nucleotide sequence of a mature protein coding sequence of clone ydl0_1
deposited under
accession number ATCC 98834. in other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone ydl0_1
deposited under accession number ATCC 98834. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:40 having biological activity, the
fragment
preferably comprising eight {more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:40, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:40 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 65 to amino acid
74 of SEQ
ID N0:40.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:39.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
2 0 (aa} SEQ ID N0:39, but excluding the poly(A) tail at the
3' end of SEQ ID N0:39; and
(ab} the nucleotide sequence of the cDNA insert of clone
ydl0_1 deposited under accession number ATCC 98834;
(ii) hybridizing said probes) to human genomic DNA in
2 5 conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
3 0 (i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:39, but excluding the poly(A) tail at the
3' end of SEQ ID N0:39; and
63
CA 02328062 2000-11-08
WO 99158642 PCTNS99110843
(bb) the nucleotide sequence of the cDNA insert of clone
ydl0_1 deposited under accession number ATCC 98834;
{ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:39, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:39 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:39
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:39. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:39 from nucleotide 179 to
nucleotide
601, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:39 from nucleotide 179 to nucleotide 601, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:39 from
nucleotide
179 to nucleotide 601. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:39 from nucleotide 356 to nucleotide 601, and extending contiguously from a
2 0 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:39 from
nucleotide 356 to nucleotide 601, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:39 from nucleotide 356 to nucleotide 601.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
2 5 consisting of:
(a) the amino acid sequence of SEQ ID N0:40;
(b) a fragment of the amino acid sequence of SEQ ID N0:40, the
fragment comprising eight contiguous amino acids of SEQ ID N0:40; and
(c) the amino acid sequence encoded by the cDNA insert of clone
3 0 ydl0_1 deposited under accession number ATCC 98834;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:40. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:40 having biological activity, the fragment
preferably
64
CA 02328062 2000-11-08
WO 99/58642 PCT/US99110843
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:40, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:40 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 65 to amino acid 74 of SEQ TD N0:40.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:41;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:41 from nucleotide 324 to nucleotide 1559;
{c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:41 from nucleotide 387 to nucleotide 1559;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yf5_1 deposited under accession number
ATCC 98834;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yf5_1 deposited under accession number ATCC 98834;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yf5_1 deposited under accession number ATCC
2 0 98834;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yf5_1 deposited under accession number ATCC 98834;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:42;
2 5 (i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:42 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:42;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
3 0 (k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
CA 02328062 2000-11-08
WO 99158642 PCT/US99/10843
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:41.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:41 from nucleotide 324 to nucleotide 1559; the nucleotide sequence of SEQ
ID N0:41
from nucleotide 387 to nucleotide 1559; the nucleotide sequence of the full-
length protein
coding sequence of clone yf5_1 deposited under accession number ATCC 98834; or
the
nucleotide sequence of a mature protein coding sequence of clone yf5_1
deposited under
accession number ATCC 98834. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yf5_1
deposited under accession number ATCC 98834. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:42 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:42, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:42 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 201 to amino acid
210 of
SEQ ID N0:42.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:41.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
{aa) SEQ ID N0:41, but excluding the poly(A) tail at the
3' end of SEQ ID N0:41; and
(ab) the nucleotide sequence of the cDNA insert of clone
3 0 yf5_1 deposited under accession number ATCC 98834;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probes};
66
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/~ 0843
and
{b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba} SEQ ID N0:41, but excluding the poly(A) tail at the
3' end of SEQ ID N0:41; and
(bb) the nucleotide sequence of the cDNA insert of clone
yf5_1 deposited under accession number ATCC 98834;
{ii} hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:41, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:41 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:41
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:41. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
2 0 corresponding to the cDNA sequence of SEQ ID N0:41 from nucleotide 324 to
nucleotide
1559, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:41 from nucleotide 324 to nucleotide 1559, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:41 from
nucleotide
324 to nucleotide 1559. Also preferably the polynucleotide isolated according
to the above
2 5 process comprises a nucleotide sequence corresponding to the cDNA sequence
of SEQ ID
N0:41 from nucleotide 387 to nucleotide 1559, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:41 from
nucleotide 387 to nucleotide 1559, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:41 from nucleotide 387 to nucleotide 1559.
3 0 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:42;
67
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99/10843
(b) a fragment of the amino acid sequence of SEQ ID N0:42, the
fragment comprising eight contiguous amino acids of SEQ ID N0:42; and
(c) the amino acid sequence encoded by the cDNA insert of clone yf5_1
deposited under accession number ATCC 98834;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:42. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:42 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:42, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:42 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 201 to amino acid 210 of SEQ ID N0:42.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynudeotide comprising the nucleotide sequence of SEQ ID
N0:43;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:43 from nucleotide 257 to nucleotide 649;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:43 from nucleotide 335 to nucleotide 649;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ya67_1 deposited under accession
number
ATCC 98864;
(e) a polynucleotide encoding the full-length protein encoded by the
2 5 cDNA insert of clone ya67_1 deposited under accession number ATCC 98864;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ya67 1 deposited under accession number ATCC
98864;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
3 0 insert of clone ya67 1 deposited under accession number ATCC 98864;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:44;
68
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:44 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:44;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a~(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynudeotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide~that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:43.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:43 from nucleotide 257 to nucleotide 649; the nucleotide sequence of SEQ ID
N0:43
from nucleotide 335 to nucleotide 649; the nucleotide sequence of the full-
length protein
coding sequence of clone ya67 1 deposited under accession number ATCC 98864;
or the
nucleotide sequence of a mature protein coding sequence of clone ya67 1
deposited under
accession number ATCC 98864. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone ya67 1
2 0 deposited under accession number ATCC 98864. In further preferred
embodiments, the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:44 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:44, or a polynucleotide encoding a protein comprising
a
2 5 fragment of the amino acid sequence of SEQ ID N0:44 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 60 to amino and 69
of SEQ
ID N0:44.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:43.
3 0 Further embodiments of the invention provide isolated polynucleotides
produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
69
CA 02328062 2000-11-08
WO 99/58642 PCTNS99110843
{i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:43, but excluding the poly(A) tail at the
3' end of SEQ ID N0:43; and
(ab) the nucleotide sequence of the cDNA insert of clone
ya67_1 deposited under accession number ATCC 98864;
(ii) hybridizing said probes} to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ha) SEQ ID N0:43, but excluding the poly(A) tail at the
3' end of SEQ ID N0:43; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 0 ya67 1 deposited under accession number ATCC 98864;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:43, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:43 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:43
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:43. Also preferably the
3 0 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:43 from nucleotide 257 to
nucleotide
649, and extending rnntiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:43 from nucleotide 257 to nucleotide 649, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:43 from
nucleotide
CA 02328062 2000-11-08
WO 99/58642 Ptr'T/US99/10843
257 to nucleotide 649. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:43 from nucleotide 335 to nucleotide 649, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:43 from
nucleotide 335 to nucleotide 649, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:43 from nucleotide 335 to nucleotide 649.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:44;
(b) a fragment of the amino acid sequence of SEQ TD N0:44, the
fragment comprising eight contiguous amino acids of SEQ ID N0:44; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ya67 1 deposited under accession number ATCC 98864;
the protein being .substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:44. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:44 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 0 of SEQ ID N0:44, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:44 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 60 to amino acid 69 of SEQ ID N0:44.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
2 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:45;
(b} a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:45 from nucleotide 89 to nucleotide 787;
(c) a polynucleotide comprising the nucleotide sequence of the full-
3 0 length protein coding sequence of clone ya70_1 deposited under accession
number
ATCC 98864;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ya70_1 deposited under accession number ATCC 98864;
71
CA 02328062 2000-11-08
WO 99158642 PCTIUS99/10843
{e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ya70_1 deposited under accession number ATCC
98864;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ya70_1 deposited under accession number ATCC 98864;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:46;
{h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:46 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:46;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-{h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (ar(h) and that has a length that is
at least
25% of the length of SEQ ID N0:45.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:45 from nucleotide 89 to nucleotide 787; the nucleotide sequence of the
full-length
protein coding sequence of clone ya70_1 deposited under accession number ATCC
98864;
or the nucleotide sequence of a mature protein coding sequence of clone ya70_1
deposited
under accession number ATCC 98864. In other preferred embodiments, the
2 5 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone ya70_1 deposited under accession number ATCC 98864. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:46 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
3 0 preferably thirty) contiguous amino ands of SEQ ID N0:46, or a
polynucleotide encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:46
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 111
to amino acid 120 of SEQ ID N0:46.
72
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:45.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
{aa) SEQ ID N0:45, but excluding the poly(A} tail at the
3' end of SEQ ID N0:45; and
(ab) the nucleotide sequence of the cDNA insert of clone
ya70_i deposited under accession number ATCC 9$864;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
2 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:45, but excluding the poly{A) tail at the
3' end of SEQ ID N0:45; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 5 ya70_1 deposited under accession number ATCC 98864;
(ii) hybridizing said primer{s) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
3 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:45, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:45 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:45
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:45. Also preferably the
73
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:45 from nucleotide 89 to
nucleotide
787, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:45 from nucleotide 89 to nucleotide 787, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:45 from
nucleotide
89 to nucleotide 787.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:46;
(b) a fragment of the amino acid sequence of SEQ ID N0:46, the
fragment comprising eight contiguous amino acids of SEQ ID N0:46; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ya70_1 deposited under accession number ATCC 98864;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:46. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:46 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 0 of SEQ ID N0:46, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:46 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 111 to amino acid 120 of SEQ ID N0:46.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
2 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:47;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:47 from nucleotide 1017 to nucleotide 1265;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:47 from nucleotide 1068 to nucleotide 1265;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yb51 1 deposited under accession
number
ATCC 98864;
74
CA 02328062 2000-11-08
WO 99/58642 PCTNS99110843
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yb51_1 deposited under accession number ATCC 98864;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yb51 1 deposited under accession number ATCC
98864;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yb51_1 deposited under accession number ATCC 98864;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:48;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:48 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:48;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a}-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (ar(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
2 0 one of the polynucleotides specified in (a)-(i) and that has a length that
is at least
25% of the length of SEQ ID N0:47.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:47 from nucleotide 1017 to nucleotide 1265; the nucleotide sequence of SEQ
ID N0:47
from nucleotide 1068 to nucleotide 1265; the nucleotide sequence of the full-
length
2 5 protein coding sequence of clone yb51_1 deposited under accession number
ATCC 98864;
or the nucleotide sequence of a mature protein coding sequence of clone ybSl 1
deposited
under accession number ATCC 98864. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yb51_1 deposited under accession number ATCC 98864. In further
preferred
3 0 embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:48 having
biological
activity, the fragment preferably comprising eight {more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:48, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:48
having
CA 02328062 2000-11-08
WO 99/58642 PCT/US99110843
biological activity, the fragment comprising the amino acid sequence from
amino acid 36
to amino acid 45 of SEQ ID N0:48.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:47.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected fram the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:47, but excluding the poly(A) tail at the
3' end of SEQ ID N0:47; and
(ab) the nucleotide sequence of the cDNA insert of clone
yb51 1 deposited under accession number ATCC 98864;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:47, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:47; and
(bb) the nucleotide sequence of the cDNA insert of clone
yb51 1 deposited under accession number ATCC 98864;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:47, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
76
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
ID N0:47 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:47
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:47. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:47 from nucleotide 1017 to
nucleotide
1265, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:47 from nucleotide 1017 to nucleotide 1265, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:47 from
nucleotide
1017 to nucleotide 1265. Also preferably the polynucleotide isolated according
to the
above process comprises a nucleotide sequence corresponding to the cDNA
sequence of
SEQ ID N0:47 from nucleotide 1068 to nucleotide 1265, and extending
contiguously from
a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:47 from
nucleotide 1068 to nucleotide 1265, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:47 from nucleotide 1068 to nucleotide 1265.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:48;
(b) a fragment of the amino acid sequence of SEQ ID N0:48, the
fragment comprising eight contiguous amino acids of SEQ ID N0:48; and
2 0 (c) the amino acid sequence encoded by the cDNA insert of clone
yb51_1 deposited under accession number ATCC 98864;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:48. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
2 5 amino acid sequence of SEQ ID N0:48 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino ands
of SEQ ID N0:48, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:48 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 36 to amino acid 45 of SEQ ID N0:48.
3 0 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:49;
77
CA 02328062 2000-11-08
WO 99158642 PCTNS99/10843
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:49 from nucleotide 13 to nucleotide 306;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yb101 1 deposited under accession
number ATCC 98864;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yb101 1 deposited under accession number ATCC 98864;
(e) a polynudeotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yb101_1 deposited under accession number
ATCC 98864;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yb102_1 deposited under accession number ATCC 98864;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:50;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:50 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:50;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
2 0 (j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
2 5 one of the polynudeotides specified in (ar(h) and that has a length that
is at least
25% of the length of SEQ ID N0:49.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:49 from nucleotide 13 to nucleotide 306; the nucleotide sequence of the
full-length
protein coding sequence of clone yb101 1 deposited under accession number ATCC
3 0 98864; or the nucleotide sequence of a mature protein coding sequence of
clone yb101_1
deposited under accession number ATCC 98864. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yb101 1 deposited under accession number ATCC 98864. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
78
CA 02328062 2000-11-08
WO 99158642 PCT/US99/10843
comprising a fragment of the amino acid sequence of SEQ TD N0:50 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino ands of SEQ ID N0:50, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:50
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 44
to amino acid 53 of SEQ ID N0:50.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:49.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:49, but excluding the poly(A) tail at the
3' end of SEQ ID N0:49; and
(ab) the nucleotide sequence of the cDNA insert of clone
yb101 1 deposited under accession number ATCC 98864;
(ii) hybridizing said probes) to human genomic DNA in
2 0 conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
2 5 (i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:49, but excluding the poly(A) tail at the
3' end of SEQ ID N0:49; and
3 0 (bb) the nucleotide sequence of the cDNA insert of clone
yb101_1 deposited under accession number ATCC 98864;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
. (iii) amplifying human DNA sequences; and
79
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99110843
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:49, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:49 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:49
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:49. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:49 from nucleotide 13 to
nucleotide
306, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:49 from nucleotide 13 to nucleotide 306, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:49 from
nucleotide
13 to nucleotide 306.
In other eiinbodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:50;
(b) a fragment of the amino acid sequence of SEQ ID N0:50, the
fragment comprising eight contiguous amino acids of SEQ ID N0:50; and
(c) the amino acid sequence encoded by the cDNA insert of clone
2 0 yb101_1 deposited under accession number ATCC 98864;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:50. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:50 having biological activity, the fragment
preferably
2 5 comprising eight (more preferably twenty, most preferably thirty)
contiguous amino acids
of SEQ ID NO:50, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:50 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 44 to amino acid 53 of SEQ ID N0:50.
In one embodiment, the present invention provides a composition comprising an
3 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:51;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:51 from nucleotide 284 to nucleotide 706;
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yb124_1 deposited under accession
number ATCC 98864;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yb124_1 deposited under accession number ATCC 98864;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yb124_1 deposited under accession number
ATCC 98864;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yb124_I deposited under accession number ATCC 98864;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:52;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:52 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:52;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(ar(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
2 0 (k) a polynudeotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h) and that has a length that is
at least
25% of the length of SEQ ID N0:51.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:51 from nucleotide 284 to nucleotide 706; the nucleotide sequence of the
full-length
protein coding sequence of clone yb124_1 deposited under accession number ATCC
98864; or the nucleotide sequence of a mature protein coding sequence of clone
yb124_1
deposited under accession number ATCC 98864. In other preferred embodiments,
the
3 0 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone yb124_1 deposited under accession number ATCC 98864. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:52 having
biological
activity, the .fragment preferably comprising eight (more preferably twenty,
most
81
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
preferably thirty) contiguous amino acids of SEQ ID N0:52, or a polynucleatide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:52
having
biological activity, the fragment comprising the amino acid sequence from
amino acid b5
to amino acid 74 of SEQ ID N0:52.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:51.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
{i) preparing one or mare polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
{aa) SEQ ID N0:51, but excluding the poly(A) tail at the
3' end of SEQ ID N0:51; and
(ab) the nucleotide sequence of the cDNA insert of clone
yb124_1 deposited under accession number ATCC 98864;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
2 0 probe{s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
2 5 the group consisting of:
(ba) SEQ ID NO:51, but excluding the poly(A) tail at the
3' end of SEQ ID N0:51; and
(bb) the nucleotide sequence of the cDNA insert of clone
yb124_1 deposited under accession number ATCC 98864;
3 0 (ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
82
CA 02328062 2000-11-08
WO 99158642 PCTNS99110843
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:51, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:51 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:51
, but
excluding the poly{A) tail at the 3' end of SEQ ID N0:51. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:51 from nucleotide 284 to
nucleotide
706, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:51 from nucleotide 284 to nucleotide 706, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:51 from
nucleotide
284 to nucleotide 706.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID NO:52;
{b) a fragment of the amino acid sequence of SEQ ID NO:52, the
fragment comprising eight contiguous amino acids of SEQ ID N0:52; and
(c) the amino acid sequence encoded by the cDNA insert of clor<e
yb124_1 deposited under accession number ATCC 98864;
2 0 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:52. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:52 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino ands
2 5 of SEQ ID N0:52, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:52 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 65 to amino acid 74 of SEQ ID N0:52.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
3 0 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:53;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:53 from nucleotide 1106 to nucleotide 1447;
83
CA 02328062 2000-11-08
WO 99/58642 PCTNS99110843
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:53 from nucleotide 1187 to nucleotide 1447;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yb125_1 deposited under accession
number ATCC 98864;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yb125_1 deposited under accession number ATCC 98864;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yb125_1 deposited under accession number
ATCC 98864;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yb125_1 deposited under accession number ATCC 98864;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:54;
1 S (i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:54 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:54;
{j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-{g) above;
2 0 (k) a polynucleotide which encodes a species homologue of the protein
of (h) or {i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
2 5 one of the polynucleotides specified in (a)-(i) and that has a length that
is at least
25% of the length of SEQ ID N0:53.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:53 from nucleotide 1106 to nucleotide 1447; the nucleotide sequence of SEQ
ID N0:53
from nucleotide 1187 to nucleotide 1447; the nucleotide sequence of the full-
length
3 0 protein coding sequence of clone yb125_1 deposited under accession number
ATCC
98864; or the nucleotide sequence of a mature protein coding sequence of clone
yb125_1
deposited under accession number ATCC 98864. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yb125_1 deposited under accession number ATCC 98864. In further
preferred
84
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99/10843
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:54 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino ands of SEQ ID N0:54, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:54
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 52
to amino acid 61 of SEQ ID N0:54.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:53. .
2 0 Further embodiments of the invention provide isolated polynucleotides
produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:53, but excluding the poly(A) tail at the
3' end of SEQ ID N0:53; and
(ab) the nucleotide sequence of the cDNA insert of clone
yb125_1 deposited under accession number ATCC 98864;
2 0 (ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 5 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:53, but excluding the poly(A) tail at the
3 0 3' end of SEQ ID N0:53; and
{bb) the nucleotide sequence of the cDNA insert of clone
yb125_1 deposited under accession number ATCC 98864;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
CA 02328062 2000-11-08
WO 99/58642 PC'T/US99/10843
(iii) amplifying human DNA sequences; and
(iv) isolating the polynudeotide products of step (b)(iii).
Preferably the polynudeotide isolated according to the above process comprises
a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:53, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:53 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:53
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:53. Also preferably the
polynudeotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:53 from nucleotide 1106 to
nucleotide
1447, and extending rnntiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:53 from nucleotide 1106 to nucleotide 1447, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:53 from
nucleotide
1106 to nucleotide 1447. Also preferably the polynudeotide isolated according
to the
above process comprises a nucleotide sequence corresponding to the cDNA
sequence of
SEQ ID N0:53 from nucleotide 1187 to nucleotide 1447, and extending
contiguously from
a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:53 from
nucleotide 1187 to nucleotide 1447, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:53 from nucleotide 1187 to nucleotide 1447.
In other embodiments, the present invention provides a composition comprising
2 0 a protein, wherein said protein comprises an amino acid sequence selected
from the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:54;
(b) a fragment of the amino acid sequence of SEQ ID N0:54, the
fragment comprising eight contiguous amino acids of SEQ ID N0:54; and
2 5 (c) the amino add sequence encoded by the cDNA insert of clone
yb125_1 deposited under accession number ATCC 98864;
the protein being substantially flee from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:54. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
3 0 amino acid sequence of SEQ ID N0:54 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino aads
of SEQ ID N0:54, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:54 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 52 to amino acid 61 of SEQ ID N0:54.
86
CA 02328062 2000-11-08
WO 99158642 PCT/US99110843
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ TD
N0:55;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:55 from nucleotide 28 to nucleotide 417;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yb179_1 deposited under accession
number ATCC 98864;
(d) a polynucleotide_ encoding the full-length protein encoded by the
cDNA insert of clone ybI79_1 deposited under accession number ATCC 98864;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yb179_1 deposited under accession number
ATCC 98864;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yb179_1 deposited under accession number ATCC 98864;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:56;
(h) a polynucleotide encoding a protein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:56 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:56;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
2 5 of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (ar(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
3 0 25% of the length of SEQ ID NO:55.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:55 from nucleotide 28 to nucleotide 417; the nucleotide sequence of the
full-length
protein coding sequence of clone yb179_1 deposited under accession number ATCC
98864; or the nucleotide sequence of a mature protein coding sequence of clone
yb179_1
87
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
deposited under accession number ATCC 98864. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yb179_1 deposited under accession number ATCC 98864. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:56 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:56, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:56
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 60
to amino acid 69 of SEQ ID N0:56.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:55.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:55, but excluding the poly(A) tail at the
2 0 3' end of SEQ ID N0:55; and
(ab) the nucleotide sequence of the cDNA insert of clone
yb179_1 deposited under accession number ATCC 98864;
{ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 5 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:55, but excluding the poly(A) tail at the
3' end of SEQ ID N0:55; and
88
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(bb) the nucleotide sequence of the cDNA insert of clone
yb179_1 deposited under accession number ATCC 98864;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b}(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:55, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:55 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:55
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:55. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:55 from nucleotide 28 to
nucleotide
417, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ iD N0:55 from nucleotide 28 to nucleotide 417, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:55 from
nucleotide
28 to nucleotide 417.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:56;
(b) a fragment of the amino acid sequence of SEQ ID NO:56, the
fragment comprising eight contiguous amino acids of SEQ ID N0:56; and
(c) the amino acid sequence encoded by the cDNA insert of clone
2 5 yb179_1 deposited under accession number ATCC 98864;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:56. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ TD N0:56 having biological activity, the fragment
preferably
3 0 comprising eight (more preferably twenty, most preferably thirty)
contiguous amino acids
of SEQ ID N0:56, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:56 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 60 to amino acid 69 of SEQ ID N0:56.
89
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
in one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:57;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:57 from nucleotide 56 to nucleotide 1084;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:57 from nucleotide 107 to nucleotide 1084;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yc48_1 deposited under accession
number
ATCC 98864;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yc48_1 deposited under accession number ATCC 98864;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yc4$_1 deposited under accession number ATCC
98864;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yc48_1 deposited under accession number ATCC 98864;
(h) a polynucleotide encoding a protein comprising the amino acid
2 0 sequence of SEQ ID N0:58;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:58 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:58;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
2 5 (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynudeotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
3 0 (m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:57.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:57 from nucleotide 56 to nucleotide 1084; the nucleotide sequence of SEQ ID
N0:57
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
from nucleotide 107 to nucleotide 1084; the nucleotide sequence of the full-
length protein
coding sequence of clone yc48_1 deposited under accession number ATCC 98864;
or the
nucleotide sequence of a mature protein coding sequence of clone yc48_1
deposited under
accession number ATCC 98864. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yc48_1
deposited under accession number ATCC 98864. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:58 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:58, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:58 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 166 to amino acid
175 of
SEQ ID N0:58.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
1 S ID N0:57.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
2 0 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:57, but excluding the poly(A) tail at the
3' end of SEQ ID N0:57; and
(ab) the nucleotide sequence of the cDNA insert of clone
2 5 yc48_1 deposited under accession number ATCC 98864;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
3 0 and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
91
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99/10843
(ba) SEQ ID N0:57, but excluding the poly(A) tail at the
3' end of SEQ ID N0:57; and
(bb) the nucleotide sequence of the cDNA insert of clone
yc48_1 deposited under accession number ATCC 98864;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
{iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:57, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:57 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:57
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:57. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:57 from nucleotide 56 to
nucleotide
1084, and extending rnntiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:57 from nucleotide 56 to nucleotide 1084, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:57 from
nucleotide
56 to nucleotide 1084. Also preferably the polynucleotide isolated according
to the above
2 0 process comprises a nucleotide sequence corresponding to the cDNA sequence
of SEQ ID
N0:57 from nucleotide 107 to nucleotide 1084, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:57 from
nucleotide 107 to nucleotide 1084, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:57 from nucleotide 107 to nucleotide 1084.
2 5 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:58;
(b) a fragment of the amino acid sequence of SEQ ID N0:58, the
3 0 fragment comprising eight contiguous amino acids of SEQ ID N0:58; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yc48_1 deposited under accession number ATCC 98864;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:58. In further
preferred
92
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:58 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty} contiguous
amino ands
of SEQ ID N0:58, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:58 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 166 to amino acid 175 of SEQ ID N0:58.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:59;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:59 from nucleotide 373 to nucleotide 660;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:59 from nucleotide 436 to nucleotide 660;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ye21 1 deposited under accession
number
ATCC 98864;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ye21_1 deposited under accession number ATCC 98864;
2 0 (f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ye21 1 deposited under accession number ATCC
98864;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ye21 1 deposited under accession number ATCC 98864;
2 5 (h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:60;
(i) a polynudeotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:60 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:60;
3 0 (j) a polynucleotide which is an allelic variant of, a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
93
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10$43
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-{i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:59.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:59 from nucleotide 373 to nucleotide 660; the nucleotide sequence of SEQ ID
N0:59
from nucleotide 436 to nucleotide 660; the nucleotide sequence of the full-
length protein
coding sequence of clone ye21_1 deposited under accession number ATCC 98864;
or the
nucleotide sequence of a mature protein coding sequence of clone ye21_1
deposited under
accession number ATCC 98864. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone ye21 1
deposited under accession number ATCC 98864. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:60 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:60, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:60 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 43 to amino acid
52 of SEQ
2 0 ID N0:60.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:59.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
2 S {a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:59, but excluding the poly(A) tail at the
3 0 3' end of SEQ ID N0:59; and
(ab) the nucleotide sequence of the cDNA insert of clone
ye21 1 deposited under accession number ATCC 98864;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
94
CA 02328062 2000-11-08
WO 99158642 PCTNS99/10843
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or mare polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:59, but excluding the poly(A) tail at the
3' end of SEQ ID N0:59; and
(bb) the nucleotide sequence of the cDNA insert of clone
ye21 1 deposited under accession number ATCC 98864;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynudeotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:59, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:59 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:59
, but
2 0 excluding the poly(A) tail at the 3' end of SEQ ID N0:59. Also preferably
the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:59 from nucleotide 373 to
nucleotide
660, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:59 from nucleotide 373 to nucleotide 660, to a
nucleotide
2 5 sequence corresponding to the 3' end of said sequence of SEQ ID N0:59 from
nucleotide
373 to nucleotide 660. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:59 from nucleotide 436 to nucleotide 660, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:59 from
3 0 nucleotide 436 to nucleotide 660, to a nucleotide sequence corresponding
to the 3' end of
said sequence of SEQ ID N0:59 from nucleotide 436 to nucleotide 660.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(a) the amino acid sequence of SEQ ID N0:60;
(b) a fragment of the amino acid sequence of SEQ ID N0:60, the
fragment comprising eight contiguous amino acids of SEQ ID N0:60; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ye21 1 deposited under accession number ATCC 98864;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID NO:60. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequ~ce of SEQ ID N0:60 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:60, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:60 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 43 to amino acid 52 of SEQ ID N0:60.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a} a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:61;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:61 from nucleotide 119 to nucleotide 466;
2 0 (c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ye22_1 deposited under accession
number
ATCC 98864;
{d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ye22_1 deposited under accession number ATCC 98864;
2 5 (e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ye22_1 deposited under accession number ATCC
98864;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ye22_1 deposited under accession number ATCC 98864;
3 0 (g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:62;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:62 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:62;
96
CA 02328062 2000-11-08
WO 99/58642 PCTNS99110843
{i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h) and that has a length that is
at least
25% of the length of SEQ ID N0:61.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:61 from nucleotide 119 to nucleotide 466; the nucleotide sequence of the
full-length
protein coding sequence of clone ye22_1 deposited under accession number ATCC
98864;
or the nucleotide sequence of a mature protein coding sequence of clone ye22_1
deposited
under accession number ATCC 98864. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone ye22_1 deposited under accession number ATCC 98864. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:62 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
2 0 preferably thirty) contiguous amino acids of SEQ ID N0:62, or a
polynucleotide encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:62
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 53
to amino acid 62 of SEQ ID N0:62.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:61.
Further embodiments of the invention provide isolated poiynucleotides produced
according to a process self from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
3 0 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID NO:61, but excluding the poly(A} tail at the
3' end of SEQ ID N0:61; and
97
CA 02328062 2000-11-08
WO 99158642 PCT/US99/10843
(ab) the nucleotide sequence of the cDNA insert of clone
ye22_1 deposited under accession number ATCC 98864;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleoHdes detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65. degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:61, but excluding the poly(A) tail at the
3' end of SEQ ID N0:61; and
(bb) the nucleotide sequence of the cDNA insert of clone
ye22_1 deposited under accession number ATCC 98864;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 0 Preferably the polynucieotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:61, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:61 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:61,
but
excluding the poly(A) tail at the 3' end of SEQ ID N0:61. Also preferably the
2 5 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:61 from nucleotide 119 to
nucleotide
466, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:61 from nucleotide 119 to nucleotide 466, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:61 from
nucleotide
3 0 119 to nucleotide 466.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:62;
98
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99110843
(b) a fragment of the amino acid sequence of SEQ ID N0:62, the
fragment comprising eight contiguous amino acids of SEQ ID N0:62; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ye22_1 deposited under accession number ATCC 98864;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:62. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:62 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:62, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:62 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 53 to amino acid 62 of SEQ ID N0:62.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:63;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:63 from nucleotide 1212 to nucleotide 1502;
(c) a polynucleotide comprising the nucleotide sequence of the full-
2 0 length protein coding sequence of clone ye39_1 deposited under accession
number
ATCC 98861;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ye39_1 deposited under accession number ATCC 98861;
(e) a.polynucleotide comprising the nucleotide sequence of a mature
2 5 protein coding sequence of done ye39_1 deposited under accession number
ATCC
98861;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ye39_1 deposited under accession number ATCC 98861;
(g) a polynucleotide encoding a protein comprising the amino acid
3 0 sequence of SEQ ID N0:64;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:64 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:64;
99
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynudeotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynudeotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (ar(h) and that has a length that is
at least
25% of the length of SEQ ID N0:63.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:63 from nucleotide 1212 to nucleotide 1502; the nucleotide sequence of the
full-length
protein coding sequence of clone ye39_1 deposited under accession number ATCC
98861;
or the nucleotide sequence of a mature protein coding sequence of clone ye39_1
deposited
under accession number ATCC 98861. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone ye39_1 deposited under accession number ATCC 98861. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:64 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
2 0 preferably thirty) contiguous amino acids of SEQ ID N0:64, or a
polynucleotide encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID NO:b4
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 43
to amino acid 52 of SEQ ID N0:64.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 5 ID N0:63.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a} a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
3 0 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:63, but excluding the poly{A) tail at the
3' end of SEQ ID N0:63; and
100
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(ab) the nucleotide sequence of the cDNA insert of clone
ye39_i deposited under accession number ATCC 98861;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
{i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:63, but excluding the poly(A) tail at the
3' end of SEQ ID N0:63; and
(bb) the nucleotide sequence of the cDNA insert of clone
. ye39_1 deposited under accession number ATCC 98861;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:63, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:63 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:63
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:63. Also preferably the
2 5 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:63 from nucleotide 1212 to
nucleotide
1502, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:63 from nucleotide 1212 to nucleotide 1502, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:63 from
nucleotide
3 0 1212 to nucleotide 1502.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:64;
101
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(b) a fragment of the amino acid sequence of SEQ ID N0:64, the
fragment comprising eight contiguous amino acids of SEQ ID N0:64; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ye39_1 deposited under accession number ATCC 98861;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:64. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:64 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino ands
of SEQ ID N0:64, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:64 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 43 to amino acid 52 of SEQ ID N0:64.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:65;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:65 from nucleotide 81 to nucleotide 887;
(c) a polynucleotide comprising the nucleotide sequence of the full-
2 0 length protein coding sequence of clone yf9_1 deposited under accession
number
ATCC 98861;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yf9_1 deposited under accession number ATCC 98861;
(e) a polynucleotide comprising the nucleotide sequence of a mature
2 5 protein coding sequence of clone yf9_1 deposited under accession number
ATCC
98861;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yf9_1 deposited under accession number ATCC 98861;
(g) a polynucleotide encoding a protein comprising the amino acid
3 0 sequence of SEQ ID N0:66;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:66 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:66;
102
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99/10843
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-{f) above;
(j) a polynudeotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynudeotides specified in (ar(h); and
(1) a polynudeotide that hybridizes under stringent~conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
250 of the length of SEQ ID N0:65.
Preferably, such polynudeotide comprises the nucleotide sequence of SEQ ID
N0:65 from nucleotide 81 to nucleotide 887; the nucleotide sequence of the
full-length
protein coding sequence of done yf9_1 deposited under accession number ATCC
98861;
or the nucleotide sequence of a mature protein coding sequence of clone yf9_1
deposited
under accession number ATCC 98861. Tn other preferred embodiments, the
25 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone yf9_1 deposited under accession number ATCC 98861. In further
preferred
embodiments, the present invention provides a polynudeotide encoding a protein
comprising a fragment of the amino acid sequence of SEQ ID N0:66 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
2 0 preferably thirty) contiguous amino acids of SEQ ID NO:b6, or a
polynucleotide encoding
a protein comprising a fragment of the amino add sequence of SEQ ID N0:66
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 129
to amino acid 138 of SEQ ID N0:66.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 5 ID N0:65.
Further embodiments of the invention provide isolated polynudeotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynudeotide probes that hybridize
3 0 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
{aa) SEQ ID N0:65; and
(ab) the nucleotide sequence of the cDNA insert of clone
yf9_1 deposited under accession number ATCC 98861;
103
CA 02328062 2000-11-08
WO 99158642 PCT/US99/10843
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b} a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:65; and
(bb) the nucleotide sequence of the cDNA insert of clone
yf9_1 deposited under accession number ATCC 98861;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleoHde products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:65, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
2 0 ID N0:65 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:65 . Also
preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:65 from
nucleotide 81 to nucleotide 887, and extending contiguously from a nucleotide
sequence
corresponding to the 5' end of said sequence of SEQ ID N0:65 from nucleotide
81 to
2 5 nucleotide 887, to a nucleotide sequence corresponding to the 3' end of
said sequence of
SEQ ID N0:65 from nucleotide 81 to nucleotide 887.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
3 0 (a) the amino acid sequence of SEQ ID N0:66;
(b) a fragment of the amino acid sequence of SEQ ID N0:66, the
fragment comprising eight contiguous amino acids of SEQ ID N0:66; and
(c} the amino acid sequence encoded by the cDNA insert of clone yf9_1
deposited under accession number ATCC 98861;
104
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:66. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:66 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:66, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:66 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 129 to amino acid 138 of SEQ ID N0:66.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:67;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:67 from nucleotide 63 to nucleotide 305;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yh4_1 deposited under accession number
ATCC 98861;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yh4 1 deposited under accession number ATCC 98861;
2 0 (e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yh4_1 deposited under accession number ATCC
98861;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yh4_1 deposited under accession number ATCC 98861;
2 5 (g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:68;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:68 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:68;
3 0 (i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-{f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
105
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h) and that has a length that is
at least
25% of the length of SEQ ID N0:67.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:67 from nucleotide 63 to nucleotide 305; the nucleotide sequence of the
full-length
protein coding sequence of clone yh4_1 deposited under accession number ATCC
98861;
or the nucleotide sequence of a mature protein coding sequence of clone yh4_1
deposited
under accession number ATCC 98861. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yh4_1 deposited under accession number ATCC 98861. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:68 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:68, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:68
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 35
to amino acid 44 of SEQ ID N0:68.
2 0 Other embodiments provide the gene corresponding to the cDNA sequ~ce of
SEQ
ID N0:67.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
{a) a process comprising the steps of:
2 5 (i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:67, but excluding the poly(A) tail at the
3' end of SEQ ID N0:67; and
3 0 (ab) the nucleotide sequence of the cDNA insert of clone
yh4_1 deposited under accession number ATCC 98861;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
106
CA 02328062 2000-11-08
WO 99158642 PCTNS99/10843
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:67, but excluding the poly(A) tail at the
3' end of SEQ ID N0:67; and
2 0 (bb) the nucleotide sequence of the cDNA insert of clone
yh4_1 deposited under accession number ATCC 98861;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:67, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:67 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:67
, but
2 0 excluding the poly(A) tail at the 3' end of SEQ ID N0:67. Also preferably
the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:67 from nucleotide 63 to
nucleotide
305, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:67 from nucleotide 63 to nucleotide 305, to a
nucleotide
2 5 sequence corresponding to the 3' end of said sequence of SEQ ID N0:67 from
nucleotide
63 to nucleotide 305.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
3 0 (a) ~ the amino acid sequence of SEQ ID N0:68;
(b) a fragment of the amino acid sequence of SEQ ID N0:68, the
fragment comprising eight contiguous amino acids of SEQ ID N0:68; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yh4_1 deposited under accession number ATCC 98861;
107
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:68. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:68 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:68, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:68 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 35 to amino acid 44 of SEQ ID N0:68.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:69;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:69 from nucleotide 332 to nucleotide 685;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:69 from nucleotide 422 to nucleotide 685;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yi4_1 deposited under accession number
ATCC 98861;
2 0 (e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yi4_1 deposited under accession number ATCC 98861;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yi4_1 deposited under accession number ATCC
98861;
2 5 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yi4_1 deposited under accession number ATCC 98861;
{h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:70;
(i) a polynucleotide encoding a protein comprising a fragment of the
3 0 amino acid sequence of SEQ ID N0:70 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:70;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
108
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:69.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:69 from nucleotide 332 to nucleotide 685; the nucleotide sequence of SEQ ID
N0:69
from nucleotide 422 to nucleotide 685; the nucleotide sequence of the full-
length protein
coding sequence of clone yi4_1 deposited under accession number ATCC 98861; or
the
nucleotide sequence of a mature protein coding sequence of clone yi4_1
deposited under
accession number ATCC 98861. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yi4_1
deposited under accession number ATCC 98861. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:70 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:70, or a polynucleotide encoding a protein comprising
a
2 0 fragment of the amino acid sequence of SEQ ID N0:70 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 54 to amino acid
63 of SEQ
ID N0:70.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:69.
2 5 Further embodiments of the invention provide isolated polynucleotides
produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
3 0 consisting of:
(aa) SEQ ID N0:69, but excluding the poly(A) tail at the
3' end of SEQ ID N0:69; and
(ab) the nucleotide sequence of the cDNA insert of clone
yi4_1 deposited under accession number ATCC 98861;
109
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(ii) hybridizing said probe{s) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:69, but excluding the poly(A) tail at the
3' end of SEQ ID N0:69; and
(bb) the nucleotide sequence of the cDNA insert of clone
yi4_1 deposited under accession number ATCC 98861;
(ii) hybridizing said primer{s) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:69, and
2 0 extending contiguously from a nucleotide sequence corresponding to the 5'
end of SEQ
ID N0:69 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:69
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:69. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:69 from nucleotide 332 to
nucleotide
2 5 685, and extending contiguously from a nucleotide sequence corresponding
to the 5' end
of said sequence of SEQ ID N0:69 from nucleotide 332 to nucleotide 685, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:69 from
nucleotide
332 to nucleotide 685. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
3 0 N0:69 from nucleotide 422 to nucleotide 685, and extending contiguously
from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:69 from
nucleotide 422 to nucleotide 685, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:69 from nucleotide 422 to nucleotide 685.
110
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:70;
(b) a fragment of the amino acid sequence of SEQ ID N0:70, the
fragment comprising eight contiguous amino acids of SEQ ID N0:70; and
(c) the amino acid sequence encoded by the cDNA insert of clone yi4_1
deposited under accession number ATCC 98861;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:70. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino.acid sequence of SEQ ID N0:70 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:70, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:70 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 54 to amino acid 63 of SEQ ID N0:70.
In one embodiment, the present invention provides a composition comprising an
isolated polynudeotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:71;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:71 from nucleotide I43 to nucleotide 502;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:71 from nucleotide 203 to nucleotide 502;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yj3_1 deposited under accession number
ATCC 98861;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yj3_1 deposited under accession number ATCC 98861;
3 0 (f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yj3_1 deposited under accession number ATCC
98861;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yj3_i deposited under accession number ATCC 98861;
111
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:72;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:72 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:72;
(j) a polynucleotide which is an allelic variant of a polynudeotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in {a~(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in {a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:71.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:71 from nucleotide 143 to nucleotide 502; the nucleotide sequ~ce of SEQ ID
N0:71
from nucleotide 203 to nucleotide 502; the nucleotide sequence of the full-
length protein
coding sequence of clone yj3_1 deposited under accession number ATCC 98861; or
the
nucleotide sequence of a mature protein coding sequence of clone yj3_1
deposited under
2 0 accession number ATCC 98861. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yj3_1
deposited under accession number ATCC 98861. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:72 having biological activity, the
fragment
2 5 preferably rnmprising eight (more preferably twenty, most preferably
thirty) contiguous
amino acids of SEQ ID N0:72, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:72 having biological
activity, the
fragment rnmprising the amino acid sequence from amino acid 55 to amino acid
64 of SEQ
ID N0:72.
3 0 Other embodiments provide the gene corresponding to the cDNA sequence of
SEQ
ID N0:71.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
112
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(i) preparing one or more polynucleatide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:71, but excluding the poly(A) tail at the
3' end of SEQ ID N0:71; and
(ab) the nucleotide sequence of the cDNA insert of clone
yj3_1 deposited under accession number ATCC 98861;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating. the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:71, but excluding the poly(A) tail at the
3' end of SEQ ID N0:71; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 0 yj3_1 deposited under accession number ATCC 98861;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b){iii).
2 5 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:71, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:71 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:71,
but
excluding the poly(A) tail at the 3' end of SEQ ID N0:71. Also preferably the
3 0 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:71 from nucleotide 143 to
nucleotide
502, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:71 from nucleotide 143 to nucleotide 502, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:71 from
nucleotide
113
CA 02328062 2000-11-08
PCTlUS99/10843
143 to nucleotide 502. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:71 from nucleotide 203 to nucleotide 502, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:71 from
nucleotide 203 to nucleotide 502, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:71 from nucleotide 203 to nucleotide 502.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:72;
(b) a fragment of the amino acid sequence of SEQ ID N0:72, the
fragment comprising eight contiguous amino acids of SEQ ID N0:72; and
(c) the amino acid sequence encoded by the cDNA insert of clone yj3_1
deposited under accession number ATCC 98861;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:72. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:72 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino ands
2 0 of SEQ ID N0:72, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:72 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 55 to amino acid 64 of SEQ ID N0:72.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:73;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:73 from nucleotide 30 to nucleotide 1004;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:73 from nucleotide 129 to nucleotide 1004;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yj7 1 deposited under accession number
ATCC 98861;
114
CA 02328062 2000-11-08
WO 99158642 PCTIUS99/10843
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yj7_1 deposited under accession number ATCC 98861;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yj7 1 deposited under accession number ATCC
98861;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yj7 1 deposited under accession number ATCC 98861;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:74;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:74 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:74;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
2 0 one of the polynucleotides specified in (a)-(i) and that has a length that
is at least
25% of the length of SEQ ID N0:73.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:73 from nucleotide 30 to nucleotide 1004; the nucleotide sequence of SEQ ID
N0:73
from nucleotide 129 to nucleotide 1004; the nucleotide sequence of the full-
length protein
coding sequence of clone yj7 1 deposited under accession number ATCC 98861; or
the
nucleotide sequence of a mature protein coding sequence of clone yj7 1
deposited under
accession number ATCC 98861. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yj7_1
deposited under accession number ATCC 98861. In further preferred embodiments,
the
3 0 present invention provides a polynucleotide encoding a protein comprising
a fragment
of the amino acid sequence of SEQ ID N0:74 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:74, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:74 having biological
activity, the
115
CA 02328062 2000-11-08
WO 99158642 PCT/US99/10843
fragment comprising the amino acid sequence from amino acid 157 to amino acid
166 of
SEQ ID N0:74.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:73.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:73, but excluding the poly(A) tail at the
3' end of SEQ ID N0:73; and
(ab) the nucleotide sequence of the cDNA insert of clone
yj7 1 deposited under accession number ATCC 98861;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
{iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:73, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:73; and
(bb) the nucleotide sequence of the cDNA insert of clone
yj7 1 deposited under accession number ATCC 98861;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step {b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:73, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
116
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
ID N0:73 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:73
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:73. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:73 from nucleotide 30 to
nucleotide
1004, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:73 from nucleotide 30 to nucleotide 1004, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:73 from
nucleotide
30 to nucleotide 1004. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:73 from nucleotide 129 to nucleotide 1004, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:73 from
nucleotide 129 to nucleotide 1004, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:73 from nucleotide 129 to nucleotide 1004.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:74;
(b) a fragment of the amino acid sequence of SEQ ID N0:74, the
fragment comprising eight contiguous amino acids of SEQ ID N0:74; and
2 0 (c) the amino acid sequence encoded by the cDNA insert of clone yj7 1
deposited under accession number ATCC 98861;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:74. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
2 5 amino acid sequence of SEQ ID N0:74 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:74, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:74 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 157 to amino acid 166 of SEQ ID N0:74.
3 0 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) a polynudeotide comprising the nucleotide sequence of SEQ ID
N0:75;
117
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99/10843
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:75 from nucleotide 109 to nucleotide 1047;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yjl0_1 deposited under accession
number
ATCC 98861;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yj20_1 deposited under accession number ATCC 98861;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yjl0_1 deposited under accession number ATCC
98861;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yjl0_1 deposited under accession number ATCC 98861;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:76;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:76 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:76;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
2 0 (j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (ar(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
2 5 one of the polynucleotides specified in (a)-(h) and that has a length that
is at least
25% of the length of SEQ ID N0:75.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:75 from nucleotide 109 to nucleotide 1047; the nucleotide sequence of the
full-length
protein coding sequence of clone yjl0_1 deposited under accession number ATCC
98861;
3 0 or the nucleotide sequence of a mature protein coding sequence of clone
yjl0_1 deposited
under accession number ATCC 98861. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yjl0_1 deposited under accession number ATCC 98861. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
118
CA 02328062 2000-11-08
WO 99/58642 PCT/US99110843
comprising a fragment of the amino acid sequence of SEQ ID N0:76 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:76, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:76
having
biological activity, the fragment comprising the amino acid sequence from
amino and 151
to amino acid 160 of SEQ ID N0:76.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:75.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
1 S (aa) SEQ ID N0:75, but excluding the poly(A) tail at the
3' end of SEQ ID N0:75; and
(ab) the nucleotide sequence of the cDNA insert of clone
yjl0_1 deposited under accession number ATCC 98861;
(ii) hybridizing said probes) to human genomic DNA in
2 0 conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
2 5 (i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:75, but excluding the poly(A) tail at the
3' end of SEQ ID N0:75; and
3 0 (bb) the nucleotide sequence of the cDNA insert of clone
yjl0_1 deposited under accession number ATCC 98861;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
119
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:75, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:75 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:75
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:75. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:75 from nucleotide 109 to
nucleotide
1047, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:75 from.nucleotide 109 to nucleotide 1047, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:75 from
nucleotide
109 to nucleotide 2047.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:76;
(b) a fragment of the amino acid sequence of SEQ ID N0:76, the
fragment comprising eight contiguous amino acids of SEQ ID N0:76; and
(c) the amino acid sequence encoded by the cDNA insert of clone
2 0 yjl0_1 deposited under accession number ATCC 98861;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:76. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:76 having biological activity, the fragment
preferably
2 5 comprising eight (more preferably twenty, most preferably thirty)
contiguous amino acids
of SEQ ID N0:76, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:76 having biological activity, the fragment comprising the amino acid
sequence
from amino acid I51 to amino. acid 160 of SEQ ID N0:76.
In one embodiment, the present invention provides a composition comprising an
3 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:77;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:77 from nucleotide 42 to nucleotide 1196;
120
CA 02328062 2000-11-08
WO 99158642 PCTNS99/10843
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:77 from nucleotide 558 to nucleotide 1196;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yj28_1 deposited under accession
number
ATCC 98861;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yj28_1 deposited under accession number ATCC 98861;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yj28_1 deposited under accession number ATCC
98861;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yj28_1 deposited under accession number ATCC 98861;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:78;
{i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:78 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:78;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g} above;
2 0 (k) a polynucleotide which encodes a species homologue of the protein
of (h} or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
2 5 one of the polynucleotides specified in (a)-(i) and that has a length that
is at least
25% of the length of SEQ TD N0:77.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:77 from nucleotide 42 to nucleotide 1196; the nucleotide sequence of SEQ ID
N0:77
from nucleotide 558 to nucleotide 1196; the nucleotide sequence of the full-
length protein
3 0 coding sequence of clone yj28_1 deposited under accession number ATCC
98861; or the
nucleotide sequence of a mature protein coding sequence of clone yj28_1
deposited under
accession number ATCC 98861. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yj28_1
deposited under accession number ATCC 98861. In further preferred embodiments,
the
121
CA 02328062 2000-11-08
WO 99/58642 PCT/US99110843
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:78 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:78, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:78 having biological
activity, the
fragment rnmprising the amino acid sequence from amino acid 187 to amino acid
196 of
SEQ ID N0:78.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:77.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:77, but excluding the poly(A) tail at the
3' end of SEQ ID N0:77; and
(ab) the nucleotide sequence of the cDNA insert of clone
yj28_1 deposited under accession number ATCC 98861;
2 0 (ii) hybridizing said probe{s) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 5 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID NO:77, but excluding the poly(A) tail at the
3 0 3' end of SEQ ID N0:77; and
(bb) the nucleotide sequence of the cDNA insert of clone
yj28_1 deposited under accession number ATCC 98861;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
122
CA 02328062 2000-11-08
WO 99/58642 PC'T/US99/10843
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:77, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:77 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:77
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:77. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:77 from nucleotide 42 to
nucleotide
1196, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:77 from nucleotide 42 to nucleotide 1196, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:77 from
nucleotide
42 to nucleotide 1196. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:77 from nucleotide 558 to nucleotide 1196, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:77 from
nucleotide 558 to nucleotide 1196, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:77 from nucleotide 558 to nucleotide 1196.
In other embodiments, the present invention provides a composition comprising
2 0 a protein, wherein said protein comprises an amino acid sequence selected
from the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:78;
(b) a fragment of the amino acid sequence of SEQ ID N0:78, the
fragment comprising eight contiguous amino acids of SEQ ID N0:78; and
2 5 (c} the amino acid sequence encoded by the cDNA insert of clone
yj28_1 deposited under accession number ATCC 98861;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:78. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
3 0 amino acid sequence of SEQ ID N0:78 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:78, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:78 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 187 to amino acid 196 of 5EQ ID N0:78.
123
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:79;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:79 from nucleotide 29 to nucleotide 1156;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:79 from nucleotide 995 to nucleotide 1156;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yj29_1 deposited under accession
number
ATCC 98861;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yj29_1 deposited under accession number ATCC 98861;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yj29_1 deposited under accession number ATCC
98861;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yj29_l deposited under accession number ATCC 98861;
(h) a polynucleotide encoding a protein comprising the amino acid
2 0 sequence of SEQ ID N0:80;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:80 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID NO:80;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
2 5 (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
3 0 (m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:79.
Preferably, such polynudeotide comprises the nucleotide sequence of SEQ ID
N0:79 from nucleotide 29 to nucleotide 1156; the nucleotide sequence of SEQ ID
N0:79
124
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99I10843
from nucleotide 995 to nucleotide 1156; the nucleotide sequence of the full
length protein
coding sequence of clone yj29_1 deposited under accession number ATCC 98861;
or the
nucleotide sequence of a mature protein coding sequence of clone yj29_1
deposited under
accession number ATCC 98861. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yj29_1
deposited under accession number ATCC 98861. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:80 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:80, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:80 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 183 to amino acid
192 of
SEQ ID N0:80.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:79.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
2 0 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:79, but excluding the poly(A) tail at the
3' end of SEQ ID N0:79; and
(ab) the nucleotide sequence of the cDNA insert of clone
2 5 yj29_1 deposited under accession number ATCC 98861;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
3 0 and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
125
CA 02328062 2000-11-08
WO 99!58642 PCT/US99/10843
(ba) SEQ ID N0:79, but excluding the poly(A) tail at the
3' end of SEQ ID N0:79; and
(bb) the nucleotide sequence of the cDNA insert of clone
yj29_1 deposited under accession number ATCC 98861;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:79, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:79 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:79
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:79. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:79 from nucleotide 29 to
nucleotide
1156, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:79 from nucleotide 29 to nucleotide 1156, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:79 from
nucleotide
29 to nucleotide 1156. Also preferably the polynucleotide isolated according
to the above
2 0 process comprises a nucleotide sequence corresponding to the cDNA sequence
of SEQ ID
N0:79 from nucleotide 995 to nucleotide 1156, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:79 from
nucleotide 995 to nucleotide 1156, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:79 from nucleotide 995 to nucleotide 1156.
2 5 In other embodiments, the present inv~tion provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:80;
(b) a fragment of the amino acid sequence of SEQ ID NO:80, the
3 0 fragment comprising eight contiguous amino acids of SEQ ID N0:80; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yj29_1 deposited under accession number ATCC 98861;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino and sequence of SEQ ID N0:80. In further preferred
126
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:80 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:80, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:80 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 283 to amino acid 192 of SEQ ID N0:80.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:81;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:81 from nucleotide 93 to nucleotide 398;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:81 from nucleotide 321 to nucleotide 398;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yj32_1 deposited under accession
number
ATCC 98861;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yj32_1 deposited under accession number ATCC 98861;
2 0 (f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yj32_1 deposited under accession number ATCC
98861;
{g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yj32_1 deposited under accession number ATCC 98861;
2 5 (h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:82;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:82 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:82;
3 0 (j) a polynucleotide which is an allelic variant of a polynucleotide of
(a}-{g} above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i} above ;
127
CA 02328062 2000-11-08
WO 99158642 PCTNS99/10843
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:81.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:81 from nucleotide 93 to nucleotide 398; the nucleotide sequence of SEQ ID
N0:81
from nucleotide 321 to nucleotide 398; the nucleotide sequence of the full-
length protein
coding sequence of clone yj32_1 deposited under accession number ATCC 98861;
or the
nucleotide sequence of a mature protein coding sequence of clone yj32_1
deposited under
accession number ATCC 98861. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yj32_1
deposited under accession number ATCC 98861. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:82 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:82, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:82 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 46 to amino acid
55 of SEQ
2 0 ID N0:82.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:81.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
2 5 (a) a process comprising the steps of:
(i) preparing one or more polynlicleotide probes that hybridize
in bX SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:81, but excluding the poly(A) tail at the
3 0 3' end of SEQ ID N0:81; and
(ab) the nucleotide sequence of the cDNA insert of clone
yj32_1 deposited under accession number ATCC 98861;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
128
CA 02328062 2000-11-08
WO 99/58642 PCT/US99110843
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:81, but excluding the poly(A) tail at the
3' end of SEQ ID N0:81; and
(bb) the nucleotide sequence of the cDNA insert of clone
yj32_1 deposited under accession number ATCC 98861;
(ii) hybridizing said primer{s) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b){iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:81, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:81 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:81
, but
2 0 excluding the poly(A) tail at the 3' end of SEQ ID N0:81. Also preferably
the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
rnrresponding to the cDNA sequence of SEQ ID N0:81 from nucleotide 93 to
nucleotide
398, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:81 from nucleotide 93 to nucleotide 398, to a
nucleotide
2 5 sequence corresponding to the 3' end of said sequence of SEQ ID N0:81 from
nucleotide
93 to nucleotide 398. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:81 from nucleotide 321 to nucleotide 398, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:81 from
3 0 nucleotide 321 to nucleotide 398, to a nucleotide sequence corresponding
to the 3' end of
said sequence of SEQ ID N0:81 from nucleotide 321 to nucleotide 398.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
129
CA 02328062 2000-11-08
WO 99/58642 PCT/US99I10843
(a) the amino acid sequence of SEQ ID N0:82;
(b) ~ a fragment of the amino acid sequence of SEQ ID N0:82, the
fragment comprising eight contiguous amino acids of SEQ ID N0:82; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yj32_1 deposited under accession number ATCC 98861;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:82. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:82 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:82, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:82 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 46 to amino acid 55 of SEQ ID N0:82.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:83;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:83 from nucleotide 167 to nucleotide 1264;
2 0 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:83 from nucleotide 233 to nucleotide 1264;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yb186_1 deposited under accession
number ATCC 98872;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yb186_1 deposited under accession number ATCC 98872;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yb186_1 deposited under accession number
ATCC 98872;
3 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yb186_1 deposited under accession number ATCC 98872;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:84;
130
CA 02328062 2000-11-08
WO 99158642 PCTNS99I10843
(i} a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:84 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:84;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i}; and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (ar(i) and that has a length that is
at least
25% of the length of SEQ ID N0:83.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:83 from nucleotide 167 to nucleotide 1264; the nucleotide sequence of SEQ
ID N0:83
from nucleotide 233 to nucleotide 1264; the nucleotide sequence of the full-
length protein
coding sequence of clone yb186_1 deposited under accession number ATCC 98872;
or the
nucleotide sequence of a mature protein coding sequence of clone yb186_1
deposited
under accession number ATCC 98872. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
2 0 of clone yb186_1 deposited under accession number ATCC 98872. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:84 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:84, or a polynucleotide
encoding
2 5 a protein comprising a fragment of the amino acid sequence of SEQ ID N0:84
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 178
to amino acid 187 of SEQ ID N0:84.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:83.
3 0 Further embodiments of the invention provide isolated polynucleotides
produced
according to a process selected from the group consisting of:
(a} a process comprising the steps of:
131
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(i) preparing one or more polynudeotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:83, but excluding the poly(A) tail at the
3' end of SEQ ID N0:83; and
(ab) the nucleotide sequence of the cDNA insert of clone
yb186_i deposited under accession number ATCC 98872;
{ii) hybridizing said probes) to human Qennm;~ nt~a ;"
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating . the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) ~ preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:83, but excluding the poly(A) tail at the
3' end of SEQ ID N0:83; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 0 yb186_1 deposited under accession number ATCC 98872;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:83, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:83 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:83
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:83. Also preferably the
3 0 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:83 from nucleotide 167 to
nucleotide
1264, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:83 from nucleotide 167 to nucleotide 1264, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:83 from
nucleotide
132
CA 02328062 2000-11-08
WO 99/58642 PCTIUS991f 0843
167 to nucleotide 1264. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:83 from nucleotide 233 to nucleotide 1264, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:83 from
nucleotide 233 to nucleotide 1264, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:83 from nucleotide 233 to nucleotide 1264.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:84;
(b) a fragment of the amino acid sequence of SEQ ID N0:84, the
fragment comprising eight contiguous amino acids of SEQ ID N0:84; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yb186_1 deposited under accession number ATCC 98872;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:84. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:84 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 0 of SEQ ID N0:84, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:84 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 178 to amino acid 187 of SEQ ID N0:84.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
2 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:85;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:85 from nucleotide 832 to nucleotide 1416;
(c) a polynucleotide comprising the nucleotide sequence of the full-
3 0 length protein coding sequence of clone yb226_1 deposited under accession
number ATCC 98872;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yb226_1 deposited under accession number ATCC 98872;
I33
CA 02328062 2000-11-08
WO 99158642 PCTNS99/10843
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yb226_1 deposited under accession number
ATCC 98872;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yb226_1 deposited under accession number ATCC 98872;
(g} a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:86;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:86 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:86;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a poiynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:85.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:85 from nucleotide 832 to nucleotide 1416; the nucleotide sequence of the
full-length
protein coding sequence of clone yb226_1 deposited under accession number ATCC
98872; or the nucleotide sequence of a mature protein coding sequence of clone
yb226_1
deposited under accession number ATCC 98872. In other preferred embodiments,
the
2 5 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone yb226_1 deposited under accession number ATCC 98872. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:86 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
3 0 preferably thirty} contiguous amino acids of SEQ ID N0:86, or a
polynucleotide encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:86
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 92
to amino acid 101 of SEQ ID N0:86.
134
CA 02328062 2000-11-08
WO 99/58642 PCT/US99110843
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:85.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:85, but excluding the poly(A) tail at the
3' end of SEQ ID N0:85; and
(ab) the nucleotide sequence of the cDNA insert of clone
yb226_1 deposited under accession number ATCC 98872;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
2 0 hybridize in 6X SSC at b5 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:85, but excluding the poly(A) tail at the
3' end of SEQ ID N0:85; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 5 yb226_1 deposited under accession number ATCC 98872;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
3 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:85, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:85 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:85
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:85. Also preferably the
135
CA 02328062 2000-11-08
WO 99158642 PCT/US99/10843
polynucleotide isolated acrnrding to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:85 from nucleotide 832 to
nucleotide
1416, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:85 from nucleotide 832 to nucleotide 1416, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:85 from
nucleotide
832 to nucleotide 1416.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:86;
(b) a fragment of the amino acid sequence of SEQ ID N0:86, the
fragment comprising eight contiguous amino acids of SEQ ID N0:86; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yb226_1 deposited under accession number ATCC 98872;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:86. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:86 having biological activity, the fragment
preferably
comprising eight {more preferably twenty, most preferably thirty) contiguous
amino acids
2 0 of SEQ ID N0:86, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:86 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 92 to amino acid 101 of SEQ ID N0:86.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
2 5 (a} a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:87;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:87 from nucleotide 155 to nucleotide 745;
(c) a polynucleotide comprising the nucleotide sequence of the full-
3 0 length protein coding sequence of clone yd50 1 deposited under accession
number ATCC 98872;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yd50_1 deposited under accession number ATCC 98872;
136
CA 02328062 2000-11-08
WO 99158642 PCTIUS99110843
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yd50_1 deposited under accession number
ATCC 98872;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yd50_1 deposited under accession number ATCC 98872;
{g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:88;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:88 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:88;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a}-{f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or {h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleoddes specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:87.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
NO:87 from nucleotide 155 to nucleotide 745; the nucleotide sequence of the
full-length
protein coding sequence of clone yd50_1 deposited under accession number ATCC
98872;
or the nucleotide sequence of a mature protein coding sequence of clone yd50_1
deposited
under accession number ATCC 98872. In other preferred embodiments, the
2 5 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone yd50_1 deposited under accession number ATCC 98872. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:88 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
3 0 preferably thirty) contiguous amino acids of SEQ ID N0:88, or a
polynucleotide encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:88
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 93
to amino acid 102 of SEQ ID N0:88.
137
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:87.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa} SEQ ID N0:87, but excluding the poly(A) tail at the
3' end of SEQ ID N0:87; and
(ab) the nucleotide sequence of the cDNA insert of clone
yd50_1 deposited under accession number ATCC 98872;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
2 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:87, but excluding the poly(A) tail at the
3' end of SEQ ID N0:87; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 5 yd50_1 deposited under accession number ATCC 98872;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
3 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:87, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:87 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:87
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:87. Also preferably the
138
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:87 from nucleotide 155 to
nucleotide
745, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:87 from nucleotide 155 to nucleotide 745, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:87 from
nucleotide
155 to nucleotide 745.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:88;
(b) a fragment of the amino acid sequence of SEQ ID N0:88, the
fragment comprising eight contiguous amino acids of SEQ ID N0:88; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yd50_1 deposited under accession number ATCC 98872;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:88. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:88 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 0 of SEQ ID N0:88, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:88 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 93 to amino acid 102 of SEQ ID N0:88.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
2 5 (a} a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:89;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:89 from nucleotide 42 to nucleotide 317;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:89 from nucleotide 111 to nucleotide 327;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yd51_1 deposited under accession
number ATCC 98872;
139
CA 02328062 2000-11-08
WO 99/58642 PCT1t1S99/10843
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yd51_1 deposited under accession number ATCC 98872;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yd51_1 deposited under accession number
ATCC 98872;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yd51_1 deposited under accession number ATCC 98872;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:90;
(i) a polynudeotide, encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:90 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:90;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
2 0 one of the polynucleotides specified in (a)-(i) and that has a length that
is at least
25% of the length of SEQ ID N0:89.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:89 from nucleotide 42 to nucleotide 317; the nucleotide sequence of SEQ ID
N0:89
from nucleotide 111 to nucleotide 317; the nucleotide sequence of the full-
length protein
2 5 coding sequence of clone yd51 I deposited under accession number ATCC
98872; or the
nucleotide sequence of a mature protein coding sequence of clone yd51 1
deposited under
accession number ATCC 98872. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yd5i 1
deposited under accession number ATCC 98872. In further preferred embodiments,
the
3 0 present invention provides a polynucleoHde encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:90 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:90, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:90 having biological
activity, the
140
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
fragment comprising the amino and sequence from amino acid 41 to amino acid 50
of SEQ
ID N0:90.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:89.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in bX SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:89, but excluding the poly(A) tail at the
3' end of SEQ ID N0:89; and
(ab) the nucleotide sequence of the cDNA insert of clone
yd51_1 deposited under accession number ATCC 98872;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probes};
and
2 0 (b) a process comprising the steps of:
(i} preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C'to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:89, but excluding the poly(A) tail at the
3' end of SEQ ID N0:89; and
(bb) the nucleotide sequence of the cDNA insert of clone
yd51 1 deposited under accession number ATCC 98872;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv} isolating the polynucleotide products of step (b)(iii}.
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:89, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
141
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
ID N0:89 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:89
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:89. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:89 from nucleotide 42 to
nucleotide
317, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:89 from nucleotide 42 to nucleotide 317, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:89 from
nucleotide
42 to nucleotide 327. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:89 from nucleotide 111 to nucleotide 317, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:89 from
nucleotide 111 to nucleotide 317, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:89 from nucleotide 111 to nucleotide 317.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino and sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:90;
(b) a fragment of the amino acid sequence of SEQ ID N0:90, the
fragment comprising eight contiguous amino acids of SEQ ID N0:90; and
2 0 (c) the amino acid sequence encoded by the cDNA insert of clone
yd51 1 deposited under accession number ATCC 98872;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:90. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
2 5 amino acid sequence of SEQ ID N0:90 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, mast preferably thirty) contiguous
amino aclds
of SEQ ID N0:90, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:90 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 41 to amino acid 50 of SEQ ID N0:90.
3 0 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:91;
142
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:91 from nucleotide 7 to nucleotide 603;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:91 from nucleotide 244 to nucleotide 603;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yd73_1 deposited under accession
number ATCC 98872;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yd73_1 deposited under accession number ATCC 98872;
(f) a polynucleotide, comprising the nucleotide sequence of a mature
protein coding sequence of clone yd73_1 deposited under accession number
ATCC 98872;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yd73_1 deposited under accession number ATCC 98872;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:92;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:92 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:92;
2 0 (j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of {h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
2 5 one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:91.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
3 0 N0:91 from nucleotide 7 to nucleotide 603; the nucleotide sequence of SEQ
ID N0:91 from
nucleotide 244 to nucleotide 603; the nucleotide sequence of the full-length
protein coding
sequence of clone yd73_1 deposited under accession number ATCC 98872; or the
nucleotide sequence of a mature protein coding sequence of clone yd73_1
deposited under
accession number ATCC 98872. In other preferred embodiments, the
polynucleotide
143
CA 02328062 2000-11-08
WO 99/58641 PCT/US99/10843
encodes the full length or a mature protein encoded by the cDNA insert of
clone yd73_1
deposited under accession number ATCC 98872. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:92 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID NO:92, or a polynudeotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:92 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 94 to amino acid
103 of
SEQ ID N0:92.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:91.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at b5 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:91, but excluding the poly(A) tail at the
3' end of SEQ ID N0:91; and
2 0 (ab) the nucleotide sequence of the cDNA insert of clone
yd73_I deposited under accession number ATCC 98872;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
2 5 probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
3 0 the group consisting of:
(ba) SEQ ID N0:91, but excluding the poly(A) tail at the
3' end of SEQ ID N0:91; and
(bb) the nucleotide sequence of the cDNA insert of done
yd73_1 deposited under accession number ATCC 98872;
144
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv} isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:91, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:91 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:91,
but
excluding the poly(A) tail at the 3' end of SEQ ID N0:91. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:91 from nucleotide 7 to
nucleotide
603, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:91 from nucleotide 7 to nucleotide 603, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:91 from
nucleotide
7 to nucleotide 603. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:91 from nucleotide 244 to nucleotide 603, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:91 from
nucleotide 244 to nucleotide 603, to a nucleotide sequence corresponding to
the 3' end of
2 0 said sequence of SEQ ID N0:91 from nucleotide 244 to nucleotide 603.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:92;
2 5 (b) a fragment of the amino acid sequence of SEQ ID N0:92, the
fragment comprising eight contiguous amino acids of SEQ ID N0:92; and
(c) the amino acld sequence encoded by the cDNA insert of clone
yd73_1 deposited under accession number ATCC 98872;
the protein being substantially free from other mammalian proteins. Preferably
such
3 0 protein comprises the amino acid sequence of SEQ ID N0:92. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:92 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino ands
of SEQ ID N0:92, or a protein comprising a fragment of the amino acid sequence
of SEQ
145
CA 02328062 2000-11-08
WO 99/58642 PCT/US99I10843
ID N0:92 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 94 to amino acid 103 of SEQ ID N0:92.
In one embodiment, the present invention provides a composition comprising an
isolated polynudeotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:93;
(b) a polynudeotide comprising the nucleotide sequence of SEQ ID
N0:93 from nucleotide 367 to nucleotide 747;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:93 from nucleotide 667 to nucleotide 747;
{d) a polynudeotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ye43_1 deposited under accession
number
ATCC 98872; '
(e) a polynudeotide encoding the full-length protein encoded by the
cDNA insert of clone ye43_1 deposited under accession number ATCC 98872;
(f) a polynudeotide comprising the nucleotide sequence of a mature
protein coding sequence of done ye43_1 deposited under accession number ATCC
98872;
(g) a polynudeotide encoding a mature protein encoded by the cDNA
2 0 insert of clone ye43_i deposited under accession number ATCC 98872;
{h) a polynudeotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:94;
{i} a polynudeotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:94 having biological activity, the fragment
2 5 comprising eight contiguous amino acids of SEQ ID N0:94;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
{a)-(g) above;
(k) a polynudeotide which encodes a species homologue of the protein
of (h) or (i) above ;
3 0 (1) a polynudeotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(i); and
(m) a polynudeotide that hybridizes under stringent conditions to any
one of the polynudeotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:93.
146
CA 02328062 2000-11-08
WO 99/58642 PCT1US99/10843
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:93 from nucleotide 367 to nucleotide 747; the nucleotide sequence of SEQ ID
N0:93
from nucleotide 667 to nucleotide 747; the nucleotide sequence of the full-
length protein
coding sequence of clone ye43_1 deposited under accession number ATCC 98872;
or the
nucleotide sequence of a mature protein coding sequence of clone ye43_1
deposited under
accession number ATCC 98872. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone ye43_1
deposited under accession number ATCC 98872. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:94 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ 1T7 N0:94, or a polynucleotide encoding a protein
comprising a
fragment of the amino acid sequence of SEQ ID N0:94 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 58 to amino acid
67 of SEQ
ID N0:94.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:93.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
2 0 (a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:93, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:93; and
(ab) the nucleotide sequence of the cDNA insert of clone
ye43_1 deposited under accession number ATCC 98872;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
3 0 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
147
CA 02328062 2000-11-08
WO 99/58642 ~ PCTlUS99110843
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:93, but excluding the poly(A) tail at the
3' end of SEQ ID N0:93; and
(bb) the nucleotide sequence of the cDNA insert of clone
ye43_1 deposited under accession number ATCC 98872;
(ii) hybridizing said primer{s) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:93, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:93 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:93
, but
excluding the poly(A) tail at the 3' end of SEQ TD N0:93. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:93 from nucleotide 367 to
nucleotide
747, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
2 0 of said sequence of SEQ ID N0:93 from nucleotide 367 to nucleotide 747, to
a nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:93 from
nucleotide
367 to nucleotide 747. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:93 from nucleotide 667 to nucleotide 747, and extending contiguously from a
2 5 nucleotide sequence con~esponding to the 5' end of said sequence of SEQ ID
N0:93 from
nucleotide 667 to nucleotide 747, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:93 from nucleotide 667 to nucleotide 747.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
3 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:94;
(b) a fragment of the amino acid sequence of SEQ ID N0:94, the
fragment comprising eight contiguous amino acids of SEQ ID NO:94; and
148
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(c) the amino acid sequence encoded by the cDNA insert of clone
ye43_1 deposited under accession number ATCC 98872;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:94. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:94 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:94, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:94 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 58 to amino acid 67 of SEQ ID N0:94.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:95;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:95 from nucleotide 632 to nucleotide 1492;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:95 from nucleotide 1460 to nucleotide 1492;
(d) a polynucleotide comprising the nucleotide sequence of the full-
2 0 length protein coding sequence of clone yh71 1 deposited under accession
number
ATCC 98872;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yh71_1 deposited under accession number ATCC 98872;
(f) a polynucleotide comprising the nucleotide sequence of a mature
2 5 protein coding sequence of clone yh71_1 deposited under accession number
ATCC
98872;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yh71 1 deposited under accession number ATCC 98872;
(h) a polynucleotide encoding a protein comprising the amino acid
3 0 sequence of SEQ ID N0:96;
(i) a polynucleotide enrnding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:96 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:96;
149
CA 02328062 2000-11-08
WO 99158642 PCT/US99110843
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynudeotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (ar(i) and that has a length that is
at least
25% of the length of SEQ ID N0:95.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:95 from nucleotide 632 to nucleotide 1492; the nucleotide sequence of SEQ
ID N0:95
from nucleotide 1460 to nucleotide 1492; the nucleotide sequence of the full-
length
protein coding sequence of clone yh71_1 deposited under accession number ATCC
98872;
or the nucleotide sequence of a mature protein coding sequence of clone yh71_1
deposited
under accession number ATCC 98872. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yh71 1 deposited under accession number ATCC 98872. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:96 having
biological
2 0 activity, the fragment preferably comprising eight (more preferably
twenty, most
preferably thirty) contiguous amino acids of SEQ ID N0:96, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:96
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 138
to amino acid 147 of SEQ ID N0:96.
2 5 Other embodiments provide the gene corresponding to the cDNA sequence of
SEQ
ID N0:95.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
3 0 (i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID NO:95, but excluding the poly(A) tail at the
3' end of SEQ ID N0:95; and
150
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(ab) the nucleotide sequence of the cDNA insert of clone
yh71_1 deposited under accession number ATCC 98872;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65.degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:95, but excluding the poly(A) tail at the
3' end of SEQ ID N0:95; and
(bb) the nucleotide sequence of the cDNA insert of clone
yh71 1 deposited under accession number ATCC 98872;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b}(iii).
2 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:95, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:95 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:95
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:95. Also preferably the
2 5 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:95 from nucleotide 632 to
nucleotide
1492, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:95 from nucleotide 632 to nucleotide 1492, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:95 from
nucleotide
3 0 632 to nucleotide 1492. Also preferably the polynucleotide isolated
according to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:95 from nucleotide 1460 to nucleotide 1492, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:95 from
151
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
nucleotide 1460 to nucleotide 1492, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:95 from nucleotide 1460 to nucleotide 1492.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:96;
(b) a fragment of the amino acid sequence of SEQ ID N0:96, the
fragment comprising eight contiguous amino acids of SEQ ID N0:96; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yh71 1 deposited under accession number ATCC 98872;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:96. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:96 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:96, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:96 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 138 to amino acid 147 of SEQ ID N0:96.
In one embodiment, the present invention provides a composition comprising an
2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:97;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:97 from nucleotide 349 to nucleotide 771;
2 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:97 from nucleotide 490 to nucleotide 771;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yh100_1 deposited under accession
number ATCC 98872;
3 0 (e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yh100_1 deposited under accession number ATCC 98872;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yh100_1 deposited under accession number
ATCC 98872;
152
CA 02328062 2000-11-08
WO 99/58642 PCT/US99110843
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yhl~ 1 deposited under accession number ATCC 98872;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:98;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:98 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:98;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which enrndes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:97.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:97 from nucleotide 349 to nucleotide 771; the nucleotide sequence of SEQ ID
N0:97
from nucleotide 490 to nucleotide 771; the nucleotide sequence of the full-
length protein
2 0 coding sequence of clone yh100_1 deposited under accession number ATCC
98872; or the
nucleotide sequence of a mature protein coding sequence of clone yh100_1
deposited
under accession number ATCC 98872. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yh100_1 deposited under accession number ATCC 98872. In further
preferred
2 5 embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:98 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:98, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:98
having
3 0 biological activity, the fragment comprising the amino acid sequence from
amino acid 65
to amino acid 74 of SEQ ID N0:98.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:97.
153
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
Further embodiments of the invention provide isolated polynucleoddes produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:97, but excluding the poly(A) tail at the .
3' end of SEQ ID N0:97; and
(ab} the nucleotide sequence of the cDNA insert of clone
yhl~ 1 deposited under accession number ATCC 98872;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
2 0 (ba) SEQ ID N0:97, but excluding the poly(A) tail at the
3' end of SEQ ID N0:97; and
(bb) the nucleotide sequence of the cDNA insert of clone
yh100_1 deposited under accession number ATCC 98872;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii} amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:97, and
3 0 extending contiguously from a nucleotide sequence corresponding to the 5'
end of SEQ
ID N0:97 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:97
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:97. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:97 from nucleotide 349 to
nucleotide
154
CA 02328062 2000-11-08
WO 99/58642 PCTNS99I10843
771, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:97 from nucleotide 349 to nucleotide 771, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:97 from
nucleotide
349 to nucleotide 771. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:97 from nucleotide 490 to nucleotide 771, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:97 from
nucleotide 490 to nucleotide 771, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:97 from nucleotide 490 to nucleotide 771.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:98;
(b) a fragment of the amino acid sequence of SEQ ID N0:98, the
fragment comprising eight contiguous amino acids of SEQ ID N0:98; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yh100_1 deposited under accession number ATCC 98872;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:98. In further
preferred
2 0 embodiments, the present invention provides a protein comprising a
fragment of the
amino acid sequence of SEQ ID N0:98 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino adds
of SEQ ID N0:98, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:98 having biological activity, the fragment comprising the amino acid
sequence
2 5 from amino acid 65 to amino acid 74 of SEQ ID N0:98.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:99;
3 0 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:99 from nucleotide 165 to nucleotide 416;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:99 from nucleotide 261 to nucleotide 416;
155
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yi3_1 deposited under accession number
ATCC 98872;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yi3_1 deposited under accession number ATCC 98872;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yi3_i deposited under accession number ATCC
98872;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
I O insert of clone yi3 1 deposited under accession number ATCC 98872;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:100;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:100 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:100;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
2 0 (1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:99.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:99 from nucleotide 165 to nucleotide 416; the nucleotide sequence of SEQ ID
N0:99
from nucleotide 261 to nucleotide 416; the nucleotide sequence of the full-
length protein
coding sequence of clone yi3_1 deposited under accession number ATCC 98872; or
the
nucleotide sequence of a mature protein coding sequence of clone yi3_1
deposited under
3 0 accession number ATCC 98872. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yi3_1
deposited under accession number ATCC 98872. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID NO:100 having biological activity, the
fragment
156
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/108A3
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:100, or a polynucleotide encoding a protein
comprising a
fragment of the amino acid sequence of SEQ ID N0:100 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 37 to amino and 46
of SEQ
ID N0:100.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:99.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:99, but excluding the poly(A) tail at the
3' end of SEQ ID N0:99; and
(ab) the nucleotide sequence of the cDNA insert of clone
yi3_1 deposited under accession number ATCC 98872;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 0 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
2 5 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba} SEQ ID N0:99, but excluding the poly(A) tail at the
3' end of SEQ ID N0:99; and
(bb) the nucleotide sequence of the cDNA insert of clone
3 0 yi3_1 deposited under accession number ATCC 98872;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
157
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:99, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:99 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:99
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:99. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:99 from nucleotide 165 to
nucleotide
416, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:99 from nucleotide 165 to nucleotide 416, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:99 from
nucleotide
165 to nucleotide 416. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:99 from nucleotide 261 to nucleotide 416, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:99 from
nucleotide 261 to nucleotide 416, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:99 from nucleotide 261 to nucleotide 416.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
2 0 (a) the amino acid sequence of SEQ ID N0:100;
(b) a fragment of the amino acid sequence of SEQ ID N0:100, the
fragment comprising eight contiguous amino acids of SEQ ID N0:100; and
(c) the amino acid sequence encoded by the cDNA insert of clone yi3_1
deposited under accession number ATCC 98872;
2 5 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:100. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID NO:100 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
3 0 of SEQ ID N0:100, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID NO:I00 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 37 to amino acid 46 of SEQ ID NO:100.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
158
CA 02328062 2000-11-08
WO 99158642 PCT/US99/10843
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:101;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:101 from nucleotide 141 to nucleotide 995;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:101 from nucleotide 213 to nucleotide 995;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yj23_1 deposited under accession
number
ATCC 98872;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yj23_1 deposited under accession number ATCC 98872;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yj23_1 deposited under accession number ATCC
98872;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yj23_1 deposited under accession number ATCC 98872;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:102;
(i) a polynucleotide encoding a protein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:102 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:102;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(ar(g) above;
{k) a polynucleotide which encodes a species homologue of the protein
2 5 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
3 0 25% of the length of SEQ ID NO:lOI.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:101 from nucleotide 141 to nucleotide 995; the nucleotide sequence of SEQ
ID N0:101
from nucleotide 213 to nucleotide 995; the nucleotide sequence of the full-
length protein
coding sequence of clone yj23_1 deposited under accession number ATCC 98872;
or the
159
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
nucleotide sequence of a mature protein coding sequence of clone yj23_1
deposited under
accession number ATCC 98872. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yj23_1
deposited under accession number ATCC 98872. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:102 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:102, or a polynucleotide encoding a protein
comprising a
fragment of the amino acid sequence of SEQ ID N0:102 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 137 to amino acid
146 of
SEQ ID N0:102.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:101.
Further embodiments of the invention provide isalated polynudeotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
2 0 (aa) SEQ ID N0:101, but excluding the poly{A) tail at the
3' end of SEQ ID N0:101; and
(ab) the nucleotide sequence of the cDNA insert of clone
yj23_1 deposited under accession number ATCC 98872;
(ii) hybridizing said probes) to human genomic DNA in
2 5 conditions at least as stringent as 4X SSC at 50 degrees C; and
{iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
3 0 (i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:101, but excluding the poly(A) tail at the
3' end of SEQ ID N0:101; and
160
CA 02328062 2000-11-08
WO 99/58642 PCTNS99110843
(bb) the nucleotide sequence of the cDNA insert of clone
yj23_1 deposited under accession number ATCC 98872;
(ii) hybridizing said primer{s) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:101, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID NO:101 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:101, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:101. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:101 from nucleotide 141 to
nucleotide
995, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:101 from nucleotide 141 to nucleotide 995, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID NO:101 from
nucleotide
141 to nucleotide 995. Also preferably the poiynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:101 from nucleotide 213 to nucleotide 995, and extending contiguously from
a
2 0 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:101 from
nucleotide 213 to nucleotide 995, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:101 from nucleotide 213 to nucleotide 995.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
2 5 consisting of:
(a) the amino acid sequence of SEQ ID N0:102;
(b) a fragment of the amino acid sequence of SEQ ID N0:102, the
fragment comprising eight contiguous amino acids of SEQ ID N0:102; and
(c) the amino acid sequence encoded by the cDNA insert of clone
3 0 yj23_1 deposited under accession number ATCC 98872;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:102. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:102 having biological activity, the fragment
preferably
161
CA 02328062 2000-11-08
WO 99158642 PCTNS99/10843
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:102, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:102 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 137 to amino acid 146 of SEQ ID N0:102.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:103;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:103 from nucleotide 13 to nucleotide 747;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:103 from nucleotide 67 to nucleotide 747;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone y19_1 deposited under accession number
ATCC 98872;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone y19_1 deposited under accession number ATCC 98872;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone y19_1 deposited under accession number ATCC
2 0 98872;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone y19_1 deposited under accession number ATCC 98872;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:104;
2 5 (i) a polynucleotide encoding a protein comprising a. fragment of the
amino acid sequence of SEQ ID N0:104 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:104;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
3 0 (k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
162
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:103.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:103 from nucleotide 13 to nucleotide 747; the nucleotide sequence of SEQ ID
N0:103
from nucleotide 67 to nucleotide 747; the nucleotide sequence of the full-
length protein
coding sequence of clone yl9_1 deposited under accession number ATCC 98872; or
the
nucleotide sequence of a mature protein coding sequence of clone y19_1
deposited under
accession number ATCC 98872. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone y19_1
deposited under accession number ATCC 98872. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:104 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:104, or a polynucleotide encoding a protein
comprising a
fragment of the amino acid sequence of SEQ ID N0:104 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 117 to amino acid
126 of
SEQ ID N0:104.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:103.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:103, but excluding the poly(A) tail at the
3' end of SEQ ID N0:103; and
(ab) the nucleotide sequence of the cDNA insert of clone
3 0 y19_1 deposited under accession number ATCC 98872;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
163
CA 02328062 2000-11-08
WO 99!58642 PGTIUS99I10843
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:103, but excluding the poly(A) tail at the
3' end of SEQ ID N0:103; and
(bb) the nucleotide sequence of the cDNA insert of clone
y19_1 deposited under accession number ATCC 98872;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:103, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID NO:I03 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:103 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:103. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
2 0 corresponding to the cDNA sequence of SEQ ID N0:103 from nucleotide 13 to
nucleotide
747, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:103 from nucleotide 13 to nucleotide 747, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:103 from
nucleotide
13 to nucleotide 747. Also preferably the polynucleotide isolated according to
the above
2 5 process comprises a nucleotide sequence corresponding to the cDNA sequence
of SEQ ID
N0:103 from nucleotide 67 to nucleotide 747, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:103 from
nucleotide 67 to nucleotide 747, to a nucleotide sequence corresponding to the
3' end of
said sequence of SEQ ID N0:103 from nucleotide 67 to nucleotide 747.
3 0 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:104;
164
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
(b) a fragment of the amino acid sequence of SEQ ID N0:104, the
fragment comprising eight contiguous amino acids of SEQ ID N0:104; and
(c) the amino acid sequence encoded by the cDNA insert of clone y19_1
deposited under accession number ATCC 98872;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:104. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:104 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:104, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:104 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 117 to amino acid 126 of SEQ ID N0:104.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:105;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:105 from nucleotide 375 to nucleotide 728;
(c) a polynucleotide comprising the nucleotide sequence of the full-
2 0 length protein coding sequence of clone ya66_1 deposited under accession
number
ATCC 98887;
(d) a polynudeotide encoding the full-length protein encoded by the
cDNA insert of clone ya66_1 deposited under accession number ATCC 98887;
(e) a polynucleotide comprising the nucleotide sequence of a mature
2 5 protein coding sequence of clone ya66_1 deposited under accession number
ATCC
98887;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ya66_1 deposited under accession number ATCC 98887;
(g) a polynucleotide encoding a protein comprising the amino acid
3 0 sequence of SEQ ID N0:106;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:106 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:106;
165
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h} above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (ar(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h) and that has a length that is
at least
25% of the length of SEQ ID N0:105.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:105 from nucleotide 375 to nucleotide 728; the nucleotide sequence of the
full-length
protein coding sequence of clone ya66_1 deposited under accession number ATCC
98887;
or the nucleotide sequence of a mature protein coding sequence of clone ya66_1
deposited
under accession number ATCC 98887. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yak 1 deposited under accession number ATCC 98887. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:106 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
2 0 preferably thirty) contiguous amino acids of SEQ ID N0:106, or a
poiynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:106
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 54 to amino acid 63 of SEQ ID N0:106.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 5 ID N0:105.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
3 0 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:105, but excluding the poly(A) tail at the
3' end of SEQ ID N0:105; and
166
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99/10843
(ab) the nucleotide sequence of the cDNA insert of clone
ya66_1 deposited under accession number ATCC 98887;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleoddes detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at b5 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:105, but excluding the poly(A) tail at the
3' end of SEQ ID N0:105; and
(bb) the nucleotide sequence of the cDNA insert of clone
ya66_1 deposited under accession number ATCC 98887;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:105, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
1:L7 N0:105 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:105 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:105. Also preferably the
2 5 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:105 from nucleotide 375 to
nucleotide
728, and extending contiguously frnm a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:105 from nucleotide 375 to nucleotide 728, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:105 from
nucleotide
3 0 375 to nucleotide 728.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
{a) the amino acid sequence of SEQ ID N0:106;
167
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(b) a fragment of the amino acid sequence of SEQ ID N0:106, the
fragment comprising eight contiguous amino acids of SEQ ID N0:106; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ya66_1 deposited under accession number ATCC 98887;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:106. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:106 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:106, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:106 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 54 to amino acid 63 of SEQ ID N0:106.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:107;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID I
N0:107 from nucleotide 131 to nucleotide 457;
(c) a polynucleotide comprising the nucleotide sequence of the full-
2 0 length protein coding sequence of clone yb187_1 deposited under accession
number ATCC 98887;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yb187 1 deposited under accession number ATCC 98887;
(e) a polynucleotide comprising the nucleotide sequence of a mature
2 5 protein coding sequence of clone yb187_1 deposited under accession number
ATCC 98887;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yb187 1 deposited under accession number ATCC 98887;
(g) a polynucleotide encoding a protein comprising the amino acid
3 0 sequence of SEQ ID N0:108;
{h) a polynudeotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:108 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:108;
168
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(i) a polynudeotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
{1) a polynudeotide that hybridizes under stringent conditions to any
one of the polynudeotides specified in (a~(h) and that has a length that is at
least
25% of the length of SEQ ID N0:207.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:107 from nucleotide 131 to nucleotide 457; the nucleotide sequence of the
full-length
protein coding sequence of done yb187_1 deposited under accession number ATCC
98887; or the nucleotide sequence of a mature protein coding sequence of clone
yb187_1
deposited under accession number ATCC 98887. In other preferred embodiments,
the
polynudeotide encodes the full-length or a mature protein encoded by the cDNA
insert
of done yb187 1 deposited under accession number ATCC 98887. In further
preferred
embodiments, the present invention provides a polynudeotide encoding a protein
comprising a fragment of the amino acid sequence of SEQ ID N0:108 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
2 0 preferably thirty) contiguous amino acids of SEQ ID N0:108, or a
polynudeotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:108
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 49 to amino acid 58 of SEQ ID NO:108.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 5 ID N0:107.
Further embodiments of the invention provide isolated polynudeotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
3 0 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:107, but excluding the poly(A) tail at the
3' end of SEQ ID N0:107; and
169
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
(ab) the nucleotide sequence of the cDNA insert of done
yb187 1 deposited under accession number ATCC 98887;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynudeotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynudeotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:107, but excluding the poly(A) tail at the
3' end of SEQ ID N0:107; and
(bb) the nucleotide sequence of the cDNA insert of clone
yb187 1 deposited under accession number ATCC 98887;
{ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 0 Preferably the polynudeotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:107, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:107 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:107 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:107. Also preferably.
the
2 5 polynudeotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:107 from nucleotide 131 to
nucleotide
457, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:107 from nucleotide 131 to nucleotide 457, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:107 from
nucleotide
3 0 131 to nucleotide 457.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:108;
170
CA 02328062 2000-11-08
WO 99/58642 PCT/US99110843
(b) a fragment of the amino acid sequence of SEQ ID N0:108, the
fragment comprising eight contiguous amino acids of SEQ ID N0:108; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yb187 1 deposited under accession number ATCC 98887;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:108. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:108 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:108, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:108 having biologicai activity, the fragment comprising the amino acid
sequence
from amino acid 49 to amino acid 58 of SEQ ID N0:108.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:109;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:109 from nucleotide 458 to nucleotide 676;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:109 from nucleotide 503 to nucleotide 676;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yb219_1 deposited under accession
number ATCC 98887;
(e) a polynucleotide encoding the full-length protein encoded by the
2 5 cDNA insert of clone yb219_1 deposited under accession number ATCC 98887;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yb219_1 deposited under accession number
ATCC 98887;
(g) a polynucieotide encoding a mature protein encoded by the cDNA
3 0 insert of clone yb219_1 deposited under accession number ATCC 98887;
(h} a polynucieotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:110;
171
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:110 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID NO:110;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
{1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:109.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:109 from nucleotide 458 to nucleotide 676; the nucleotide sequence of SEQ
ID N0:109
from nucleotide 503 to nucleotide 676; the nucleotide sequence of the full-
length protein
coding sequence of clone yb219_1 deposited under accession number ATCC 98887;
or the
nucleotide sequence of a mature protein coding sequence of clone yb219_1
deposited
under accession number ATCC 98887. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
2 0 of clone yb219_1 deposited under accession number ATCC 98887. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:110 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID NO:110, or a
polynucleotide
2 5 encoding a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:110
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 31 to amino acid 40 of SEQ ID N0:110.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:109.
3 0 Further embodiments of the invention provide isolated polynucleotides
produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
172
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:109, but excluding the poly(A) tail at the
3' end of SEQ ID N0:109; and
(ab) the nucleotide sequence of the cDNA insert of clone
yb219_1 deposited under accession number ATCC 98887;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba} SEQ ID N0:109, but excluding the poly(A) tail at the
3' end of SEQ ID N0:109; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 0 yb219_1 deposited under accession number ATCC 98887;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:109, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:109 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:109 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:109. Also preferably the
3 0 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:109 from nucleotide 458 to
nucleotide
676, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:109 from nucleotide 458 to nucleotide 676, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:109 from
nucleotide
173
CA 02328062 2000-11-08
WO 99158642 PCTNS99/10843
458 to nucleotide 676. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:109 from nucleotide 503 to nucleotide 676, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:109 from
nucleotide 503 to nucleotide 676, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:109 from nucleotide 503 to nucleotide 676.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:110;
(b) a fragment of the amino acid sequence of SEQ ID NO:110, the
fragment comprising eight contiguous amino acids of SEQ ID N0:110; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yb219_1 deposited under accession number ATCC 98887;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:110. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:110 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 0 of SEQ ID NO:110, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID NO:I10 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 31 to amino acid 40 of SEQ ID NO:110.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
2 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:111;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:111 from nucleotide 238 to nucleotide 396;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 NO:111 from nucleotide 277 to nucleotide 396;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yb228_1 deposited under accession
number ATCC 98887;
174
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yb228_1 deposited under accession number ATCC 98887;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yb228_1 deposited under accession number
ATCC 98887;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yb228_1 deposited under accession number ATCC 98887;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:112;
2 0 (i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:112 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:112;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
1 S (k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
2 0 one of the polynucleotides specified in (a)-(i) and that has a length that
is at least
25% of the length of SEQ ID N0:111.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:111 from nucleotide 238 to nucleotide 396; the nucleotide sequence of SEQ
ID N0:111
from nucleotide 277 to nucleotide 396; the nucleotide sequence of the full-
length protein
2 5 coding sequence of clone yb228_1 deposited under accession number ATCC
98887; or the
nucleotide sequence of a mature protein coding sequence of clone yb228_1
deposited
under accession number ATCC 98887. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yb228_1 deposited under accession number ATCC 98887. In further
preferred
3 0 embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:112 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:112, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:112
175
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
having biological activity, the fragment rnmprising the amino acid sequence
from amino
acid 21 to amino acid 30 of SEQ ID N0:112.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID NO:111.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
{i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
{aa) SEQ ID NO:111, but excluding the paly(A) tail at the
3' end of SEQ ID N0:111; and
(ab) the nucleotide sequence of the cDNA insert of clone
yb228_1 deposited under accession number ATCC 98887;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:111, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID NO:111; and
(bb) the nucleotide sequence of the cDNA insert of clone
yb228_1 deposited under accession number ATCC 98887;
{ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:111, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
176
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
ID NO:111 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:111, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:111. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:111 from nucleotide 238 to
nucleotide
396, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID NO:I11 from nucleotide 238 to nucleotide 396, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:111 from
nucleotide
238 to nucleotide 396. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:111 from nucleotide 277 to nucleotide 396, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:111 from
nucleotide 277 to nucleotide 396, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:111 from nucleotide 277 to nucleotide 396.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID NO:I12;
(b) a fragment of the amino acid sequence of SEQ ID N0:1I2, the
fragment comprising eight contiguous amino acids of SEQ ID N0:112; and
2 0 (c) the amino acid sequence encoded by the cDNA insert of clone
yb228_1 deposited under accession number ATCC 98887;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:112. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
2 5 amino acid sequence of SEQ ID N0:112 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:112, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:112 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 21 to amino acid 30 of SEQ ID N0:112.
3 0 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) ' a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:113;
177
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:113 from nucleotide 6 to nucleotide 722;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:113 from nucleotide 375 to nucleotide 722;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yc27 1 deposited under accession
number
ATCC 98887;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yc27 1 deposited under accession number ATCC 98887;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yc27 1 deposited under accession number ATCC
98887;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yc27 1 deposited under accession number ATCC 98887;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:114;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:114 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:114;
2 0 (j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
2 5 one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:113.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
3 0 NO:I13 from nucleotide 6 to nucleotide 722; the nucleotide sequence of SEQ
ID N0:1I3
from nucleotide 375 to nucleotide 722; the nucleotide sequence of the full-
length protein
coding sequence of clone yc27 1 deposited under accessian number ATCC 98887;
or the
nucleotide sequence of a mature protein coding sequence of clone yc27 1
deposited under
accession number ATCC 98887. In other preferred embodiments, the
poiynucleotide
178
CA 02328062 2000-11-08
WO 99/58b42 PCT/US99110843
encodes the full length or a mature protein encoded by the cDNA insert of
clone yc27 1
deposited under accession number ATCC 98887. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:114 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, mast preferably thirty)
contiguous
amino acids of SEQ ID N0:114, or a polynucleotide encoding a protein
comprising a
fragment of the amino acid sequence of SEQ ID N0:114 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 114 to amino acid
123 of
SEQ ID N0:114.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:113.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
{a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:113, but excluding the poly(A) tail at the
3' end of SEQ ID N0:113; and
2 0 (ab) the nucleotide sequence of the cDNA insert of clone
yc27_1 deposited under accession number ATCC 98887;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
2 5 probe{s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
3 0 the group consisting of:
(ba) SEQ ID N0:113, but excluding the poly(A) tail at the
3' end of SEQ ID N0:113; and
{bb) the nucleotide sequence of the cDNA insert of clone
yc27 1 deposited under accession number ATCC 98887;
179
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:113, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:113 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:113 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:113. Also preferably the
polynucieotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:113 from nucleotide 6 to
nucleotide
722, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:113 from nucleotide 6 to nucleotide 722, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:113 from
nucleotide
6 to nucleotide 722. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:113 from nucleotide 375 to nucleotide 722, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:113 from
nucleotide 375 to nucleotide 722, to a nucleotide sequence corresponding to
the 3' end of
2 0 said sequence of SEQ ID N0:113 from nucleotide 375 to nucleotide 722.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:114;
2 5 (b) a fragment of the amino acid sequence of SEQ ID N0:114, the
fragment comprising eight contiguous amino acids of SEQ ID N0:114; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yc27 1 deposited under accession number ATCC 98887;
the protein being substantially free from other mammalian proteins. Preferably
such
3 0 protein comprises the amino acid sequence of SEQ ID N0:114. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID NO:114 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:114, or a protein comprising a fragment of the amino acid
sequence of SEQ
180
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
ID N0:114 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 114 to amino acid 123 of SEQ ID N0:114.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
{a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:115;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:115 from nucleotide 382 to nucleotide 681;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yc49_1 deposited under accession
number
ATCC 98887;
{d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yc49_1 deposited under accession number ATCC 98887;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yc49_1 deposited under accession number ATCC
98887;
{f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yc49_1 deposited under accession number ATCC 98887;
(g) a polynucleotide encoding a protein comprising the amino acid
2 0 sequence of SEQ ID N0:116;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:116 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:116;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
2 5 (a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of {g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-{h); and
3 0 (1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h) and that has a length that is
at least
25% of the length of SEQ ID N0:115.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:115 from nucleotide 382 to nucleotide 681; the nucleotide sequence of the
full-length
181
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
protein coding sequence of clone yc49_1 deposited under accession number ATCC
98887;
or the nucleotide sequence of a mature protein coding sequence of clone yc49_1
deposited
under accession number ATCC 98887. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yc49_1 deposited under accession number ATCC 98887. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:116 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:116, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:116
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 45 to amino acid 54 of SEQ ID N0:116.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:115.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
2 0 consisting of: '
(aa) SEQ ID N0:115, but excluding the poly(A) tail at the
3' end of SEQ ID N0:115; and
(ab) the nucleotide sequence of the cDNA insert of clone
yc49_1 deposited under accession number ATCC 98887;
2 5 (ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
3 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
182
CA 02328062 2000-11-08
WO 99158642 PCT/US99I10843
(ba) SEQ ID N0:115, but excluding the poly(A) tail at the
3' end of SEQ ID N0:115; and
(bb) the nucleotide sequence of the cDNA insert of clone
yc49_1 deposited under accession number ATCC 98887;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynudeotide isolated according to the above process comprises
a
nucleotide sequence corresponding to .the cDNA sequence of SEQ ID N0:115, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:115 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:115 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:115. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:115 from nucleotide 382 to
nucleotide
681, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:115 from nucleotide 382 to nucleotide 681, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:115 from
nucleotide
382 to nucleotide 681.
2 0 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:116;
(b) a fragment of the amino acid sequence of SEQ ID N0:116, the
2 5 fragment comprising eight contiguous amino acids of SEQ ID N0:116; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yc49_1 deposited under accession number ATCC 98887;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:116. In further
preferred
3 0 embodiments, the present invention provides a protein comprising a
fragment of the
amino acid sequence of SEQ ID N0:116 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:116, or a protein comprising a fragment of the amino acid
sequence of SEQ
183
CA 02328062 2000-11-08
WO 99158642 PCT/US99110843
ID N0:116 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 45 to amino acid 54 of SEQ ID N0:116.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:117;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:117 from nucleotide 71 to nucleotide 364;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yd40_1 deposited under accession
number ATCC 988$7;
{d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yd40_1 deposited under accession number ATCC 98887;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yd40_1 deposited under accession number
ATCC 98887;
(f) a polynucleotide encoding'a mature protein encoded by the cDNA
insert of clone yd40_1 deposited under accession number ATCC 98887;
(g) a polynucleotide encoding a protein comprising the amino acid
2 0 sequence of SEQ ID N0:118;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:118 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:118;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
3 0 (1) ' a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:117.
Preferably, such polynucleotide comprises the nucleotide~sequence of SEQ ID
N0:117 from nucleotide 71 to nucleotide 364; the nucleotide sequence of the
full-length
184
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
protein coding sequence of clone yd~ 1 deposited under accession number ATCC
98887;
or the nucleotide sequence of a mature protein coding sequence of clone yd40_1
deposited
under accession number ATCC 98887. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yd9:0_1 deposited under accession number ATCC 98887. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID NO:118 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:118, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:118
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 44 to amino acid 53 of SEQ ID N0:118.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:117.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
{i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
2 0 consisting of:
(aa) SEQ ID N0:117, but excluding the poly(A) tail at the
3' end of SEQ ID NO:117; and
(ab) the nucleotide sequence of the cDNA insert of clone
yd4a_1 deposited under accession number ATCC 98887;
2 5 (ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
3 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
185
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(ba) SEQ ID N0:117, but excluding the poly(A) tail at the
3' end of SEQ ID N0:117; and
(bb) the nucleotide sequence of the cDNA insert of clone
yd40_1 deposited under accession number ATCC 98887;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to .the cDNA sequence of SEQ ID N0:117, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:117 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:117 , but
excluding the poly(A) tail at the 3' end of SEQ ID NO:117. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:117 from nucleotide 71 to
nucleotide
364, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:117 from nucleotide 71 to nucleotide 364, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:117 from
nucleotide
71 to nucleotide 364.
2 0 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID NO:118;
(b) a fragment of the amino acid sequence of SEQ ID N0:118, the
2 5 fragment comprising eight contiguous amino acids of SEQ ID N0:118; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yd40_1 deposited under accession number ATCC 98887;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:118. In further
preferred
3 0 embodiments, the present invention provides a protein comprising a
fragment of the
amino acid sequence of SEQ ID N0:118 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:118, or a protein comprising a fragment of the amino acid
sequence of SEQ
186
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
ID N0:118 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 44 to amino acid 53 of SEQ ID N0:118.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:119;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:119 from nucleotide 75 to nucleotide 725;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yd64_1 deposited under accession
number ATCC 98887;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yd~ 1 deposited under accession number ATCC 98887;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yd64_1 deposited under accession number
ATCC 98887;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yd64-1 deposited under accession number ATCC 98887;
(g) a polynucleotide encoding a protein comprising the amino acid
2 0 sequence of SEQ ID N0:120;
(h) a poiynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:120 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:120;
(i) a poiynucleotide which is an allelic variant of a polynucleotide of
2 5 (a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
3 0 (1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (ar(h) and that has a length that is
at least
25% of the length of SEQ ID N0:119.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:119 from nucleotide 75 to nucleotide 725; the nucleotide sequence of the
full-length
187
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
protein coding sequence of clone ydE~_1 deposited under accession number ATCC
98887;
or the nucleotide sequence of a mature protein coding sequence of clone yd64_1
deposited
under accession number ATCC 98887. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone ydE~_1 deposited under accession number ATCC 98887. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:120 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:120, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:120
having biological activity, the fragment comprising the amino acid sequence
from amino
and 103 to amino acid 112 of SEQ ID N0:120.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:119.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
2 0 consisting of:
(aa) SEQ ID N0:119, but excluding the poly(A) tail at the
3' end of SEQ ID N0:119; and
(ab) the nucleotide sequence of the cDNA insert of clone
yd~ 1 deposited under accession number ATCC 98887;
2 5 (ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
3 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
188
CA 02328062 2000-11-08
WO 99/58642 PCT/US99110843
(ba) SEQ ID N0:119, but excluding the poly(A) tail at the
3' end of SEQ ID N0:119; and
(bb) the nucleotide sequence of the cDNA insert of clone
yd~ 1 deposited under accession number ATCC 98887;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(~) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to . the cDNA sequence of SEQ ID N0:119, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:119 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:119 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:119. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:119 from nucleotide 75 to
nucleotide
725, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:119 from nucleotide 75 to nucleotide 725, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:119 from
nucleotide
75 to nucleotide 725.
2 0 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:120;
(b) a fragment of the amino acid sequence of SEQ ID N0:120, the
2 5 fragment comprising eight contiguous amino acids of SEQ ID N0:120; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yd~ 1 deposited under accession number ATCC 98887;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ 1D N0:120. In further
preferred
3 0 embodiments, the present invention provides a protein comprising a
fragment of the
amino acid sequence of SEQ ID N0:120 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:120, or a protein comprising a fragment of the amino acid
sequence of SEQ
189
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
ID N0:120 having biological activity, the fragment comprising the amino acid
sequence
from amina acid 103 to amino acid 112 of SEQ ID N0:120.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:121;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:121 from nucleotide 256 to nucleotide 780;
(c} a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:121 from nucleotide 412 to nucleotide 780;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ye47 1 deposited under accession
number
ATCC 98887;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ye47 1 deposited under accession number ATCC 98887;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ye47 1 deposited under accession number ATCC
98887;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
2 0 insert of clone ye47 1 deposited under accession number ATCC 98887;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:122;
(i) a polynudeotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:122 having biological activity, the fragment
2 5 comprising eight contiguous amino acids of SEQ ID N0:122;
a polynucleotide which is an allelic variant of a polynucleotide of
(a}-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
3 0 (1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in {a~-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:121.
190
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:121 from nucleotide 256 to nucleotide 780; the nucleotide sequence of SEQ
ID N0:121
from nucleotide 412 to nucleotide 780; the nucleotide sequence of the full-
length protein
coding sequence of clone ye47 1 deposited under accession number ATCC 98887;
or the
nucleotide sequence of a mature protein coding sequence of clone ye47 1
deposited under
accession number ATCC 98887. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone ye47 1
deposited under accession number ATCC 98887. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:122 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:122, or a polynucleotide encoding a protein
comprising a
fragment of the amino acid sequence of SEQ 1D N0:122 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 82 to amino acid
91 of SEQ
ID N0:122.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:121.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
2 0 (a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:121, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:121; and
(ab) the nucleotide sequence of the cDNA insert of clone
ye47 1 deposited under accession number ATCC 98887;
{ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
3 0 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
191
CA 02328062 2000-11-08
WO 99/58642 PC'T/US99/10843
(i) preparing, one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:121, but excluding the poly(A) tail at the
3' end of SEQ ID N0:121; and
(bb) the nucleotide sequence of the cDNA insert of done
ye47 1 deposited under accession number ATCC 98887;
{ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:121, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:121 to a nucleotide sequence corresponding to the 8' end of SEQ ID
N0:121, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:121. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:121 kom nucleotide 256 to
nucleotide
780, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
2 0 of said sequence of SEQ ID N0:121 from nucleotide 256 to nucleotide 780,
to a nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:121 kom
nucleotide
256 to nucleotide 780. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:121 from nucleotide 412 to nucleotide 780, and extending contiguously from
a
2 5 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:121 from
nucleotide 412 to nucleotide 780, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:121 from nucleotide 412 to nucleotide 780.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected kom
the group
3 0 consisting of:
(a} the amino acid sequence of SEQ ID N0:122;
(b) a fragment of the amino acid sequence of SEQ ID N0:122, the
fragment comprising eight contiguous amino acids of SEQ ID N0:122; and
192
CA 02328062 2000-11-08
WO 99/58642 PCTNS99I10843
(c) the amino acid sequence encoded by the cDNA insert of clone
ye47 1 deposited under accession number ATCC 98887;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:122. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:122 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:122, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:122 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 82 to amino acid 91 of SEQ ID N0:122.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:123;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:123 from nucleotide 127 to nucleotide 405;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:123 from nucleotide 268 to nucleotide 405;
(d) a polynucleotide comprising the nucleotide sequence of the full-
2 0 length protein coding sequence of clone yh50_1 deposited under accession
number
ATCC 98887;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yh50_1 deposited under accession number ATCC 98887;
(f) a polynucleotide comprising the nucleotide sequence of a mature
2 5 protein coding sequence of clone yh50_1 deposited under accession number
ATCC
98887;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yh50_1 deposited under accession number ATCC 98887;
(h) a polynucleotide encoding a protein comprising the amino acid
3 0 sequence of SEQ ID N0:124;
(i) a polynucleotide encoding a protein rnmprising a fragment of the
amino acid sequence of SEQ ID N0:124 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:124;
193
CA 02328062 2000-11-08
WO 99158642 PCT/US99/10843
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a}-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in {ar(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(i) and that has a length that is
at least
25% of the length of SEQ ID N0:123.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:123 from nucleotide 127 to nucleotide 405; the nucleotide sequence of SEQ
ID N0:123
from nucleotide 268 to nucleotide 405; the nucleotide sequence of the full-
length protein
coding sequence of clone yh50_1 deposited under accession number ATCC 98887;
or the
nucleotide sequence of a mature protein coding sequence of clone yh50_1
deposited under
accession number ATCC 98887. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yh50_1
deposited under accession number ATCC 98887. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:124 having biological activity, the
fragment
2 0 preferably comprising eight (more preferably twenty, most preferably
thirty) contiguous
amino acids of SEQ ID N0:124, or a polynucleotide encoding a protein
comprising a
fragment of the amino acid sequence of SEQ ID N0:124 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 41 to amino acid
50 of SEQ
ID N0:124.
2 5 Other embodiments provide the gene corresponding to the cDNA sequence of
SEQ
ID N0:123.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
3 0 (i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:123, but excluding the poly(A) tail at the
3' end of SEQ ID N0:123; and
194
CA 02328062 2000-11-08
WO 99158642 PCT/US99/10843
(ab) the nucleotide sequence of the cDNA insert of clone
yh50_1 deposited under accession number ATCC 98887;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
S (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynudeotide primers that
hybridize in 6X SSC at 65.degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:123, but excluding the poly{A) tail at the
3' end of SEQ ID N0:123; and
(bb) the nucleotide sequence of the cDNA insert of clone
yh50_1 deposited under accession number ATCC 98887;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b){iii).
2 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:123, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:123 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:123 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:123. Also preferably the
2 5 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:123 from nucleotide 127 to
nucleotide
405, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:123 from nucleotide 227 to nucleotide 405, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:123 from
nucleotide
3 0 127 to nucleotide 405. Also preferably the polynucleotide isolated
according to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:123 from nucleotide 268 to nucleotide 405, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:123 from
195
CA 02328062 2000-11-08
WO 99158642 PCT/US99110843
nucleotide 268 to nucleotide 405, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:123 from nucleotide 268 to nucleotide 405.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:124;
(b) a fragment of the amino acid sequence of SEQ ID N0:124, the
fragment comprising eight contiguous amino acids of SEQ ID N0:124; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yh50_1 deposited under accession number ATCC 98887;
the protein being substantially free from other rriammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:124. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:124 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:124, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:124 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 41 to amino acid 50 of SEQ ID N0:124.
In one embodiment, the present invention provides a composition comprising an
2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:125;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:125 from nucleotide 1175 to nucleotide 1480;
2 5 (c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yh53_1 deposited under accession
number
ATCC 98887;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yh53_1 deposited under accession number ATCC 98887;
3 0 (e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yh53_1 deposited under accession number ATCC
98887;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yh53_1 deposited under accession number ATCC 98887;
196
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:126;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:126 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:126;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h) and that has a length that is
at least
25% of the length of SEQ ID N0:125.
preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:125 from nucleotide 1175 to nucleotide 1480; the nucleotide sequence of the
full-
length protein coding sequence of clone yh53_1 deposited under accession
number ATCC
98887; or the nucleotide sequence of a mature protein coding sequence of clone
yh53_1
deposited under accession number ATCC 98887. In other preferred embodiments,
the
2 0 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone yh53_1 deposited under accession number ATCC 98887. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:126 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
2 5 preferably thirty) contiguous amino acids of SEQ ID N0:126, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:126
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 46 to amino acid 55 of SEQ ID N0:126.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
3 0 ID N0:125.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
197
CA 02328062 2000-11-08
WO 99/58642 PCT/US99110843
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa} SEQ ID N0:125, but excluding the poly(A) tail at the
3' end of SEQ ID N0:125; and
(ab) the nucleotide sequence of the cDNA insert of clone
yh53_1 deposited under accession number ATCC 98887;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
20 (iii) isolating .the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in bX SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:125, but excluding the poly(A) tail at the
3' end of SEQ ID N0:125; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 0 yh53_1 deposited under accession number ATCC 98887;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:125, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:125 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:125 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:125. Also preferably the
3 0 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:125 from nucleotide 1175 to
nucleotide 1480, and extending contiguously from a nucleotide sequence
corresponding
to the 5' end of said sequence of SEQ ID N0:125 from nucleotide 1175 to
nucleotide 1480,
198
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99/10843
to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ
ID N0:125
from nucleotide 1175 to nucleotide 1480.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:126;
(b) a fragment of the amino acid sequence of SEQ ID N0:126, the
fragment comprising eight contiguous amino acids of SEQ ID N0:126; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yh53_1 deposited under accession number ATCC 98887;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:126. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:126 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:126, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:126 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 46 to amino acid 55 of SEQ ID N0:126.
In one embodiment, the present invention provides a composition comprising an
2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:127;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:127 from nucleotide 65 to nucleotide 319;
2 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:127 from nucleotide 173 to nucleotide 319;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yh98_1 deposited under accession
number
ATCC 98887;
3 0 (e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yh98_1 deposited under accession number ATCC 98887;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yh98_1 deposited under accession number ATCC
98887; .
199
CA 02328062 2000-11-08
WO 99/58642 PCT/US99110843
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yh98_1 deposited under accession number ATCC 98887;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:128;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:128 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:128;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleodde that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (ar(i) and that has a length that is
at least
25% of the length of SEQ ID N0:127.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:127 from nucleotide 65 to nucleotide 319; the nucleotide sequence of SEQ ID
NO:127
from nucleotide 173 to nucleotide 319; the nucleotide sequence of the full-
length protein
2 0 coding sequence of clone yh98_1 deposited under accession number ATCC
98887; or the
nucleotide sequence of a mature protein coding sequence of clone yh98_1
deposited under
accession number ATCC 98887. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yh98_1
deposited under accession number ATCC 98887. In further preferred embodiments,
the
2 5 present invention provides a polynucleotide encoding a protein comprising
a fragment
of the amino acid sequence of SEQ ID N0:128 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:128, or a polynucleotide encoding a protein
comprising a
fragment of the amino acid sequence of SEQ ID N0:128 having biological
activity, the
3 0 fragment comprising the amino acid sequence from amino arid 37 to amino
and 46 of SEQ
ID N0:128.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:127.
200
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
Further embodiments of the invention.provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i} preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:127, but excluding the poly(A) tail at the
3' end of SEQ ID N0:127; and
(ab) the nucleotide sequence of the cDNA insert of clone
yh98_1 deposited under accession number ATCC 98887;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
2 0 (ba) SEQ ID N0:127, but excluding the poly(A) tail at the
3' end of SEQ ID N0:127; and
(bb) the nucleotide sequence of the cDNA insert of clone
yh98_1 deposited under accession number ATCC 98887;
{ii) hybridizing said primers) to human genomic DNA in
2 5 conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:127, and
3 0 extending contiguously from a nucleotide sequence corresponding to the 5'
end of SEQ
ID N0:127 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:127 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:127. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:127 from nucleotide 65 to
nucleotide
. 201
CA 02328062 2000-11-08
WO 99/58642 PCT/US99110843
319, and extending contiguously from a nucleotide sequence corresponding to
the 5.' end
of said sequence of SEQ ID N0:127 from nucleotide 65 to nucleotide 319, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:127 from
nucleotide
65 to nucleotide 319. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:127 from nucleotide 173 to nucleotide 319, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:127 from
nucleotide 173 to nucleotide 319, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:127 from nucleotide 173 to nucleotide 319.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:128;
(b) a fragment of the amino acid sequence of SEQ ID N0:128, the
fragment comprising eight contiguous amino acids of SEQ ID N0:128; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yh98_1 deposited under accession number ATCC 98887;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:128. In further
preferred
2 0 embodiments, the present invention provides a protein comprising a
fragment of the
amino acid sequence of SEQ ID N0:128 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:128, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:128 having biological activity, the fragment comprising the amino acid
sequence
2 5 from amino acid 37 to amino acid 46 of SEQ ID N0:128.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:129;
3 0 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:129 from nucleotide 122 to nucleotide 469;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:129 from nucleotide 263 to nucleotide 469;
202
CA 02328062 2000-11-08
WO 99/SS642 PCTNS99110843
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ya69_1 deposited under accession
number
ATCC 98915;
{e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ya69_1 deposited under accession number ATCC 98915;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ya69_2 deposited under accession number ATCC
98915;
(g) a polynucleotide encoding a mature.protein encoded by the cDNA
insert of clone ya69_1 deposited .under accession number ATCC 98915;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:130;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:130 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:130;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
2 0 (1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ II3 N0:129.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:129 from nucleotide 122 to nucleotide 469; the nucleotide sequence of SEQ
ID N0:129
from nucleotide 263 to nucleotide 469; the nucleotide sequence of the full-
length protein
coding sequence of clone ya69_1 deposited under accession number ATCC 98915;
or the
nucleotide sequence of a mature protein coding sequence of clone ya69_1
deposited under
3 0 accession number ATCC 98915. In other preferred embodiments, the
.polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of done
ya69_1
deposited under accession number ATCC 98915. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:130 having biological activity, the
fragment
203
CA 02328062 2000-11-08
WO 99158642 PCT/US99I10843
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino ands of SEQ ID N0:130, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:130 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 53 to amino acid
62 of SEQ
ID N0:130.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:129.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:129, but excluding the poly(A) tail at the
3' end of SEQ ID N0:129; and
(ab) the nucleotide sequence of the cDNA insert of clone
ya69_1 deposited under accession number ATCC 98915;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 0 {iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
2 5 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:129, but excluding the poly{A) tail at the
3' end of SEQ ID N0:129; and
(bb) the nucleotide sequence of the cDNA insert of clone
3 0 ya69_1 deposited under accession number ATCC 98915;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
204
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:129, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:129 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:129 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:129. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:129 from nucleotide 122 to
nucleotide
469, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:129 from nucleotide 122 to nucleotide 469, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:129 from
nucleotide
122 to nucleotide 469. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:129 from nucleotide 263 to nucleotide 469, and extending contiguously from
a
nucleotide sequence rnrresponding to the 5' end of said sequence of SEQ ID
N0:129 from
nucleotide 263 to nucleotide 469, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:129 from nucleotide 263 to nucleotide 469.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
2 0 (a) the amino acid sequence of SEQ ID N0:130;
(b) a fragment of the amino acid sequence of SEQ ID N0:130, the
fragment comprising eight contiguous amino acids of SEQ ID N0:130; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ya69_1 deposited under accession number ATCC 98915;
2 5 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:130. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:130 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
3 0 of SEQ ID N0:130, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:130 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 53 to amino acid 62 of SEQ ID N0:130:
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
205
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(a) a polynucleotide comprising the nucleotide sequence of SEQ TD
N0:131;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:131 from nucleotide 36 to nucleotide 554;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:131 from nucleotide 183 to nucleotide 554;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ydI07~1 deposited under accession
number ATCC 98915;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yd107 1 deposited under accession number ATCC 98915;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yd107_1 deposited under accession number
ATCC 98915;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yd107 1 deposited under accession number ATCC 98915;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:132;
(i) a polynucleotide encoding a protein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:132 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:132;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
2 5 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in {a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
3 0 25% of the length of SEQ ID N0:131.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:131 from nucleotide 36 to nucleotide 554; the nucleotide sequence of SEQ ID
N0:131
from nucleotide 183 to nucleotide 554; the nucleotide sequence of the full-
length protein
coding sequence of clone yd107 1 deposited under accession number ATCC 98915;
or the
206
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
nucleotide sequence of a mature protein coding sequence of clone yd107 1
deposited
under accession number ATCC 98915. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yd107 1 deposited under accession number ATCC 98915. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:132 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:132, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:132
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 81 to amino acid 90 of SEQ ID N0:132.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:131.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
2 0 (aa) SEQ ID N0:131, but excluding the poly(A) tail at the
3' end of SEQ ID N0:131; and
and
(ab) the nucleotide sequence of the cDNA insert of clone
yd107 1 deposited under accession number ATCC 98915;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
(b) a process comprising the steps of:
3 0 (i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:131, but excluding the poly(A) tail at the
3' end of SEQ ID N0:131; and
207
CA 02328062 2000-11-08
WO 99/58642 PCT/US99110843
(bb) the nucleotide sequence of the cDNA insert of clone
yd107 1 deposited under accession number ATCC 98915;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:131, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:131 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:131, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:131. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:131 from nucleotide 36 to
nucleotide
554, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
25 of said sequence of SEQ ID N0:131 from nucleotide 36 to nucleotide 554, to
a nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:131 from
nucleotide
36 to nucleotide 554. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:131 from nucleotide 183 to nucleotide 554, and extending contiguously from
a
2 0 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:131 from
nucleotide 183 to nucleotide 554, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:131 from nucleotide 183 to nucleotide 554.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino aad sequence selected from
the group
2 5 consisting of:
(a) the amino acid sequence of SEQ ID N0:132;
(b) a fragment of the amino acid sequence of SEQ ID N0:132, the
fragment comprising eight contiguous amino acids of SEQ ID N0:132; and
(c) the amino acid sequence encoded by the cDNA insert of clone
3 0 yd107 1 deposited under accession number ATCC 98915;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:132. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:132 having biological activity, the fragment
preferably
208
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
comprising eight {more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ 1D N0:132, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:132 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 81 to amino acid 90 of $EQ ID N0:132.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:133;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:133 from nucleotide 8 to nucleotide 493;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:133 from nucleotide 53 to nucleotide 493;
{d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yd145_1 deposited under accession
number ATCC 98915;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yd145_1 deposited under accession number ATCC 98915;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yd145_1 deposited under accession number
2 0 ATCC 98915;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yd145_1 deposited under accession number ATCC 98915;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:134;
2 5 (i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:134 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:134;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
3 0 (k) a polynudeotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-{i); and
209
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10$43
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:133.
Preferably, such polynucleoiide comprises the nucleotide sequence of SEQ ID
N0:133 from nucleotide 8 to nucleotide 493; the nucleotide sequence of SEQ ID
N0:133
from nucleotide 53 to nucleotide 493; the nucleotide sequence of the full-
length protein
coding sequence of clone yd145_1 deposited under accession number ATCC 98915;
or the
nucleotide sequence of a mature protein coding sequence of clone yd145_1
deposited
under accession number ATCC 98915. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yd145_1 deposited under accession number ATCC 98915. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:134 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:134, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:134
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 76 to amino acid 85 of SEQ ID N0:134.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:133.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:133, but excluding the poly{A) tail at the
3' end of SEQ ID N0:133; and
(ab) the nucleotide sequence of the cDNA insert of clone
3 0 yd145_1 deposited under accession number ATCC 98915;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as, 4X SSC at 50 degrees C; and
{iii) isolating the DNA polynucleotides detected with the
probe(s);
210
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99110843
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:133, but excluding the poly(A) tail at the
3' end of SEQ ID N0:133; and
(bb) the nucleotide sequence of the cDNA insert of clone
yd145_1 deposited under accession number ATCC 98915;
(ii) hybridizing said primer{s) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:133, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:133 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:133 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:133. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
2 0 corresponding to the cDNA sequence of SEQ ID N0:133 from nucleotide 8 to
nucleotide
493, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:133 from nucleotide 8 to nucleotide 493, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:133 from
nucleotide
8 to nucleotide 493. Also preferably the polynucleotide isolated according to
the above
2 5 process comprises a nucleotide sequence corresponding to the cDNA sequence
of SEQ ID
N0:133 from nucleotide 53 to nucleotide 493, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:133 from
nucleotide 53 to nucleotide 493, to a nucleotide sequence corresponding to the
3' end of
said sequence of SEQ ID N0:133 from nucleotide 53 to nucleotide 493.
3 0 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:134;
211
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99110843
(b) a fragment of the amino acid sequence of SEQ ID N0:134, the
fragment comprising eight contiguous amino acids of SEQ ID N0:134; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yd145_1 deposited under accession number ATCC 98915;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:134. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:134 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:134, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:134 having biological activity, the fragment comprising the amino acid
sequence
from amino and 76 to amino acid 85 of SEQ ID N0:134.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
{a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:135;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:135 from nucleotide 21 to nucleotide 308;
(c) a polynucleotide comprising the nucleotide sequence of the full-
2 0 length protein coding sequence of clone yh24_1 deposited under accession
number
ATCC 98915;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yh24_1 deposited under accession number ATCC 98915;
(e) a polynucleotide comprising the nucleotide sequence of a mature
2 5 protein coding sequence of clone yh24_l deposited under accession number
ATCC
98915;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yh24_1 deposited under accession number ATCC 98915;
(g) a polynucleotide encoding a protein comprising the amino acid
3 0 sequence of SEQ ID N0:136;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:136 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:136;
212
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
{k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:135.
Preferably, such polynucleotide. comprises the nucleotide sequence of SEQ ID
N0:135 from nucleotide 21 to nucleotide 308; the nucleotide sequence of the
full-length
protein coding sequence of clone yh24_1 deposited under accession number ATCC
98915;
or the nucleotide sequence of a mature protein coding sequence of clone yh24_1
deposited
under accession number ATCC 98915. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yh24_1 deposited under accession number ATCC 98915. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:136 having
biological
activity, the fragment preferably comprising eight {more preferably twenty,
most
2 0 preferably thirty) contiguous amino acids of SEQ ID N0:136, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:136
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 43 to amino acid 52 of SEQ ID N0:136.
Other embodiments provide the gee corresponding to the cDNA sequence of SEQ
2 5 ID N0:135.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
3 0 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:135, but excluding the poly(A) tail at the
3' end of SEQ ID N0:135; and
213
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99I10843
(ab) the nucleotide sequence of the cDNA insert of clone
yh24_1 deposited under accession number ATCC 98915;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:135, but excluding the poly(A) tail at the
3' end of SEQ ID N0:135; and
(bb) the nucleotide sequence of the cDNA insert of clone
yh24_1 deposited under accession number ATCC 98915;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:135, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID NO:I35 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:135 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:135. Also preferably the
2 5 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:135 from nucleotide 21 to
nucleotide
308, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:135 from nucleotide 21 to nucleotide 308, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:135 from
nucleotide
3 0 21 to nucleotide 308.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:136;
214
CA 02328062 2000-11-08
WO 99/58642 PCT/US99I10843
(b) a fragment of the amino acid sequence of SEQ ID N0:136, the
fragment comprising eight contiguous amino acids of SEQ ID N0:136; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yh24_1 deposited under accession number ATCC 98915;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:136. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:136 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino ands
of SEQ ID N0:136, or a profiein comprising a fragment of the amino acid
sequence of SEQ
ID N0:136 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 43 to amino acid 52 of SEQ ID N0:136.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
25 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:137;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:137 from nucleotide 214 to nucleotide 735;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:137 from nucleotide 634 to nucleotide 735;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yill 1 deposited under accession
number
ATCC 98915;
(e) a polynucleotide encoding the full-length protein encoded by the
25 cDNA insert of clone yill 1 deposited under accession number ATCC 98915;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yill_1 deposited under accession number ATCC
98915;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
3 0 insert of clone yill 1 deposited under accession number ATCC 98915;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:138;
215
CA 02328062 2000-11-08
WO 99/58642 PCT/US99110843
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:138 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:138;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a}-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(i) and that has a length that is
at least
25% of the length of SEQ ID N0:137.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:137 from nucleotide 214 to nucleotide 735; the nucleotide sequence of SEQ
ID N0:137
from nucleotide 634 to nucleotide 735; the nucleotide sequence of the full-
length protein
coding sequence of clone yill 1 deposited under accession number ATCC 98915;
or the
nucleotide sequence of a mature protein coding sequence of clone yill 1
deposited under
accession number ATCC 98915. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yill_1
2 0 deposited under accession number ATCC 98915. In further preferred
embodiments, the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:138 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:138, or a polynucleotide encoding a protein
comprising a
2 5 fragment of the amino acid sequence of SEQ ID N0:138 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 82 to amino acid
91 of SEQ
ID N0:138.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:137.
3 0 Further embodiments of the invention provide isolated polynucleotides
produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
216
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:137, but excluding the poly(A) tail at the
3' end of SEQ ID N0:137; and
(ab) the nucleotide sequence of the cDNA insert of clone
yill_1 deposited under accession number ATCC 98915;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA poiynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:137, but excluding the poly(A) tail at the
3' end of SEQ ID N0:137; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 0 yill 1 deposited under accession number ATCC 98915;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:137, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:137 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:137 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:137. Also preferably the
3 0 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:137 from nucleotide 214 to
nucleotide
735, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:137 from nucleotide 214 to nucleotide 735, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID NO:137 from
nucleotide
217
CA 02328062 2000-11-08
WO 99158642 PCTNS99/10843
214 to nucleotide 735. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:137 from nucleotide 634 to nucleotide 735, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:137 from
nucleotide 634 to nucleotide 735, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:137 from nucleotide 634 to nucleotide 735.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:138;
(b) a fragment of the amino acid sequence of SEQ ID N0:138, the
fragment comprising eight contiguous amino acids of SEQ ID N0:138; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yill 1 deposited under accession number ATCC 98915;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:138. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:138 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 0 of SEQ ID N0:138, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:138 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 82 to amino acid 91 of SEQ ID N0:138.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
2 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:139;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:139 from nucleotide 668 to nucleotide 937;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:139 from nucleotide 848 to nucleotide 937;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yil8_1 deposited under accession
number
ATCC 98915;
218
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yil8_1 deposited under accession number ATCC 98915;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yil8_l deposited under accession number ATCC
98915;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yil8_1 deposited under accession number ATCC 98915;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:140;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:140 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:140;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleodde that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
2 0 one of the polynucleotides specified in (a~(i) and that has a length that
is at least
25% of the length of SEQ ID N0:139.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:139 from nucleotide 668 to nucleotide 937; the nucleotide sequence of SEQ
ID N0:139
from nucleotide 848 to nucleotide 937; the nucleotide sequence of the full-
length protein
2 5 coding sequence of clone yil8_1 deposited under accession number ATCC
98915; or the
nucleotide sequence of a mature protein coding sequence of clone yil8_1
deposited under
accession number ATCC 98915. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yil8_1
deposited under accession number ATCC 98915. In further preferred embodiments,
the
3 0 present invention provides a polynucleotide encoding a protein comprising
a fragment
of the amino acid sequence of SEQ ID N0:140 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:140, or a polynucleotide encoding a protein
comprising a
fragment of the amino acid sequence of SEQ ID N0:140 having biological
activity, the
219
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
fragment comprising the amino acid sequence from amino acid 40 to amino acid
49 of SEQ
ID N0:140.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:139.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:139, but excluding the poly(A} tail at the
3' end of SEQ ID N0:139; and
(ab) the nucleotide sequence of the cDNA insert of clone
yil8_1 deposited under accession number ATCC 98915;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:139, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:139; and
(bb) the nucleotide sequence of the cDNA insert of clone
yil8_1 deposited under accession number ATCC 98915;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:139, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
220
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99/10843
ID N0:139 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:139 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:139. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:139 from nucleotide 668 to
nucleotide
937, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:139 from nucleotide 668 to nucleotide 937, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:139 from
nucleotide
668 to nucleotide 937. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:139 from nucleotide 848 to nucleotide 937, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:139 from
nucleotide 848 to nucleotide 937, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:139 from nucleotide 848 to nucleotide 937.
In other embodiments, the present invention provides a composition comprising
2 5 a protein, wherein said protein comprises an amino acid sequence selected
from the group
consisting of:
(a) the amino acid sequence of SEQ ID NO:I40;
(b) a fragment of the amino acid sequence of SEQ ID N0:140, the
fragment comprising eight contiguous amino acids of SEQ ID N0:140; and
2 0 (c) the amino acid sequence encoded by the cDNA insert of clone
yil8_1 deposited under accession number ATCC 98915;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:140. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
2 5 amino acid sequence of SEQ ID N0:140 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:140, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:140 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 40 to amino acid 49 of SEQ ID N0:140.
3 0 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:141;
221
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:141 from nucleotide 171 to nucleotide 407;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:141 from nucleotide 258 to nucleotide 407;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ykl4_1 deposited under accession
number
ATCC 98915;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ykl4_1 deposited under accession number ATCC 98915;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ykl4_1 deposited under accession number ATCC
98915;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ykl4_1 deposited under accession number ATCC 98915;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:142;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:142 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:142;
2 0 (j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-{g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
2 5 one of the polynucleotides specified in (ar(i); and
(m) a polynudeotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:141.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
3 0 N0:141 from nucleotide 171 to nucleotide 407; the nucleotide sequence of
SEQ ID N0:141
from nucleotide 258 to nucleotide 407; the nucleotide sequence of the full-
length protein
coding sequence of clone ykl4_1 deposited under accession number ATCC 98915;
or the
nucleotide sequence of a mature protein coding sequence of clone ykl4_1
deposited under
accession number ATCC 98915. In other preferred embodiments, the
polynucleotide
222
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99/10843
encodes the full-length or a mature protein encoded by the cDNA insert of
clone ykl4_1
deposited under accession number ATCC 98915. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:142 having biological activity, the
fragment
preferably rnmprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:142, or a polynucleotide encoding a protein
comprising a
fragment of the amino acid sequence of SEQ ID N0:142 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 34 to amino acid
43 of SEQ
ID N0:142.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
TD N0:141.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:141, but excluding the poly(A) tail at the
3' end of SEQ ID N0:141; and
2 0 (ab) the nucleotide sequence of the cDNA insert of clone
ykl4_1 deposited under accession number ATCC 98915;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
2 5 probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
3 0 the group consisting of:
(ba) SEQ ID N0:141, but excluding the poly(A) tail at the
3' end of SEQ ID N0:141; and
(bb) the nucleotide sequence of the cDNA insert of clone
ykl4_1 deposited under accession number ATCC 98915;
223
CA 02328062 2000-11-08
WO 99/58642 PCT/US99110843
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b}(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:141, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:141 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:141, but
excluding the poiy(A) tail at the 3' end of SEQ ID N0:141. Also preferably the
polynudeotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:141 from nucleotide 171 to
nucleotide
407, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:141 from nucleotide 171 to nucleotide 407, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:141 from
nucleotide
171 to nucleotide 407. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:141 from nucleotide 258 to nucleotide 407, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:141 from
nucleotide 258 to nucleotide 407, to a nucleotide sequence corresponding to
the 3' end of
2 0 said sequence of SEQ ID N0:141 from nucleotide 258 to nucleotide 407.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:142;
2 5 (b) a fragment of the amino acid sequence of SEQ ID N0:142, the
fragment comprising eight contiguous amino acids of SEQ ID N0:142; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ykl4_1 deposited under accession number ATCC 98915;
the protein being substantially free from other mammalian proteins. Preferably
such
3 0 protein comprises the amino acid sequence of SEQ ID N0:142. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:142 having biological activity, the fragment
preferably
rnmprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:142, or a protein comprising a fragment of the amino acid
sequence of SEQ
224
CA 02328062 2000-11-08
WO 99/58642 PCTNS99/10843
ID N0:142 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 34 to amino acid 43 of SEQ ID N0:142.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:143;
(b) a poiynucieotide comprising the nucleotide sequence of SEQ ID
N0:143 from nucleotide 164 to nucleotide 457;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yk39_1 deposited under accession
number
ATCC 98915;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yk39_1 deposited under accession number ATCC 98915;
(e) , a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yk39_1 deposited under accession number ATCC
98915;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yk39_1 deposited under accession number ATCC 98915;
(g) a polynucleotide encoding a protein comprising the amino acid
2 0 sequence of SEQ ID N0:144;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:144 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:144;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
2 5 (a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (ar(h); and
3 0 (1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:143.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:143 from nucleotide 164 to nucleotide 457; the nucleotide sequence of the
full-length
225
CA 02328062 2000-11-08
WO ~/~Z PCT/US99/10843
protein coding sequence of clone yk39_1 deposited under accession number ATCC
98915;
or the nucleotide sequence of a mature protein coding sequence of clone
y1c39_1 deposited
under accession number ATCC 98915. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yk39_1 deposited under accession number ATCC 98915. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:144 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:144, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:144
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 44 to amino acid 53 of SEQ ID N0:144.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
II? N0:143.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
2 0 consisting of:
(aa) SEQ ID N0:143, but excluding the poly(A) tail at the
3' end of SEQ ID N0:143; and
(ab) the nucleotide sequence of the cDNA insert of clone
yk39_1 deposited under accession number ATCC 98915;
2 5 (ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii} isolating the DNA polynucleotides detected with the
probe(s);
and
3 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
226
CA 02328062 2000-11-08
WO 99158642 PCT/US99/10843
(ba) SEQ ID N0:143, but excluding the poly(A) tail at the
3' end of SEQ ID N0:143; and
(bb) the nucleotide sequence of the cDNA insert of clone
yk39_1 deposited under accession number ATCC 98915;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
2 0 nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:143,
and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID NO:143 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:143 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:143. Also preferably the
polynudeotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:143 from nucleotide 164 to
nucleotide
457, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:143 from nucleotide 164 to nucleotide 457, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:143 from
nucleotide
164 to nucleotide 457.
2 0 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:144;
(b) a fragment of the amino and sequence of SEQ ID N0:144, the
2 5 fragment comprising eight contiguous amino acids of SEQ ID N0:144; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yk39_1 deposited under accession number ATCC 98915;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:144. In further
preferred
3 0 embodiments, the present invention provides a protein comprising a
fragment of the
amino acid sequence of SEQ ID N0:144 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, mast preferably thirty) contiguous
amino acids
of SEQ ID N0:144, or a protein comprising a fragment of the amino acid
sequence of SEQ
227
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
ID N0:144 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 44 to amino acid 53 of SEQ ID N0:144.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:145;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:145 from nucleotide 72 to nucleotide 500;
(c} a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:145 from nucleotide 255 to nucleotide 500;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yk91 1 deposited under accession
number
ATCC 98915;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yk91_1 deposited under accession number ATCC 98915;
{f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yk91 1 deposited under accession number ATCC
98915;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
2 0 insert of clone yk91_1 deposited under accession number ATCC 98915;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:146;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:146 having biological activity, the fragment
2 5 comprising eight contiguous amino acids of SEQ ID N0:146;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
3 0 (1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i}; and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynudeotides specified in (a~(i} and that has a length that is at
least
25% of the length of SEQ ID N0:145.
228
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:145 from nucleotide 72 to nucleotide 500; the nucleotide sequence of SEQ ID
N0:145
from nucleotide 255 to nucleotide 500; the nucleotide sequence of the full-
length protein
coding sequence of clone yk91_1 deposited under accession number ATCC 98915;
or the
nucleotide sequence of a mature protein coding sequence of clone yk91_1
deposited under
accession number ATCC 98915. In other preferred embodiments, the
poiynucleotide
encodes the full length or a mature protein encoded by the cDNA insert of
clone yk91_1
deposited under accession number ATCC 98915. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:146 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:146, or a polynucleotide encoding a protein
comprising a
fragment of the amino acid sequence of SEQ ID N0:146 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 66 to amino acid
75 of SEQ
ID N0:146.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:145.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
2 0 (a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:145, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:145; and
(ab) the nucleotide sequence of the cDNA insert of clone
yk91_1 deposited under accession number ATCC 98915;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
3 0 {iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
229
CA 02328062 2000-11-08
WO 99/58642 PCT/US99110843
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:145, but excluding the poly(A) tail at the
3' end of SEQ ID N0:145; and
(bb) the nucleotide sequence of the cDNA insert of clone
yk91 1 deposited under accession number ATCC 98915;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
{iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:145, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:145 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:145 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:145. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:145 from nucleotide 72 to
nucleotide
500, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
2 0 of said sequence of SEQ ID N0:145 from nucleotide 72 to nucleotide 500, to
a nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:145 from
nucleotide
72 to nucleotide 500. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:145 from nucleotide 255 to nucleotide 500, and extending contiguously from
a
2 5 nucleotide sequence rnrresponding to the 5' end of said sequence of SEQ ID
N0:145 from
nucleotide 255 to nucleotide 500, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:145 from nucleotide 255 to nucleotide 500.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
3 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:146;
(b) a fragment of the amino acid sequence of SEQ ID N0:146, the
fragment comprising eight contiguous amino acids of SEQ ID N0:146; and
230
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
{c) the amino acid sequence encoded by the cDNA insert of clone
yk91 1 deposited under accession number ATCC 98915;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:146. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:146 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:146, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID NO:I46 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 66 to amino acid 75 of SEQ ID N0:146.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:147;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:147 from nucleotide 174 to nucleotide 620;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:147 from nucleotide 240 to nucleotide 620;
(d) a polynucleotide comprising the nucleotide sequence of the full-
2 0 length protein coding sequence of clone yk199_1 deposited under accession
number ATCC 98915;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yk199_1 deposited under accession number ATCC 98915;
(f) a polynucleotide comprising the nucleotide sequence of a mature
2 5 protein coding sequence of clone yk199_1 deposited under accession number
ATCC 98915;
(g) a polynudeotide encoding a mature protein encoded by the cDNA
insert of clone yk199_1 deposited under accession number ATCC 98915;
(h) a polynucleotide encoding a protein comprising the amino acid
3 0 sequence of SEQ ID N0:148;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:148 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:148;
231
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:147.
Preferably, such polynucleotide ~ comprises the nucleotide sequence of SEQ ID
N0:147 from nucleotide 174 to nucleotide 620; the nucleotide sequence of SEQ
ID N0:147
from nucleotide 240 tt~ nucleotide 620; the nucleotide sequence of the full-
length protein
coding sequence of clone yk199 1 deposited under accession number ATCC 98915;
or the
nucleotide sequence of a mature protein coding sequence of clone yk199_1
deposited
2 5 under accession number ATCC 98915. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yk199_1 deposited under accession number ATCC 98915. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID NO:I48 having
biological
2 0 activity, the fragment preferably comprising eight (more preferably
twenty, most
preferably thirty) contiguous amino acids of SEQ ID N0:148, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:148
having biological activity, the fragment rnmprising the amino acid sequence
from amino
acid 69 to amino acid 78 of SEQ ID N0:148.
2 5 Other embodiments provide the gene corresponding to the cDNA sequence of
SEQ
ID N0:147.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
3 0 (i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:147, but excluding the poly(A) tail at the
3' end of SEQ ID N0:147; and
232
CA 02328062 2000-11-08
WO 99/58642 PCf/US99/10843
(ab) the nucleotide sequence of the cDNA insert of clone
yk199_1 deposited under accession number ATCC 98915;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:147, but excluding the poly(A) tail at the
3' end of SEQ ID N0:147; and
(bb) the nucleotide sequence of the cDNA insert of clone
yk199_1 deposited under accession number ATCC 98915;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:147, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:147 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:147 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:147. Also preferably the
2 5 polynucleotide isolated acrnrding to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:147 from nucleotide 174 to
nucleotide
620, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID NO:147 from nucleotide 174 to nucleotide 620, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:147 from
nucleotide
3 0 I74 to nucleotide 620. Also preferably the polynucleotide isolated
according to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:147 from nucleotide 240 to nucleotide 620, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:147 from
233
CA 02328062 2000-11-08
WO 99158642 PCT/US99110843
nucleotide 240 to nucleotide 620, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:147 from nucleotide 240 to nucleotide 620.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:148;
(b) a fragment of the amino acid sequence of SEQ ID N0:148, the
fragment comprising eight contiguous amino acids of SEQ TD N0:148; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yk199_1 deposited under accession number ATCC 98915;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:148. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:148 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:148, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:148 having biological activity, the fragment comprising the amino acid
sequence
from airiino acid 69 to amino acid 78 of SEQ ID N0:148.
In one embodiment, the present invention provides a composition comprising an
2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:149;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:149 from nucleotide 325 to nucleotide 984;
2 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:149 from nucleotide 973 to nucleotide 984;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone y14 1 deposited under accession number
ATCC 98915;
3 0 (e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone y14_1 deposited under accession number ATCC 98915;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone y14_1 deposited under accession number ATCC
98915;
234
CA 02328062 2000-11-08
WO 99/58642 PCTNS99110843
{g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone y14_1 deposited under accession number ATCC 98915;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:150;
{i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:150 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:150;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (ar(i) and that has a length that is
at least
25% of the length of SEQ ID N0:149.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:149 from nucleotide 325 to nucleotide 984; the nucleotide sequence of SEQ
ID N0:149
from nucleotide 973 to nucleotide 984; the nucleotide sequence of the full-
length protein
2 0 coding sequence of clone y14_1 deposited under accession number ATCC
98915; or the
nucleotide sequence of a mature protein coding sequence of clone y14_1
deposited under
accession number ATCC 98915. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone y14_1
deposited under accession number ATCC 98915. In further preferred embodiments,
the
2 5 present invention provides a polynucleotide encoding a protein comprising
a fragment
of the amino acid sequence of SEQ ID N0:150 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:150, or a polynucleotide encoding a protein
comprising a
fragment of the amino acid sequence of SEQ ID N0:150 having biological
activity, the
3 0 fragment comprising the amino acid sequence from amino acid 105 to amino
acid 114 of
SEQ ID N0:150.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:149.
235
CA 02328062 2000-11-08
WO 99158642 PCTNS99/10843
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
{i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:149, but excluding the poly(A} tail at the
3' end of SEQ ID N0:149; and
(ab) the nucleotide sequence of the cDNA insert of clone
yl4_1 deposited under accession number ATCC 98915;
(ii) hybridizing said probes} to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
2 0 (ba) SEQ ID N0:149, but excluding the poly(A) tail at the
3' end of SEQ ID N0:149; and
(bb) the nucleotide sequence of the cDNA insert of clone
y14_1 deposited under accession number ATCC 98915;
(ii) hybridizing said primers) to human genomic DNA in
2 5 conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b}(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:149, and
3 0 extending contiguously from a nucleotide sequence corresponding to the 5'
end of SEQ
ID N0:149 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:149 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:149. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:149 from nucleotide 325 to
nucleotide
236
CA 02328062 2000-11-08
WO 99/S864Z PCTIUS99110843
984, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:149 from nucleotide 325 to nucleotide 984, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:149 from
nucleotide
325 to nucleotide 984. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:149 from nucleotide 973 to nucleotide 984, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:149 from
nucleotide 973 to nucleotide 984, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:149 from nucleotide 973 to nucleotide 984.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:150;
(b) a fragment of the amino acid sequence of SEQ ID N0:150, the
fragment comprising eight contiguous amino acids of SEQ ID N0:150; and
(c) the amino acid sequence encoded by the cDNA insert of clone yl4_1
deposited under accession number ATCC 98915;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:150. In further
preferred
2 0 embodiments, the present invention provides a protein comprising a
fragment of the
amino acid sequence of SEQ ID N0:150 having biological activity, the fragment
preferably
rnmprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:150, or a protein comprising a fragment of the amino acid
sequence of SEQ
1D N0:150 having biological activity, the fragment comprising the amino acid
sequence
2 5 from amino acid 105 to amino acid 114 of SEQ ID NO:150.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:151;
3 0 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:151 from nucleotide 119 to nucleotide 415;
{c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone y114_1 deposited under accession
number
ATCC 98915;
237
CA 02328062 2000-11-08
WO 99/58642 PCT1US99/10843
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone y114_1 deposited under accession number ATCC 98915;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone y114_1 deposited under accession number ATCC
98915;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone y114_1 deposited under accession number ATCC 98915;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:152;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:152 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:152;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
2 0 one of the polynucleotides specified in (ar(h) and that has a length that
is at least
25% of the length of SEQ 1D N0:151.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:151 from nucleotide 119 to nucleotide 415; the nucleotide sequence of the
full-length
protein coding sequence of clone y114_1 deposited under accession number ATCC
98915;
2 5 or the nucleotide sequence of a mature protein coding sequence of clone
y114_1 deposited
under accession number ATCC 98915. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone y114_1 deposited under accession number ATCC 98915. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
3 0 comprising a fragment of the amino acid sequence of SEQ ID N0:152 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:152, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:152
238
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 44 to amino acid 53 of SEQ ID N0:152.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:151.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:151, but excluding the poly(A) tail at the
3' end of SEQ ID N0:151; and
(ab) the nucleotide sequence of the cDNA insert of clone
y114_1 deposited under accession number ATCC 98915;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
{ba) SEQ ID N0:151, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:151; and
(bb) the nucleotide sequence of the cDNA insert of clone
y114_1 deposited under accession number ATCC 98915;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:151, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
239
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
ID N0:151 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:151, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:151. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:151 from nucleotide 119 to
nucleotide
415, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:151 from nucleotide 119 to nucleotide 415, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:151 from
nucleotide
119 to nucleotide 415.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:152;
(b) a fragment of the amino acid sequence of SEQ ID N0:152, the
fragment comprising eight contiguous amino acids of SEQ ID N0:152; and
(c) the amino acid sequence encoded by the cDNA insert of clone
y114_1 deposited under accession number ATCC 98915;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:152. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
2 0 amino acid sequence of SEQ ID N0:152 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:152, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:152 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 44 to amino acid 53 of SEQ ID N0:152.
2 5 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:153;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:153 from nucleotide 96 to nucleotide 377;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:153 from nucleotide 225 to nucleotide 377;
240
CA 02328062 2000-11-08
WO 99/58642 PCTIUS99110843
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ya80_1 deposited under accession
number
ATCC 98925;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ya80_1 deposited under accession number ATCC 98925;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ya80_1 deposited under accession number ATCC
98925;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ya80_1 deposited under accession number ATCC 98925;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:154;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:154 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:154;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
{k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
2 0 (1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:153.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
NO:153 from nucleotide 96 to nucleotide 377; the nucleotide sequence of SEQ ID
N0:153
from nucleotide 225 to nucleotide 377; the nucleotide sequence of the full-
length protein
coding sequence of clone ya80_1 deposited under accession number ATCC 98925;
or the
nucleotide sequence of a mature protein coding sequence of clone ya80_1
deposited under
3 0 accession number ATCC 98925. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone ya80_1
deposited under accession number ATCC 98925. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:154 having biological activity, the
fragment
241
CA 02328062 2000-11-08
WO 99158642 PCTNS99110843
preferably comprising eight {more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:154, or a polynucleotide encoding a protein
comprising a
fragment of the amino acid sequence of SEQ ID N0:154 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 42 to amino acid
51 of SEQ
ID N0:154.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:153.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:153, but excluding the poly(A) tail at the
3' end of SEQ ID N0:153; and
{ab) the nucleotide sequence of the cDNA insert of clone
ya80_1 deposited under accession number ATCC 98925;
(ii) hybridizing said probes) to human genomic DNA iri
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 0 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
2 5 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:153, but excluding the poly(A} tail at the
3' end of SEQ ID N0:153; and
(bb) the nucleotide sequence of the cDNA insert of clone
3 0 ya80_1 deposited under accession number ATCC 98925;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
242
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:153, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:153 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:153 , but
excluding the poly{A) tail at the 3' end of SEQ ID N0:153. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:153 from nucleotide 96 to
nucleotide
377, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:153 from nucleotide 96 to nucleotide 377, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:153 from
nucleotide
96 to nucleotide 377. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:153 from nucleotide 225 to nucleotide 377, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:153 from
nucleotide 225 to nucleotide 377, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:153 from nucleotide 225 to nucleotide 377.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
2 0 {a) the amino acid sequence of SEQ ID N0:154;
(b) a fragment of the amino acid sequence of SEQ ID N0:154, the
fragment comprising eight contiguous amino acids of SEQ ID N0:154; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ya80_1 deposited under accession number ATCC 98925;
2 5 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:154. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:154 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
3 0 of SEQ ID N0:154, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID NO:154 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 42 to amino acid 51 of SEQ ID N0:154.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
243
CA 02328062 2000-11-08
WO 99158642 PCTNS99/10843
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:155;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:155 from nucleotide 118 to nucleotide 681;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:155 from nucleotide 622 to nucleotide 681;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yd61_1 deposited under accession
number ATCC 98925;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yd61_1 deposited under accession number ATCC 98925;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yd61_1 deposited under accession number
ATCC 98925;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yd61 1 deposited under accession number ATCC 98925;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:156;
(i) a polynucleotide encoding a protein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:156 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:156;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
2 5 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucieotides specified in (a~(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
3 0 250 of the length of SEQ ID N0:155.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:155 from nucleotide 118 to nucleotide 681; the nucleotide sequence of SEQ
ID N0:155
from nucleotide 622 to nucleotide 681; the nucleotide sequence of the full-
length protein
coding sequence of clone yd61_1 deposited under accession number ATCC 98925;
or the
244
CA 02328062 2000-11-08
W~ gg~gg~2 PCTIUS99/10843
nucleotide sequence of a mature protein coding sequence of clone yd61 1
deposited under
accession number ATCC 98925. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yd61_1
deposited under accession number ATCC 98925. In further preferred embodiments,
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:156 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:156, or a polynucleotide encoding a protein
comprising a
fragment of the amino acid sequence of SEQ ID N0:156 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 89 to amino acid
98 of SEQ
ID N0:156.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:155.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
2 0 (aa) SEQ ID N0:155, but excluding the poly(A) tail at the
3' end of SEQ ID N0:155; and
(ab) the nucleotide sequence of the cDNA insert of clone
yd61_1 deposited under accession number ATCC 98925;
(ii) hybridizing said probes) to human genomic DNA in
2 5 conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
3 0 (i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba} SEQ ID N0:155, but excluding the poly(A) tail at the
3' end of SEQ ID NO:155; and
24.5
CA 02328062 2000-11-08
WO 99/58642 PCTNS99110843
(bb) the nucleotide sequence of the cDNA insert of clone
yd61 1 deposited under accession number ATCC 98925;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:155, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:155 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:155 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:155. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:155 from nucleotide 118 to
nucleotide
681, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ 1D N0:155 from nucleotide 118 to nucleotide 681, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:155 from
nucleotide
118 to nucleotide 681. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:155 from nucleotide 622 to nucleotide 681, and extending contiguously from
a
2 0 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:155 from
nucleotide 622 to nucleotide 681, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:155 from nucleotide 622 to nucleotide 681.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
2 5 consisting of:
(a} the amino acid sequence of SEQ ID N0:156;
(b) a fragment of the amino acid sequence of SEQ ID N0:156, the
fragment comprising eight contiguous amino acids of SEQ ID N0:15b; and
(c) the amino acid sequence encoded by the cDNA insert of clone
3 0 yd61 1 deposited under accession number ATCC 98925;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:156. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:156 having biological activity, the fragment
preferably
246
CA 02328062 2000-11-08
WO 99/58642 PCT/US99/10843
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:156, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:156 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 89 to amino acid 98 of SEQ ID N0:156.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:157;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:157 from nucleotide 261 to nucleotide 614;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yd88_1 deposited under accession
number ATCC 98925;
{d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yd88_1 deposited under accession number ATCC 98925;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yd88_1 deposited under accession number
ATCC 98925;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
2 0 insert of clone yd88_1 deposited under accession number ATCC 98925;
(g) a polynucleotide encoding a pratein comprising the amino acid
sequence of SEQ ID N0:158;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:158 having biological activity, the fragment
2 5 comprising eight contiguous amino acids of SEQ ID N0:158;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
3 0 (k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h) and that has a length that is
at least
25% of the length of SEQ ID N0:157.
247
CA 02328062 2000-11-08
WO 99/58642 PCTNS99110843
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:157 from nucleotide 261 to nucleotide 614; the nucleotide sequence of the
full-length
protein coding sequence of clone yd88_1 deposited under accession number ATCC
98925;
or the nucleotide sequence of a mature protein coding sequence of clone yd88_1
deposited
under accession number ATCC 98925. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yd8$_1 deposited under accession number ATCC 98925. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:158 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:158, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:158
having biological activity, the fragment comprising the amino and sequence
from amino
acid 54 to amino acid 63 of SEQ ID N0:158.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:157.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
2 0 (i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:157, but excluding the poly(A) tail at the
3' end of SEQ ID N0:157; and
2 5 (ab) the nucleotide sequence of the cDNA insert of clone
yd88_1 deposited under accession number ATCC 98925;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
3 0 probe(s);
and
(b) a process comprising the steps of:
248
CA 02328062 2000-11-08
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTS PART1E DE CETTE DEMANDS OU CE BREVET
COMPREND PLUS D'UN TOME.
CECI EST LE TOME . - ( DE -Z
NOTE. ~ Pour les tomes additionels, veuillez contacter le Bureau canadien des
brevets
JUMBO APPLICATIONS/PATENTS
THIS SECT10N OF THE APPLICAT10NIPATE1NT CONTAINS MORE
THAN ONE VOLUME
THtS IS VOLUME - l ~: OF ~-'
iVOTE: For additional volumes please contact the Canadian Patent Office
